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Abstract 
The mammalian immune system has evolved a complex and diverse set of 
mechanisms to detect and respond to pathogens by recognizing conserved molecular 
structures and inducing protective immune responses. While many of these mechanisms 
are capable of sensing diverse molecular structures, a large fraction of pathogen 
sensors recognize nucleic acids. Pathogen-derived nucleic acids trigger nucleic acid 
sensors that typically induce anti-viral or anti-microbial immunity, however host-derived 
nucleic acids may also activate these sensors and lead to increased risk of inflammatory 
or autoimmune disease. Animal models and humans lacking key DNA nucleases, such 
as Trex1/Dnase3, accumulate intracellular DNA and develop progressive autoimmunity 
marked by increased Type-I Interferon (IFN) expression and inflammatory signatures.  
Double-stranded DNA (dsDNA) is a potent inducer of the Type-I IFN response. 
Many of the sensors and signaling components that drive the IFN signature following 
simulation with transfected dsDNA (also called ʻInterferon Stimulatory DNAʼ or ʻISDʼ) 
remain unknown. We set out to identify novel components of the ISD pathway by 
developing a large-scale loss-of-function genetic perturbation screen of 1003 candidate 
genes. We interrogated multiple human and murine primary and immortalized cells, 
tested several Type-I IFN reporters, and considered multiple loss-of-function strategies 
before proceeding with an RNAi screen whereby mouse embryonic fibroblasts were 
stimulated with ISD and Type-IFN pathway activation was assessed by measuring 
Cxcl10 protein by ELISA.  
 iv 
Candidate genes for testing in the RNAi screen were curated from quantitative 
proteomic screens, IFN-beta and ISD stimulated mRNA expression profiles, and a 
selection of domain-based proteins including helicases, cytoplasmically located DNA-
binding proteins and a set of potential negative regulators including phosphatases, 
deubiquitinases and known signaling proteins.  
We identified a number of novel ISD pathway components including Abcf1, Ptpn1 
and Hells. We validated hits through siRNA-resistant cDNA rescue, chemical inhibition or 
targeted knockout. Additionally, we evaluated protein-protein interactions of our 
strongest validated hits to develop a network model of the ISD pathway. In addition to 
the identification of novel ISD pathway components, our enriched screening data set 
may provide a useful resource of candidate genes involved in the response to cytosolic 
DNA. 
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Introduction: The Role of Nucleic Acids In Eliciting an Immune Response 
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1.1 – Introduction  
The mammalian immune system has evolved a complex and diverse set of 
mechanisms for recognizing and inducing protective immune responses to invading 
pathogens. Considered the first line of defense against invading pathogens, the innate 
immune system is characterized by germline-encoded pattern recognition receptors 
(PRRs) that recognize conserved motifs essential to the survival of invading 
pathogens[1]. Detection of pathogens by PRRs triggers signaling pathways that 
coordinate transcription of hundreds of inflammatory genes, the products of which 
directly control infection and drive the generation of T and B lymphocyte-mediated 
immune responses[2]. There are four major PRR families that include Toll-like receptors 
(TLRs), cytosolic retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), Nod-like 
receptors and C-type lectins and function as primary sensors that detect a wide range of 
microbe-associated molecular patterns (MAMPs)[3, 4]. While these receptors are capable 
of sensing diverse molecular structures, a large fraction of pathogen detectors recognize 
nucleic acids. While triggering of nucleic acid detectors by pathogen-derived nucleic 
acids typically induces anti-viral or anti-microbial immunity, host-derived nucleic acids 
may also activate these sensors and lead to increased risk of inflammatory or 
autoimmune disease. As such, the recognition of self nucleic acids by innate immune 
receptors has been linked to several autoimmune and autoinflammatory disorders. 
In the past decade we have witnessed the rapid discovery of many innate 
sensors and with it, an appreciation for the importance of pathogen detection and 
responses in guiding the immune response[5, 6]. Among the recent discoveries is the 
recognition that double-stranded DNA (dsDNA) is a potent inducer of the antiviral, type I 
Interferon (IFN) response. However, many of the sensors and signaling components that 
drive the IFN signature following simulation with transfected dsDNA (also called 
2
ʻInterferon Stimulatory DNAʼ or ʻISDʼ) remain unknown. Summarized in Figure 1.1, the 
following discussion details our current understanding of nucleic acid sensing with a 
particular focus on the DNA sensing pathway members and their associated accessory 
proteins. Additionally, we discuss how regulation of these sensors may prevent the 
inappropriate recognition of self-nucleic acids. 
 
1.2 – Nucleic acid recognition by Toll-like receptors 
Pattern recognition receptors can be broadly characterized into two groups based 
on cellular localization. Members of the Toll-like receptor family sample pathogenic 
nucleic acids from the lumenal contents of endolysosomal compartments while a number 
of emerging receptors detect nucleic acids in the cytosol. Toll-like receptors are the best 
characterized among PRRs with 10 known TLRs in humans and 12 in mice that 
recognize conserved microbial motifs broadly shared by pathogens but distinguishable 
from host molecules. The TLR family can be generally categorized into those that are 
expressed on the cell surface and recognize microbial lipid and protein components 
(TLRs 2, 4, 5) and those that are expressed in endosomes and recognize nucleic acids 
(TLRs 3, 7, 8, 9)[5]. The TLRs implicated in the detection nucleic acids; double stranded 
RNA (dsRNA) (TLR3)[7], single stranded RNA (ssRNA) (TLR7 and TLR8)[8-10], and 
hypomethylated cytosine-guanosine (CpG) DNA (TLR9)[11, 12], share similarities in their 
architecture consisting of an extracellular domain with multiple leucine-rich repeats 
(LRRs) linked by a transmembrane domain to a conserved cytosolic signaling domain, 
the Toll/Il-1 receptor homology domain (TIR) domain[13]. TIR domain signaling, driven by 
adaptor molecules including MyD88 (Myeloid differentiation primary response gene 88) 
(TLR7, 8, 9) and/or TRIF (TIR-domain-containing adaptor inducing IFN-β ) (TLR3) 
initiates a signal cascade culminating in the activation of nuclear factor kappa b (NF-κB), 
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Figure 1.1
Nucleic acid sensors activate the transcription of type-I IFN and other infl ammatory genes. Local-
ized to endosomal compartments, Toll Like Receptors (TLR) 3, 7 and 9 recognize double-stranded RNA, 
single-stranded RNA and non-methylated CpG DNA, respectively, leading to the production of type-I 
IFN and other infl ammatory cytokines.  RIG-I like RNA helicase receptors (RLRs) recognize viral nucleic 
acids. After recognition of viral RNA, retinoic acid-inducible gene-I (RIG-I) and Mda5 recruit mitochondria-
associated viral sensor (MAVS, also known as IPS-1, Cardif, and VISA) and subsequently activates IRF3 
and IRF7 in a TBK1- and IKKi-dependent manner. Cytosolic DNA of microbial or self-origin is a potent 
trigger of type-I IFN production via the STING–TBK1–IRF3 axis, as well as other proinfl ammatory cyto-
kines (e.g., TNFa and IL-6), by engaging NF-kB signaling. Cytosolic DNA sensors DAI, RNA Polymerase 
III, IFI16, DHX36, DHX9, DDX41, LRRFIP1 and KU70 detect distinct DNA species and induce an antiviral 
response (discussed in detail in the text). The DNA-induced signaling pathway converges on the adaptor 
STING and the kinase TBK1, which phosphorylates IRF3 to mediate downstream signaling events lead-
ing to transcriptional induction of infl ammatory genes. In addition to cytosolic DNA, bacterial small mol-
ecules c-di-AMP and c-di-GMP act as potent stimulators of the type I IFN response by engaging STING 
either as a direct sensor via (cGAS) or coactivator (discussed in text).
4
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mitogen-activated protein kinase (MAPK) and interferon regulatory factors 1, 3, 5 and 7 
(IRF-1, -3, -5 and -7) [14]. Together these transcription factors drive the production of 
interferons, cytokines and chemokines as well as the induction of many additional genes 
important for the initiation of the immune response[15]. 
TLR9 was the first identified DNA receptor that recognizes nonmethylated CpG 
motifs, a hallmark of the bacterial genome[11, 12]. Largely restricted to B cells and 
plasmacytoid dendritic cells (pDCs), TLR9 has been shown to play an important role in 
detecting mouse and human cytomegalovirus (MCMV and HCMV, respectively), 
especially within pDCs[16-18], Herpes simplex virus (HSV)-1 and HSV-2[19, 20], and 
adenovirus[21]. Most of the evidence linking CpG-containing viruses to TLR9 has been 
generated through in vitro experiments, as TLR9 knockouts do not have a major defect 
in viral clearance. Together with TLR9 in vivo data, the restricted expression of TLR9, 
which does not account for DNA-induced immune responses in other cells types, 
suggests that additional sensing mechanisms must also exist and contribute to antiviral 
defenses. 
 
1.3 – Detection of RNA by cytosolic sensors  
While nucleic-acid sensing TLRs sample endolysosomal compartments for 
ligands degraded from pathogens, a different family of receptors is required to detect 
pathogen-derived nucleic acids that enter the cytosol. The last decade has revealed 
numerous classes of sensors for detecting nucleic acids including the RIG-I-like 
receptors (RLRs), inflammasome-activating sensors and type I IFN producing sensors 
(ISD sensors) which are the focus of this study.   
A hallmark of RLR interaction with viral and synthetic RNA is the induction of type 
I IFNs. The detection of RNAs by RLRs and the subsequent response requires the 
6
mitochondrial accessory protein MAVS[22-25]. Signaling via RIG-I but not MAVS may also 
require the membrane-bound protein STING, though the mechanism for this divergence 
remains unclear[26]. RLR-dependent MAVS signaling drives the recruitment of FADD, 
RIP1 and TRAF3, for the activation of mitogen-activated protein kinases (MAPKs), 
including TBK1 and IKK-I. MAPK activation subsequently enables transcription factors 
activation protein-1 (AP-1), IRF3/7 and NF-κB to translocate into the nucleus where the 
IFN-β promoter becomes activated[27].  
Soon after the identification of TLRs and their cognate ligands, animal models 
targeting various nucleic acid sensing TLRs revealed reduced but not eliminated 
responses to their respective stimuli. The search for TLR3 independent sensing of 
synthetic dsRNA led to the discovery of an entire class of nucleic acid sensors, the 
DExD ⁄ H box RNA helicases known as RIG-I, melanoma differentiation-associated gene 
5 (MDA5), and LGP2[28, 29]. RIG-I recognizes 5ʼ triphosphate ssRNAs characteristic of 
uncapped viral RNAs including flavivirus and orthomyxovirus, and short, dsRNA 
polymers[30]. The specificity of RIG-I in detecting uncapped 5ʼ triphosphate RNAs marks 
an important sensing criterion in distinguishing self from non-self RNAs[31]. In contrast, 
MDA5 may recognize longer RNA, such as synthetic dsRNA (poly I:C) and the genomes 
of picornaviruses such as encephalomyocarditis virus (EMCV)[32]. Lacking the caspase 
recruitment domains (CARDs) crucial for the activation of IRF3, the third member of the 
RLR family, LGP2 was originally described as a negative regulator of RIG-I and MDA5 
function[33]. However, recent investigations with LGP2-deficient mice reveal a critical lack 
of protection against a variety of virus types such as EMCV and furthermore provides 
evidence that LGP2 acts as a coreceptor for some RIG-I and MDA5 ligands[34].  
Evidence implicating NOD2 as an additional sensor adds further to complexity of 
cytosolic RNA sensing mechanisms. NOD2, a sensor of peptidoglycan derivative 
7
muramyldipeptide (MDP), may also sense ssRNA[35, 36]. Though detection of MDP by 
NOD2 drives a classic pro-inflammatory signature, similar to its RLR-counterparts, 
NOD2 stimulation with ssRNA drives a type I IFN response.  
 
1.4 – Detection of DNA by cytosolic sensors  
The molecular basis of cytosolic DNA recognition is still being elucidated and 
many details remain unknown. Somewhat surprisingly, the first evidence of a cytosolic 
DNA response came in 1963 when two independent groups reported that DNA or RNA 
derived from pathogens or host cells was able to activate chicken or mouse fibroblast to 
produce interferon[37, 38]. That DNA could induce an immune response remained largely 
ignored until it was rediscovered decades later. Transfection of dsDNA but not ssDNA 
derived from pathogens or host cells was found to induce MHC gene expression, as well 
as various genes involved in antigen presentation and processing including proteasome 
proteins, invariant chain, HLA-DM, the costimulatory molecule B7.1, and a host of 
signaling molecules including Stat1, Stat3, MAP kinases and the transcription factor NF-
κB[39].  Additionally, it was demonstrated that DNA released from dying cells and 
introduced into the cytosol of macrophages and bone-marrow derived dendritic cells 
(BMDCs) induced APCs to upregulate expression of MHC class I and II genes as well as 
various costimulatory molecules. Response was dependent on transfection of the ligand, 
regardless of the means to bypass the cell wall. Activation was sequence independent, 
induced by oligonucleotides (ODNs) as small as 25 bases in length and dose dependent. 
Additionally there was no response to unmethylated single-stranded CpG DNA 
demonstrating a divergence in immune responses induced by genomic DNA, 
independent of TLR9[40-42].  
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These findings led to two seminal studies demonstrating that the delivery of a 
synthetic long polymer of poly(dA-dT)·poly(dT-dA) (Poly (dA:dT)) DNA or a 45 base-pair 
immunostimulatory DNA (ISD) into the cytosol of mouse embryonic fibroblasts (MEFs), 
macrophages and dendritic cells (DCs) triggered the induction of type I IFN in a Tank-
binding kinase 1 (TBK1)/IRF3-dependent manner[43, 44]. Although no receptor for this 
pathway was identified in these initial studies, the two reports demonstrated that a DNA 
sensor (or sensors) in the cytoplasm of cells could lead to the activation of the IRF3 
pathway independent of TLR9. Since then, a number of groups have identified putative 
sensors of cytoplasmic DNA resulting in the emergence of two conceptually distinct 
signaling pathways. The first of these pathways leads to the activation of the 
inflammasome, characterized by the secretion of proinflammatory cytokines IL-1β  and 
IL-18. The second pathway, the primary focus of this study, leads to the induction of type 
I IFNs.  
 
1.5 – Inflammasome activation by cytosolic DNA 
The inflammasome is a multiprotein complex whose activation results in 
processing of caspase-1, leading to the processing of cytokines such as IL-1β , a key 
pro-inflammatory mediator that induces pyroptosis and stimulates the recruitment of 
macrophages and DCs to sites of infection or injury[45, 46]. A role for cytosolic DNA 
sensing by the inflammasome was first described using various dsDNA ligands, 
demonstrating a required minimum ligand length (greater than 250bp long) to induce 
inflammasome activation[47]. Several groups identified AIM2 (absent in melanoma 2) as 
an essential factor in the initiation of cytosolic DNA-mediated inflammasome activation[48-
51]. AIM2 recognition of cytosolic dsDNA requires two critical domains, the HIN200 DNA-
binding domain and a pyrin domain that interacts with the inflammasome adapter protein 
9
ASC (apoptotic speck protein containing a CARD).  Following DNA transfection and 
subsequent binding, AIM2 associates with ASC via homotypic pyrin-pyrin domain 
interactions, which in turn recruit pro-caspase-1, essential for the activation of caspase-1 
and proteolytic processing of IL-1β and IL-18.   
In antigen presenting cells, AIM2 is indispensible for mounting a response to 
infection with MCMV and vaccinia Virus (VACV). AIM2-dependent IL-18 secretion and 
NK cell activation are essential for an early control of mouse CMV infection in vivo[52]. 
Furthermore, AIM2 deficient mice are more susceptible to infection with Francisella 
tularensis[50, 53] and AIM2-dependent inflammasome activation has been reported for 
other bacterial infections including Listeria monocytogenes [54, 55], and Mycobacterium 
tuberculosis[56].  While multiple lines of evidence point to AIM2 as a cytosolic DNA sensor 
essential for inflammasome formation and subsequent caspase-1 activation it is 
completely dispensable for type I IFN production.   
  
1.6 – Interferon activation by cytosolic DNA sensors 
Following the discovery of the TBK1-dependent, TLR9-independent cytosolic 
DNA sensing ISD pathway, a growing number of putative sensors have been identified. 
The growing number of sensors correlates with a diversity of cell-type and ligand-specific 
responses. Similar to the cytosolic RLR pathways, cytosolic DNA recognition leads to the 
production of type I IFNs following TBK1 and IRF3 activation. The transmembrane 
protein STING is essential for facilitating ISD-pathway gene induction, including type I 
IFN production in fibroblasts, macrophages, and DCs[26, 57]. Additionally, STING is 
required for both cytoplasmic dsDNA- and HSV-1-activated type I IFN production, 
demonstrated by STING deficient animals that succumb to lethal HSV-1 infection due to 
a lack of type I IFN production[57]. A precise mechanism of STING signaling remains 
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unclear, including whether or not STING itself recognizes intracellular DNA. Furthermore, 
the adaptors or receptors acting upstream of STING remain largely unknown. A growing 
number of putative DNA sensors have been identified and may provide further insights in 
the role of STING-mediated type I IFN production. 
DNA-dependent activator of IRFs / DAI 
DNA-dependent activator of IFN-regulatory factors (DAI, also known as ZBP-1 or 
DLM-1) was among the first of the cytosolic DNA sensors to be discovered. DAI was 
identified as a candidate in a screen for genes induced following IFN-β stimulation[58, 59]. 
Overexpression of DAI enhances type I IFN production following stimulation with 
cytosolic DNA.  Small interfering RNAs (siRNAs) directed against DAI demonstrated 
reduced interferon production and resulted in enhanced replication of DNA but not RNA 
viruses.  Furthermore, DAI binding to DNA was demonstrated in vitro and in cells using 
FRET. It was also demonstrated that DAI initiates DNA-dependent physical interactions 
with TBK-1 and IRF3. However, subsequent studies in DAI -/- mice revealed normal 
responses to synthetic and viral dsDNA[60]. The intact ISD sensing pathway indicates 
that DAI is either dispensable or a there are redundant sensors of cytosolic DNA.   
RNA polymerase III  
Following the discovery of DAI, two independent studies linked RNA polymerase 
III to cytosolic DNA sensing, preferentially for AT-rich DNA[61, 62]. Present in the cytosol, 
RNA polymerase III transcribes AT-rich DNA into uncapped 5ʼ triphosphate moieties, the 
ligand for RIG-I, which in turn signals via MAVs to induce the type I IFN expression[31].  
By generating a ligand to engage the RIG-I pathway, RNA polymerase III is not a 
cytosolic DNA sensor in the direct sense.  RNA polymerase III is present in both human 
and mouse cell and detects both synthetic Poly (dA:dT) and pathogens including AT-rich 
virus, like adenovirus and Epstein-Barr virus. Furthermore, it was demonstrated that 
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RNA polymerase III mediates type I IFN responses during Legionella pneumophila and 
HSV-1 infection[63, 64]. 
IFI16/Ifi204 
The PYHIN family member IFI16 was identified in human monocytes by affinity 
purification of immune stimulatory 70mer bait derived from vaccinia virus[65]. Similar to 
AIM2 and other PYHIN family members, IFI16 has and N-terminal pyrin domain two C-
terminal DNA-binding HIN200 domains. IFI16 is predominantly expressed within the 
nucleus, but in some cells types, including macrophages, IFI16 gains access to the 
cytoplasmic compartment upon stimulation with transfected or viral DNA where it was 
found to interact in a complex with STING and TBK1 to trigger IFN-β production. In other 
cell types, including fibroblasts, IFI16 binds viral DNA in the nucleus during productive 
infection[66]. IFI16 requires signaling from STING to induce type I IFN production, 
regardless of its cellular localization.  
The murine PYHIN protein Ifi204 (p204), which shares a 37% amino-acid identity 
and a similar domain architecture, is proposed to function in an analogous manner to 
IFI16. Corroborating homologous function, knockdown of Ifi204 in macrophages and 
MEFs leads to compromised IFN-β gene induction following stimulation with transfected 
DNA or HSV-1 infection[65]. Recent studies implicate a functional role of IFI16/Ifi204 in 
resistance to HSV-1 infection in the corneal epithelium[67]. Furthermore, in a mechanism 
to evade IFI16-mediate detection, the HSV nuclear protein ICP0 targets IFI16 for 
degradation[66]. Taken together, these data implicate that both IFI16 and p204 play a role 
in cytosolic DNA sensing, driving type I IFN expression in a STING dependent manner. 
DHX36 and DHX9 
The helicases DHX36 and DHX9 have emerged as putative TLR9-independent 
sensors of cytosolic CpG-A and CpG-B DNA in pDCs, respectively[68]. The aspartate–
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glutamate–any amino acid–aspartate/ histidine box–containing helicases, belonging to 
the DEAH/RHA family of DExD/H helicases, were identified following affinity purification 
of CpG-DNA-conjugated beads from human primary PDCs. Competition assays 
demonstrated that DHX9 and DHX36 bound specifically to CpG subtypes, CpG-B or 
CpG-A, respectively.  
These distinct CpG oligodeoxynucleotides induce either type I IFN (CpG-A) or 
proinflammatory cytokines, such as TNF- α and IL-6 (CpG-B), in pDCs[69]. Similarly, 
DHX9 activation leads to IRF7-dependent IFN-α production, while activation of DHX36 
leads to NF-κB upregulation and the subsequent production of IL-6 and TNFα.  
Consistent with previous studies that implicated the existence of MyD88-dependent, 
TLR9-independent DNA sensors in pDCs, knockdown of DHX9 and DHX36 inhibited 
cytokine production following infection with HSV-1, while response to the RNA virus 
influenza A was unaffected[20, 70]. Following stimulation, DHX36 and DHX9 interact 
directly with the Toll/IL-1R domain of MyD88, triggering downstream signaling to activate 
IRF7 and NF-κB p50, respectively. 
Recent studies have further implicated DHX36 and DHX9 as putative sensors of 
dsRNA[71, 72]. Following stimulation with Poly I:C, DHX36 forms a complex with helicases 
DDX1 and DDX21 and the adapter TRIF to trigger type I IFN responses[71]. In myeloid 
DCs, DHX9 interacts with MAVS in response to dsRNA, inducing type I IFN 
responses[72]. It remains unclear whether DHX36 and DHX9 play a role in the recognition 
of RNA viruses. 
The current results describe complex dual sensing mechanisms mediated by 
DHX36 and DHX9. The helicases respond to cytosolic CpG DNA oligonucleotides and 
synthetic dsRNA driving the production of type I IFNs and proinflammatory cytokines. 
Activation of downstream effectors is initiated by adapters MyD88 (in response to CpGs), 
13
TRIF (through a DHX36-dependent signaling mechanism), and MAVS, following dsRNA 
activation of DHX9.  
DDX41 
Following the discovery of the nucleic acid sensing capacity of DHX36 and 
DHX9, a screen of the DExD/H helicase family identified DDX41 as a putative cytosolic 
DNA sensor in both mouse and human DCs[73]. Knockdown of DDX41 results in impaired 
type I IFN and proinflammatory cytokine expression following stimulation with dsDNA 
oligonucleotides and DNA viruses, including HSV-1 and adenovirus, but not following 
Poly I:C stimulation or influenza infection. Immunoprecipitation studies revealed that 
DDX41 interacts with STING in both resting conditions and following stimulation with 
Poly (dA:dT). Furthermore, DDX41 and was shown to function upstream of IRF3, NF-κB 
and MAPK. 
The current data suggest that DDX41 represents a cytosolic DNA sensor that, 
similar to IFI16, signals via STING to induce type I IFN and proinflammatory cytokine 
responses. Unlike the IFN-inducible IFI16, however, DDX41 is constitutively expressed 
at high levels in immune cells, indicative of a potential role in early immune surveillance 
of pathogenic dsDNA. 
LRRFIP1 
Identified in a cDNA screen as an HIV-1 trans-activation response (TAR) RNA- 
interacting protein, Leucine-rich repeat in flightless-I interacting protein 1 (LRRFIP1) was 
shown to bind nucleic acids through its N-terminal domain[74]. Subsequently, a targeted 
siRNA screening focusing on leucine-rich repeat-containing or interacting proteins, found 
that LRRFIP1 inhibited type I IFN production following stimulation with Listeria 
monocytogenes or infection with VSV[75]. Furthermore, LRRFIP1 knockdown inhibited 
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IFN production in response to Poly I:C, Poly (dA:dT) and a Z-form DNA analog, Poly 
(dG:dC). 
Interestingly, a novel β-catenin-dependent pathway regulates LRRFIP1-induced 
type I IFN production. β-catenin, an integral component of the Wnt signaling pathway, is 
phosphorylated following LRRFIP1-nucleic acid binding where it subsequently 
translocates to the nucleus. Following nuclear translocation, LRRFIP1 binds to IRF3, 
leading to enhanced recruitment of the histone acetyltransferase p300, enhancing 
transcription of the IFN-β gene[76].  
Together, these data demonstrate a role for LRRFIP1 in cytosolic nucleic acid 
recognition leading to enhance IFN-β transcription via a novel β-catenin-dependent 
signaling pathway. 
KU70 
A key component of the DNA repair pathway, KU70 was recently identified as a 
novel regulator of the type III IFN pathway[77]. Similar to type I IFNs, type III IFNs can 
also exert broad antiviral activity, yet they use a distinct heterodimeric receptor complex 
(IFN-lR1/IL- 10R2)[78]. KU70 was identified as a putative regulator of cytosolic DNA 
sensing in cytosolic extracts of HEK293 cells utilizing DNA-conjugated beads. 
Knockdown of KU70 partially abrogated HSV-1-induced type III IFN induction. 
Furthermore, KU70 knockdown reduced to type III IFN expression in murine 
macrophages and DCs following transfection of plasmid DNA in an IRF1- and IRF7-
dependent manner. 
The role of KU70 in the sensing of cytoplasmic DNA remains to be fully 
elucidated. It is unclear whether KU70 recognizes bacterial infections and DNA viruses 
in primary immune cells. Further, the signal transduction pathway between Ku70 and 
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IRF1 and IRF7 remains elusive. Additionally, it is unclear how the KU70-mediated 
activation of type III IFN expression contributes to the overall immune response. 
Cyclic dinucleotides 
Recently, a number of studies have provided compelling evidence of a role for 
cyclic GMP-AMP (cGAMP) as a novel second messenger triggered by cytosolic DNA 
that leads to STING-dependent expression of type I IFNs[78-82]. First, it was demonstrated 
that STING was required to mediate the intracellular response to bacterial derived 
cGAMP[79].  STING binds these small molecules directly through its C-terminal domain 
(CTD), leading to TBK1-dependent expression of type I IFNs. The resolution of crystal 
structures of human STING-CTD bound to cGAMP further demonstrated the putative 
dual role of STING as an adaptor of DNA sensing and as a direct sensor of cGAMP and 
potentially of other second messenger molecules[6, 83-85]. An in vitro complementation 
assay further demonstrated that STING directly binds cGAMP, triggering IRF3 activation 
and the induction of IFN-β in response to transfected DNA or DNA viruses[82]. 
It was subsequently demonstrated that chemically synthesized cGAMP potently 
induced IRF3 phosphorylation and type I IFN induction. Furthermore, cGAMP is induced 
following HSV-1 and vaccinia virus infection providing strong physiological evidence that 
cytosolic DNA stimulation leads to STING activation through a novel cGAMP-second 
messenger. Furthermore, recent evidence links DDX41 as a sensor for cGAMP 
potentially facilitating cGAMP signaling via STING[86]. 
Cellular extracts from active fractions of cGAMP-producing L929 cells revealed 
the interferon-inducible candidate E330016A19, prospectively called cGAS (cGAMP 
synthase)[87, 88]. Overexpression of cGAS in the presence of STING led to increased type 
I IFN production, while knockdown compromised cellular responses to transfected DNA 
or to DNA viruses including HSV-1 or VACV. Together, these studies provide compelling 
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evidence that cGAS-dependent DNA-sensing operates through a second messenger 
signaling system leading to the potent induction of type I IFNs. 
 
1.7 – Endogenous DNA ligands and autoimmunity 
As our knowledge of pattern recognition receptors and their role in microbial 
defense expands, so too does our understanding that these same receptors may be 
involved in the initiation of autoimmunity.  While PRRs provide the first line of defense 
against infection, a growing body of evidence supports the notion that autoantigens, 
particularly nucleic acids, released from apoptotic bodies, necrotic or pyroptotic cells can 
be recognized by the same receptors. Recognition of self-DNA is largely avoided, as 
cellular DNA sensors are predominantly located in the cytoplasm while host DNA is 
typically limited to the mitochondria and nucleus, thus preventing inadvertent activation 
of proinflammatory cytokines pathways. While the precise series of events between 
activation of innate immunity and initiation of autoimmunity is not well understood, there 
are several striking examples of this connection that demonstrate missteps of regulatory 
mechanisms required to subvert endogenous DNA-induced immune responses. The 
cellular endonucleases DNase-I, DNase-II, and DNase-III (also known as Trex1) 
required for the clearance of extracellular, lysosomal, and cytosolic DNA, respectively, 
represent major regulatory checkpoints that, when altered or absent have deleterious 
consequences to the host, leading to the inappropriate activation of cytokines including 
type I IFN production. Next, we review the role of the endonucleases as critical 
regulatory checkpoints necessary for the prevention of self-DNA-induced activation of 
proinflammatory cytokines. 
DNase-I 
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Crucial to reducing the potential for self-nucleic acid recognition is the 
degradation of extracellular nucleic acids. DNase-I is the major nuclease present in 
serum, urine and secreta and is responsible for the removal of DNA at sites of high cell 
turnover where it degrades extracellular dsDNA into tri- or tetraoligonucleotides. Mice 
deficient in DNase-I develop high titers of anti-nuclear antibodies (ANAs), with deposition 
of immune complexes in the glomeruli and full-blown glomerulonephritis[89, 90]. It was 
demonstrated that disease severity increased in a DNase-I dose-dependent manner, 
and correlated with increased levels of apoptosis. Similarly, a subset of patients with 
Systemic Lupus Erythematosus (SLE) have been found to have decreased levels of 
circulating DNase-I in the serum and increased apoptosis[91]. Furthermore, mutations in 
DNase-I are associated with SLE, and low DNase-I activity correlates with 
glomerulonephritis[92]. Together, these studies point to DNase-I as a crucial regulator of 
self-DNA, leading to the degradation and destruction of otherwise stimulatory circulating 
DNA. 
DNase-II 
DNase-II is expressed in lysosomes, where it degrades DNA from phagocytosed 
apoptotic and necrotic cells. Drosophila deficient in DNase-II demonstrate high levels of 
endogenous DNA that escaped degradation. The accumulation of endogenous DNA 
leads to the constitutive expression of the antibacterial genes for diptericin and attacin in 
a Toll-independent manner[93]. Mice deficient in DNase-II die in utero of anemia, coupled 
with a massive IFN-β release owing to a failure of definitive erythropoiesis in mouse fetal 
liver[94, 95]. The failure to degrade nuclei during erythropoiesis and subsequent 
accumulation of DNA in macrophages leads to a cytokine storm. DNase-II/IFNAR-
double-deficient mice are rescued from the anemia phenotype but later develop 
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polyarthritis, which is dependent on TNF-α[95]. Furthermore, TLR3 and TLR9 deficiency 
had no effect on the lethality[96].   
Adult mice with an inducible knockout form of DNase-II develop severe 
inflammatory joint disease similar to human Rheumatoid Arthritis, including synovitus 
with villus proliferation and pannus formation that filled the joint cavity, eroded cartilage, 
destroyed bones, and occasionally penetrated the bone marrow[97].  Macrophages 
carrying undigested DNA produced greater amounts of TNF-α and IFN-β when 
compared to age-matched littermate controls suggesting that macrophages could initiate 
arthritis. A recent study demonstrated the DNase-II-dependent embryonic lethality could 
be rescued by loss of STING function, completely preventing the arthritis phenotype, 
characteristic of DNase-II/IFNAR-double-deficient and inducible DNase-II deficient 
mice[98].  
The sensors that detect DNase-II substrates are unclear, but it is likely that one 
or more of the aforementioned cytosolic DNA sensor(s) drive the interferon response in 
the presence of undigested DNA, further highlighting a central role for DNA-induced 
immune responses in autoimmune diseases. 
DNase-III / TREX1  
Recently, TREX1 (also known as DNase-III) was identified as a negative 
regulator of cytosolic DNA sensors. Mutations in 3ʼ-repair exonuclease 1, or TREX1, can 
lead to autoimmunity as demonstrated in several cases of monogenic familial lupus in 
which heterozygous mutations in TREX1 gene were found in affected members of a 
family with chilblain lupus as well as patients with sporadic SLE[99]. Additional mutations 
have been described as the underlying cause of a congenital neurological disorder with 
striking similarities to SLE, Aicardi-Goutières syndrome (AGS)[100-104]. The pathology of 
AGS is indicative of an aberrant immune response; in fact, symptoms closely parallel 
19
those of acquired in utero viral infection. Similar to SLE, patients with AGS have elevated 
levels of IFN-α, progressive autoantibody activation, including elevated levels of IgG and 
IgM, skin lesions that bear pathological similarities in both diseases and intracranial 
calcification, with preference for basal ganglia, which occurs in up to 30% of patients with 
cerebral lupus[105].  
TREX1 deficient mice have elevated cytokine production and auto-antibodies 
leading to lethal autoimmune non-infectious inflammatory myocarditis[104]. Increased 
cytokine production was linked to the accumulation of cytosolic DNA derived from 
endogenous retroelements, indicating that one of the functions of Trex1 is to degrade 
cytosolic DNA derived from reverse transcribed retroelements. Crossing TREX1-
deficient mice with mice lacking IRF3 or IFNR rescued TREX1-/- animals from death, 
linking type I IFN production to the observed autoimmunity and further implicating 
TREX1 in the regulation DNA activators that would otherwise trigger innate immune 
signaling-dependent autoimmunity[104]. Recently, a role for TREX1 in HIV infection has 
described whereby HIV DNA uses TREX1 to rapidly digest viral HIV retroelements to 
avoid STING-dependent innate immune signaling that would otherwise lead to viral 
suppression. Together, these data suggest that TREX1 acts as negative regulator of the 
STING-dependent ISD-sensing pathway [106]. 
Clearance of apoptotic cells 
The role of apoptotic cells, their recognition by components of the innate immune 
system and subsequent activation of adaptive immunity through what the body may 
perceive as a “danger signal” has been well established as a potential factor in the 
development of SLE[107]. Clearance deficiencies, accompanied by the accumulation of 
apoptotic debris, maturation of antigen presenting cells (APCs) and the subsequent 
formation of anti-nuclear antibodies has been demonstrated in patients with SLE or with 
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deficiencies in complement component C1q[108-111]. Apoptotic cells have also been 
implicated in the activation of T cells in a TLR-independent manner[112]. Exposure of 
immature dendritic cells to apoptotic cells resulted in production of type I interferons, the 
upregulation of both MHC class I and II, and the subsequent development of cytotoxic T 
cells.   
Additionally, both nucleosome and dsDNA components of apoptotic cells have 
been shown to induce dendritic cell activation via toll-dependent and independent 
pathways[40, 113, 114]. Severe lymphoproliferation and a broad spectrum of autoimmune 
pathologies characterize mice lacking a TYRO3, AXL and MER (TAM) family of receptor 
tyrosine kinases, shown to be important for phagocytosis and clearance of apoptotic 
cells[115, 116]. TAM receptors have also been implicated in the negative regulation of TLR 
signaling, suggesting that the phenotype of TAM receptor-deficient mice may not be 
solely attributed to apoptotic clearance defects. Failure to clear apoptotic cells, however, 
is likely to lead to the release of self nucleic acid ligands and contributes to disease 
through mechanisms central to the ISD-sensing pathway.  
 
1.8 – Conclusion 
The past decade has seen rapid progress in understanding how cells recognize 
and respond to microbial threats via cytosolic DNA recognition. Multiple innate immune 
receptors have evolved to sample the lumenal contents of endolysosomal compartments 
as well as the cytosol to recognize diverse pathogens with a limited set of receptors. The 
same set of receptors may, in some contexts, detect endogenous nucleic acids resulting 
in the stimulation of an immune response and subsequent autoimmune pathologies. 
Understanding how different cell types recognize and respond to cytoplasmic 
DNA has profound implications for the diagnosis, prevention, and treatment of a variety 
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of diseases and may lead to the development of new vaccine strategies. Identifying 
novel sensors, adaptors, signaling molecules and other components of the ISD-sensing 
pathway may provide new candidates that could be targeted for therapeutic intervention 
of infectious, as well as autoimmune, disease.  
To this end, we set out to identify and validate novel components of the ISD-
sensing pathway. While our primary goal is to identify novel DNA sensor candidates, we 
hope to also identify components that function as accessory proteins in the signaling 
cascade following ISD stimulation and leading to the activation of type I IFNs. In the 
chapters that follow, we describe the development, execution, analysis and validation of 
a large-scale loss-of-function genetic perturbation screen targeting more than 1,000 
candidates genes designed to reveal new components in the ISD-sensing signaling 
network. 
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Chapter 2:  
Development of a High-Throughput Screening Method to Detect Nucleic Acid 
Responses 
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2.1 – Introduction: Identification of a cellular based system to detect nucleic acid 
responses 
 The following chapter details the development of a reliable, repeatable and 
robust assay for the detection of the immune response to cytosolic nucleic acids for use 
in our high throughput loss-of-function RNA-interference (RNAi) screen. Our approach 
rests on the notion that quantitative measurement of type I IFNs induced by nucleic acids 
introduced to the cytosol will allow us to use RNAi to identify non-redundant factors 
required for the normal nucleic acid response in the ISD-sensing pathway.  
 Many of the genes and pathways that contribute to the immune responses 
induced by cytosolic nucleic acids remain unknown. To enable genome-wide RNAi 
screens to find these pathways, we have developed a cellular model system to detect 
innate immune responses to nucleic acids (NA) in the cytosol, described in the following 
three steps.  
 First, to stimulate NA-sensing pathways, we generated and tested several kinds 
of NA stimuli: (1) 48bp and 24bp dsDNA or immunostimulatory DNA (ISD), which are the 
major focus of our studies; (2) synthetic and in vitro transcribed ssRNA and dsRNA 
ligands specific to other (TLR-dependent and independent) sensors including TLR3, 
TLR7/8 and RIG-I; (3) negative controls ligands, including a TLR9 ligand, unmethylated 
CpG ssDNA, and an inactive 12bp dsDNA oligonucleotide. Second, we identified an 
optimal cell line that is able to withstand multiple passages, can be amplified rapidly for 
use in screens, is amenable to siRNA transfection and/or lentiviral infection and is not 
sensitive to nonspecific effects of RNAi. Multiple human and murine cell types show 
strong type I interferon responses to nucleic acid ligands. We identified p53-/- MEFS as 
an optimal screening cell line for their reproducibility, low sensitivity to transfection and 
strength of response. Third, to identify the most robust assays, we tested quantitative 
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assays to detect type I interferon responses, including CD-tagging, GFP and Luciferase 
reporters, quantitative PCR-based interferon detection and protein detection by ELISA.  
 We considered two general approaches to our genetic perturbation screens: 
genome-wide lentiviral shRNA screens and arrayed candidate siRNA screens. For both 
approaches, optimization of the genetic perturbation system required refinement of 
multiple conditions including transfection reagent selection, volume, and order of RNAi 
treatment. Additionally, we assessed siRNA concentration, time to optimal knockdown, 
cell seeding density and media conditions. Finally, dsDNA stimulation variables, 
including ligand to transfection ratio, complex incubation time, supernatant collection 
time and cell survival, were considered following siRNA knockdown.  
 The screening workflow described below is robust, reproducible and simple to 
implement. We assessed the validity of our system with the Z-factor scoring method, 
demonstrating that our screening performance was indicative of a robust screen. The 
subsequent screen of dsDNA sensing factors resulted in a valuable resource of 
candidates and novel regulators of the ISD-sensing pathway. 
 
2.2 – Ligands and transfection reagents 
First we recapitulated recent findings that support the evidence of a cytosolic 
nucleic acid sensor in mouse embryonic fibroblasts (MEFs) [40, 42-44]. MEFs provide a 
simple model for the study of innate immunity because they allow infection with various 
viruses and effectively express type I interferon genes[14]. Zero to eight hours following 
transfection of 1ug/ml of a 48bp dsDNA ligand or interferon stimulatory DNA (ISD), a 
24bp dsDNA ligand or short ISD (shISD), single stranded 20-mer Type-B CpG or 
Polyinosinic-polycytidylic acid (Poly I:C), a synthetic analog of double-stranded RNA 
(dsRNA), total RNA was purified at different time points from C57/Bl6 MEF and lysates 
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were assessed by quantitative RT-PCR (qRT-PCR) for the expression of type I IFNs, 
including Ifn-β, Cxcl10, and Mx1 (Figure 2.1). These cytokines are hallmarks of the first 
phase immune response, regulated by Irf3 and induced by cytosolic nucleic acids[14]. 
Experiments aimed at recapitulating the described studies demonstrated robust 
interferon expression in response to lipid-transfected ISD (described in [44]) that 
increased throughout an 8-hour time course (Figure 2.1).  
 Responses were dependent on transfection but were not induced by transfection 
reagents alone (Figure 2.2A). We confirmed that the responses are sequence-
independent, length-dependent but not concentration dependent. Contrary to previous 
studies[42, 117], 24bp dsDNA ODNs transfected in equimolar amounts to 48bp DNA ODNs 
consistently induce the expression of Cxcl10 an order of magnitude lower than the 48bp 
ODN. However, we demonstrated 12bp dsDNA does not induce Ifn-β (not shown) or 
Cxcl10 expression, suggesting a minimum length DNA ODN is required to stimulate the 
IDS-sensing pathway. Synthetic dsDNA polymers (Poly (dA:dT), a repetitive synthetic 
double-stranded DNA sequence of poly(dA-dT)•poly(dT-dA) and a synthetic analog of B-
DNA, induce Ifn-β or Cxcl10. To discriminate between specific responses to dsDNA and 
non-specific responses to other nucleic acids, we developed a series of nucleic acid 
ligands to function as positive and negative controls for use in our secondary screening 
and proteomics approaches. In addition to 12bp dsDNA that does not stimulate IFN; 
TLR9-dependent, single-stranded bacterial B-type CpG, a synthetic oligonucleotide that 
contains unmethylated CpG dinucleotides, did not stimulate type I IFN directly or with 
lipid-mediated transfection(Figure 2.2B). 
 Viral and synthetic RNA ligands require RIG-I and MDA-5 to induce an immune 
response. Thus, we developed a number of ligands specific to the cytosolic RNA sensing 
pathway. In addition to synthetic double-stranded RNA polyinosine-polycytidylic acid 
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Figure 2.1
Transfection of dsDNA induces a type I IFN response. B6 MEFs were transfected with 45-base pair 
double-stranded DNA ligand (ISD), 24-base pair double-stranded DNA ligand (shISD), Type-B CpG or 
poly I:C for 2 to 8 hours. Lysates were collected and total RNA was isolated. Quantitative RT-PCR of 
Type-I interferon genes was performed from cDNAs prepared from RNA isolates. From top to bottom, 
Ifnb, Cxcl10 and Mx1 were measured relative to percent Gapdh.
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Figure 2.2
Transfection is required to induce nucleic acid-specifi c type I IFN responses in B6 MEFs. A-C) B6 
MEFs are transfected with 1ug/mL of the indicated DNA and RNA ligands for 0-8 hours. Cxcl10 induction 
was measured by quantitative RT-PCR. D) B6 MEFs are transfected with ligands with the indicated con-
centrations for six hours. Cxcl10 induction was measured by quantitative RT-PCR. E) Lipofectamine 2000 
was titrated in combination with 1ug/mL of ligand at the indicated ratios in 96-well plates. Cxcl10 induction 
was measured by quantitative RT-PCR.
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Figure 2.2 (continued)
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(Poly I:C) which, upon transfection, resembles the RNA of infectious viruses and elicits a 
consistent and strong interferon response, we used the T7 RNA polymerase to 
selectively synthesize single stranded RNA bearing a native 5ʼ triphosphate, required for 
RIG-I mediated antiviral responses[31, 118]. We have developed and tested three in vitro 
transcribed (IVT) RNAs. In addition to the 19-nucleotide immunostimulatory ssRNA 9.2s 
(3p-RNA)[119], we generated two 50-nucleotide ssRNAs derived from the 3ʼ end of 
Influenza A virus (A/Puerto Rico/8/34(H1N1)) segments 5 and 8. These sequences were 
selected for their potential immunostimulatory effects based on uridine content[120], 
containing 12 (low) and 21 (high) uridine nucleotides in segments 5 and 8 (PR8-RNA), 
respectively. We demonstrated the stimulatory effect of these ligands (3p-RNA and PR8-
RNA) to induce Ifn-β and Cxcl10 following transfection (Figure 2.2C). We continued to 
use Cxcl10 as a reliable readout for interferon-inducible genes because of its high 
induction in response to nucleic acids and its dependence on IRF3[121]. 
 Increased concentration of dsDNA ligands correlates with increased type I IFN 
expression (Figure 2.2D). High concentrations (5ug/mL) of IVT-RNA are toxic as 
demonstrated by increased Gapdh values of two to three cycles (data not shown) and a 
decrease Cxcl10 expression at higher concentrations. We also demonstrated that the  
ratio of ligand to transfection reagent influences the type I IFN response. Transfection 
efficiency can also be titrated by increasing the ratio of transfection reagent to ligand 
(Figure 2.2E).  
 To assess the influence of transfection reagents on transfection efficiency and 
toxicity, three transfection reagents were compared side-by-side using MEFs stably 
expressing a Cxcl10-PLJM6-GFP reporter as a proxy for type I IFN responses (provided 
by A. Luster, Massachusetts General Hospital, Boston), (Figure 2.3A). We considered 
the stimulatory capacity of transfection reagents alone, by adding two transfection 
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Figure 2.3
Transfection reagents infl uence induction of Type-I IFN response. A) B6 MEFs stably expressing a 
Cxcl10-PLJM6-GFP reporter were treated with the indicated transfection reagents, either alone or with 
dsDNA or dsRNA ligands at a 1:5 ratio of ligand to ul of transfection reagent. Sixteen hours following 
stimulation Cxcl10 expression was assessed by fl uorescence microscopy. B) Infl uence of penicillin/strep-
tomycin presence in MEF media on Cxcl10-GFP expression was compared 16 hours following transfec-
tion dsDNA complexes formed with Lipofectamine LTX.  Three hours following transfection with dsDNA/
LTX complexes media was replaced and compared to wells with the media unchanged.
31
Figure 2.3 (continued)
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reagents (Lipofectamine 2000, Lipofectamine 2000CD) directly to culture without the 
addition of nucleic acids and demonstrated increased GFP expression. An additional 
transfection reagent, Lipofectamine LTX, does not appear to induce GFP expression. 
Previous experiments failed to demonstrate type I IFN expression induction by 
transfection reagent alone suggesting that increased GFP expression may be toxicity-
induced auto-fluorescence. Regardless of transfection reagent, Cxcl10-GFP expression 
increased following transfection of lipid/ligand complexes. Presence or absence of 
penicillin/streptomycin does not appear to effect transfection efficiency (Figure 2.3B). 
Furthermore, replacing dsDNA complexes three hours following transfection decreased 
toxicity and increased Cxcl10-GFP reporter expression. 
 
2.3 – Identification of cells for use in genetic and biochemical screens 
Critical to our screening system is a robust cell line that is able to withstand 
multiple passages, is amenable to scalability, is easily infectible, transfectable and is not 
sensitive to immunogenic effects of RNAi. We considered several human and murine 
candidate cell lines, including: a) KBM7, the chronic myeloid leukemia (CML) cell line 
with a haploid karyotype except for chromosome 8; b) human embryonic kidney 293 
cells; c) adenocarcinomic human alveolar basal epithelial A549 cells; d) HeLa; e) primary 
human bronchial epithelial cells (HBEC); f) GM-CSF-differentiated bone-marrow dendritic 
cells (BMDCs); g) mouse embryonic fibroblasts (MEFs) from both C57BL/6 and Balb/c 
strains; h) monocyte/macrophage-like RAW 264.7 cells; and i) p53 deficient (p53-/-) 
MEFs.  
Evaluation of human haploid, immortalized and primary cells 
Loss-of-function genetic screens in haploid cells have identified pathogen host 
factors[122]. In a method that parallels genetic approaches in haploid yeast, insertional 
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mutagenesis can be implemented as a screening method by generating null alleles in 
KBM7 cells. Nucleic acid ligand transfection induced no detectable type I IFN response, 
nor expression of inflammasome response genes, IL1b, MIP1a and TNFa by quantitative 
RT-PCR (data not shown). Infection with Adenovirus (AdV), a non-enveloped, double-
stranded, linear DNA virus, produces type I IFN, interleukin-6 (IL-6) and tumor necrosis 
factor alpha (TNF-α) in an IRF3-dependent manner in BMDCs[123]. Infection with 
Vaccinia virus or AdV in KBM7 wild-type cells or a gene-trap isolate deficient in FADD, 
did not induce the expression of IFN-β, CXCL10, IFIT1, MX1 (Figure 2.4) or Il1b, MIP1a 
and TNFa (data not shown). Without a detectable nucleic acid response in the haploid 
cells, we then considered both primary and immortalized human cell lines to study the 
ISD-pathway. 
 Immortalized human cell lines (HEK293, A549 and HELA) do not respond to 
transfected dsDNA (Figure 2.5 A-C). Over a time course of eight hours, only Poly I:C and 
IVT-RNA induced a type I IFN response in HEK293. Primary human bronchial epithelial 
cells (HBECs), however, responded strongly to synthetic dsDNA (Poly (dA:dT)) six hours 
following transfection (Figure 2.5 D). In addition to increased expression of type I IFN 
genes (CXCL10, IFIT1, IFN-β and MX1), there was moderate expression of both IL-6 
and TNF-α. DNA ligands ISD and 62.ISD, a 62 base pair double-stranded DNA 
oligonucleotide, a influenza PR8-based derivative of our IVT-RNA preparation, failed to 
induce IFN-β and only moderate amounts of CXCL10 and IFIT1. 
 To further test the ISD-sensing response in HBECs we developed a Luciferase 
interferon stimulated response element (ISRE) reporter assay using 293T cells as a 
surrogate cell for transferred supernatants. Supernatants from HBECs stimulated for six 
hours were transferred to the ISRE reporters. We demonstrated that the type I IFN 
response to poly (dA:dT) stimulation in HBECs could be titrated and is sensitive to 
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Figure 2.4
Haploid cell lines do not respond to viral stimulation. KBM7 and gene-trap isolate FADD-defi cient 
KBM7 cells were infected with Vaccinia virus and Adenovirus for 24 hours. Type I IFN expression was 
measured by quantitative RT-PCR for the indicated genes.
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Figure 2.5
Transfection of double-stranded DNA induces a Type I IFN response in primary human bronchial 
epithelial cells (HBEC) but not in human cell lines. A-C) HEK293, A549, and HELA were stimulated for 
0-8 hours with 1.0ug/mL dsDNA and  0.3ug/mL RNA ligands. Lysates were collected and total RNA was 
isolated. Quantitative RT-PCR of Type-I interferon genes was performed from cDNAs prepared from RNA 
isolates. A) Expression of IFNb, CXCL10 and MX1 following stimulation was measured. B-C), Expression 
of Type-I IFN genes were measured as indicated. D) HBEC were stimulated for 6 hours with the indicated 
ligands (x-axis and legend). Expression of CXCL10, IFIT1, IFNb, IL-6, MX1 and TNFa were measured by 
quantitative RT-PCR.
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Figure 2.5 (continued)
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ligand:transfection reagent rations (Figure 2.6A). Increased concentrations of Poly 
(dA:dT) correlated with increased ISRE response. Furthermore, transfection with both 
poly dA:dT and calf-thymus DNA (CT-DNA) induced CXCL10 protein in a time-
dependent manner as measured by ELISA (Figure 2.6A). 
 To test the efficacy of HBECs as a potential screening cell, we first transfected 
cells with siRNAs targeting IRF3 and AIM2, a gene required for the initiation of the DNA-
dependent inflammasome response[48, 50, 51] (Figure 2.6B). Seventy-two hours following 
transfection, cells were stimulated with Poly (dA:dT). Supernatants transferred to ISRE 
reporter cells show a 5-fold decrease in the DNA response in IRF3-knockdown cells, as 
well as a 2-fold increase following AIM2 knockdown, relative to non-targeting control 
siRNA treated cells treated HBECs. Quantitative RT-PCR of IRF3 gene expression 
reveals a 20-fold decrease relative to non-targeting control (P-value <0.0001, Studentʼs 
t-test). Following the optimization of siRNA conditions, we tested the response of a full 
panel of control genes to Poly (dA:dT) transfection in HBECs (Figure 2.6C). As 
expected, siRNAs targeting IFN-β and IRF3 reduce the response to dsDNA by 17 and 
84 fold, respectively (P-value <0.001, Student's t-test). Both DAI and IRF7 knockdown 
resulted in moderately reduced DNA responses. Surprising, at the time, was the near 
complete elimination of the dsDNA response following knockdown of MAVS and RIG-I, 
genes required for the response to RNA ligands (31 and 28-fold, respectively, P-value 
<0.01). In an independent experiment, we validated these findings by knocking down 
IRF3 and RIG-I, stimulating with Poly (dA:dT) for 6 hours and measuring the expression 
of interferon response genes CXCL10 and MX1 (Figure 2.6D). 
 We demonstrated that transfected Poly (dA:dT) fails to induce a type I interferon 
response in HBECs following knockdown of both RIG-I and MAVS. These data conflict 
directly with mouse models that show intact interferon responses to dsDNA in the 
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Figure 2.6
Human bronchial epithelial cells (HBECs) respond to DNA, are amenable to transfection and RNAi 
but require RIGi and MAVS to respond to dsDNA. A) HBECs were stimulated with the indicated con-
centration of poly (dA:dT) and ratio of transfection reagent (Lipofectamine LTX) for six hours (left panel) or 
0-24 hours (right panel). Supernatants were collected and added to 293T ISRE reporter cells (left panel) 
or to a CXCL10 ELISA. ISRE standard curve, left inset.  B) HBECs were transfected with siRNAs target-
ing AIM2 and IRF3 for 72-hours and then stimulated with 1ug/mL Poly dA:dT for 6 hours. Supernatants 
were transferred to 293T ISRE reporters. Knockdown effi ciency over a course of indicated siRNA concen-
trations were measured by measured by quantitative RT-PCR (p-value <0.0001, two-way ANOVA). C-D) 
An siRNA panel of the indicated control genes were transfected into HBECs as described above and stim-
ulated with poly (dA:dT) for 6 hours. Interferon response was detected by ISRE reporter (C) or CXCL10 
and MX1 gene expression by quantitative RT-PCR (D), (*, p-value <0.01, **, p-value <0.001, paired t-test, 
siRNA control compared to stimulated non-targeting control).
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absence of RIG-I, an RNA helicase that senses viral RNAs, and MAVS, a downstream 
effector of RIG-I that coordinates pathways leading to the activation of NF-κB, IRF3 and 
IRF7. Additionally, we have found that only the synthetic dsDNA ODN poly (dA:dT), but 
not any other dsDNA ligand, elicits a robust interferon signal. The data, however, were 
consistent with a finding that that both RIG-I and MAVS are essential for the cytosolic 
dsDNA-signaling pathway in a Huh-7 human hepatoma cell line that is naturally RIG-I 
deficient[124]. It was subsequently demonstrated that AT-rich regions in dsDNA become a 
template for RNA Polymerase III to generate 5ʼ triphosphate RNA that signals through 
RIG-I[62, 125]. Human PBMCs produce IFN-α upon stimulation with Poly (dA:dT) and 
dsDNA ligands of varying lengths but only Poly (dA:dT) elicits an interferon response in 
293T cells in agreement with out findings[61]. Furthermore, we learned that all human 
epithelial and fibroblast cells respond only to Poly (dA:dT) in a STING-dependent 
manner, whereas monocytes and macrophages respond to all dsDNA ligands (Y. Liu, 
Keystone Conference on Dendritic Cells, 2013). We therefore returned to murine models 
for the development of our screening system. We considered both primary cells and 
immortalized cell lines to assess their type I IFN response to transfected dsDNA ligands 
in a RIG-I-independent manner.  
Evaluation of murine immortalized and primary cells 
 Bone marrow derived dendritic cells (BMDCs) from C57BL/6J mice were 
stimulated with a panel of DNA and RNA ligands for 0 to 8 hours (Figure 2.7A). Similar to 
our findings in B6 MEFs (Figure 2.2), BMDCs express Cxcl10 following stimulation with 
DNA ligands ISD, shISD, and Poly A:T, increasing over time. CpG induced expression of 
Cxcl10 occurred following four hours of stimulation consistent with the kinetics of TLR9 
expression in dendritic cells[126]. Furthermore, IVT RNA and Poly I:C induced a potent 
Cxcl10 response. Only IVT RNA induced IFN-β expression. 
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Figure 2.7.
Multiple murine cell types respond to dsDNA transfection by inducing Type-I IFNs in a time depen-
dent manner. B6 Bone-marrow derived dendritic cells (A), BALB/c MEFs (B), RAW 264.7 macrophages 
(C) and p53-/- MEFs (D) were transfected with the indicated nucleic acid ligands for 0-8 hours. Lysates 
were collected and total RNA was isolated. Quantitative RT-PCR of Type-I interferon genes was per-
formed from cDNAs prepared from RNA isolates. E) p53-/- MEFs were treated with the indicated siRNAs. 
Seventy-two hours following siRNA transfection cells were stimulated with ISD or IVT-RNA (3p-RNA) for 
26 hours. Cxcl10 protein was measured by ELISA (*, p-value <0.05, paired t-test, aired t-test, siRNA con-
trol compared to ISD stimulated non-targeting control).
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 Similar to B6 MEFs (Figure 2.2), BALB/c MEFs respond to ISD with increased 
Cxcl10 expression (Figure 2.7B) with only Poly I:C inducing an Ifn-β response. The 
monocyte/macrophage-like cell line, RAW 264.7, responds strongly to both DNA and 
RNA ligands following transfection with increased expression of Cxcl10 (Figure 2.7C). 
RNA ligands and not DNA ligands induce strong IFN-β responses .  
 We demonstrated that C57BL/6 and BALB/c MEFs, RAW264.7 macrophages, 
and 3T3 fibroblasts (data not shown), have intact ISD-sensing pathways, marked by the 
production of type I IFN following DNA stimulation. MEFs may be an useful primary cell 
to study innate responses, but they senesce after several passages and are thus not 
practical for large-scale screens (i.e. mass spectrometry experiments require as many 
as 108 cells per sample) or protocols that require multiple passages. While we have 
demonstrated robust responses in monocyte/macrophage-like RAW 264.7 cells they are 
difficult to passage and are not easily transfectable with siRNAs. Similarly, we have 
demonstrated robust Cxcl10 responses BMDCs. It is, however, difficult to produce pure 
populations of BMDCs in large numbers with GM-CSF stimulation alone and without 
sorting. Furthermore, BMDCs are not amenable to transfection of siRNAs with lipid-
based transfection reagents, typically requiring electroporation to mediate siRNA delivery 
at the cost of high cell death. 
 As an alternative to wild-type MEFs, we tested p53-deficient MEFs (p53-/-) (from 
D. Sabatini and D. Kwiatkowski, Whitehead Institute, Cambridge, MA), which are 
immortal and grow rapidly in culture (Figure 2.7D). To assess the ISD-sensing pathway 
response, p53-/- MEFs were stimulated with a panel of DNA and RNA ligands for 0 to 8 
hours. We demonstrated that Cxcl10 expression increased over time following 
stimulation with DNA ligands ISD, shISD, and Poly A:T. Additionally, IVT RNA and Poly 
I:C induced a potent Cxcl10 response but only Poly I:C induced substantial IFN-β 
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expression. We selected p53-/- MEFs as our model cell for the detection of ISD-sensing 
pathway responses. Many of the known DNA sensors are restricted to macrophages and 
APCs, and although it has been reported that any nucleated cell can produce interferon 
in response to pathogenic stimuli, there is no strong evidence pointing to a specific 
sensor in the ISD-pathway in MEFs[127].  The ISD-pathway is intact in p53-/- MEFs, 
demonstrated by robust expression of Cxcl10 and other cytokines in response to multiple 
dsDNA ligands. Furthermore, p53-/- MEFs are easily passaged and, as is described in 
detail below, are amenable to both transfection and infection with siRNAs and shRNAs, 
respectively. 
 
2.4 – Development of a quantitative assay to detect type I interferon responses of 
nucleic acids 
Following the identification of a suitable cell line, we pursued the development of 
a robust quantitative assay to detect type I IFN responses to nucleic acids for large-scale 
genome-wide pooled shRNA or arrayed siRNA screens. In addition to reproducibility, 
specificity and sensitivity, we also factored in assay costs into the decision process. 
Furthermore, we considered the utility of the assay as a future resource (for example, 
gain-of-function (cDNA) screens). 
 We focused our search for reporters of the ISD-sensing pathway on the 
expression of type I interferon genes, including cytokines, and chemokines as a proxy of 
the ISD response. These inducible effector molecules are hallmarks of the antiviral 
response and are striking characteristic of the IFN signature described in patients with 
Systemic Lupus Erythematosus (SLE) [40, 42-44, 128]. To this end, we pursued a number of 
type I IFN reporters including a CD-tagging method, GFP-tagged Cxcl10 and Ifn-β 
reporters, a Luciferase interferon stimulated response element (ISRE) reporter, 
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intracellular staining flow assays (IC Flow) and Cxcl10 and Ifn-β ELISAs. We also 
developed a highly accurate dual-reporter qPCR-based system to detect the expression 
of IFN genes and a control gene. Additionally, we considered the contribution of cell 
surface markers implicated in prior studies in the immune response to nucleic acids, 
including MHC class I and II proteins and costimulatory markers, B7.1 (CD80)[117] and 
PD-L1[44].  
Type I IFN-GFP reporters 
To complement the proposed arrayed screens, we considered the use of 
genome-wide pooled shRNA screens. In this approach, a genome-wide lentiviral shRNA 
library is infected in a single pool into p53 MEFs, containing fluorescent type I IFN 
pathway reporters. Changes in these reporters are used as a proxy for genes involved in 
the DNA sensing process; cells exhibiting a phenotype of interest caused by specific 
shRNAs are isolated by FACS. The shRNAs in the isolated population can then 
identified using custom microarrays that display cognate probes against the entire library 
of shRNAs. With this method in mind, we generated p53-/- MEFs with stable integration of 
either Ifn-β or Cxcl10 promoter-GFP constructs that typically respond with 10-100-fold 
induction of GFP. This high response threshold would be appropriate for a pooled 
screens where separation of high and low GFP expressing cells is required by FACS[22, 
129]. We infected p53-/- MEFs with Ifn-β and Cxcl10 promoter-GFP constructs and 
generated single-cell subclones identified following stimulation with recombinant Ifn-β. A 
summary of their responses to dsDNA and dsRNA can be found in Table 2.1. An 
additional round of subcloning did not improve the fold change response of transfected 
dsDNA compared to unstimulated cells (Figure 2.8A). As a pilot to demonstrate the 
potential utility of Cxcl10 GFP-reporter MEFs, we either transfected reporter subclones 
with positive and negative control siRNAs or infected them with mock-pools of multiple 
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MEFS/IP10-GFP subclones
No Stim Poly I:C Poly A:T No Stim Poly I:C Poly A:T Poly I:C Poly A:T
#1 95.34 98.09 98.83 63.61 1269.48 322.64 19.96 5.07
#17 95.95 88.63 97.78 60.67 860.25 287.26 14.18 4.73
MEFs/IFNb-GFP subclones
No Stim Poly I:C Poly A:T No Stim Poly I:C Poly A:T Poly I:C Poly A:T
#13 1.68 72.42 14.96 7.50 93.24 12.30 12.43 1.64
#22 32.86 93.32 73.63 14.19 120.72 23.69 8.51 1.67
GFP% Mean Mean folds
GFP% Mean Mean folds
Table 2.1
Developing a cell-autonomous assay for selecting bioactive RNAi treated cells. Generation of 
Type I IFN-GFP reporters.  p53-/- MEF subclones stably expressing Cxcl10 and IFNb promoter reporters 
were stimulated with 5ug/mL of transfected dsDNA or dsRNA for 24 hours. GFP induction was measured 
by FACS.
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Figure 2.8
Developing a cell-autonomous assay for selecting bioactive RNAi treated cells. Generation of 
Type I IFN-GFP reporters.  A) p53-/- MEF subclones stably expressing Cxcl10 promoter GFP reporters 
were stimulated with 5ug/mL of transfected dsDNA or dsRNA for 24 hours. GFP induction was mea-
sured by FACS. B) Increasing concentrations of control siRNA transfected Cxcl10 reporter subclones 
were stimulated with Poly (dA:dT) (left) or Poly I:C (right) according the indicated layout. Fluorescence 
was measured by microplate cytometry. Fold reduction (right panel) was measured by comparing mean 
fl orescence intensity between conditions. C) p53-/--CXCL10 reporter MEFs were infected was multiple 
shRNA control hairpins, puromycin selected and stimulated with dsDNA for 18-hours. GFP expression 
was measured by FACS.
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non-targeting shRNAs. We measured the RNAi effect following ISD stimulation by 
automated microscopy or FACS, respectively (Figure 2.8B-C). Regardless of the RNAi 
method, the results failed to demonstrate significant fold change of stimulated cells 
relative to background.  
 With ISD-mediated IFN-GFP-fold induction no higher than 5-20-fold in the p53-/- 
reporter clones, we pursued a distinct approach that utilizes retroviral integration of a 
fluorescent protein at the site of endogenous genes in their normal chromosomal 
locations. This retroviral integration at the site of the native promoter is expected to show 
more dramatic induction than artificial promoter constructs.  
CD Tagging 
 Similar to gene traps, the CD Tagging system drives the random insertion of YFP 
into genes via retroviral integration[130]. The presence of splice acceptor and donor sites 
surrounding YFP incorporates the YFP tag as part of the synthesized gene product 
(Figure 2.9A). We pursued a method to select for random YFP insertion at the site of 
ISD-pathway responsive genes. We developed the following strategy: Following infection 
of the pBabe-tagging vector, p53-/- MEFs are sorted by flow cytometry. Cells that 
spontaneously fluoresce are discarded. The remaining cells are cultured and stimulated 
with ISD. On the second round of sorting, eYFP positive cells are sorted at one cell per 
well into 384-well plates and expanded into clones. Cells are passaged from 384-well 
plates into ordinary tissue culture 96-well plates and one optical 96-well plate. The 
optical 96-well plate is used to image the proteins tagged following a second round of 
ISD stimulation. The remaining plates are used for 3ʼ RACE to detect the gene of 
insertion or freezing (Figure 2.9B).  
For compatibility with the puromycin-resistant lentiviral shRNA library, 
hygromycin and neomycin resistant CD-tagging vectors were developed (Figure 2.9C). 
51
Figure 2.9
Developing a cell-autonomous assay for selecting bioactive RNAi treated cells. Generation of 
a CD-tagged protein library. Adapted from Sigal A et al. A) The CD-tagging vector pBabeAE. Splice 
acceptor (SA) and splice donor (SD) fl anked fl uorophore sequence (FL seq), with no promoter, no start 
codon or polyA signal, is inserted into the genome by MoMLV. Flagged mRNA translates to an internally 
labeled protein, with the fluorophore protein tag (FL tag) usually near the N terminus. B) Flowchart of the 
library generation procedure. Following infection of the pBabe tagging vector, p53-/- MEFs are sorted by 
fl ow cytometry. Cells that spontaneously fl uoresce are discarded. The remaining cells are cultured and 
stimulated with dsDNA. On the second round of sorting, eYFP positive cells are sorted at one cell per 
well into 384-well plates and expanded into clones. Cells are passaged from the 384-well plate into two 
ordinary tissue culture 96-well plates and one optical 96-well plate. The optical 96-well plate was used to 
image the proteins tagged following a second round of dsDNA stimulation. The remaining plates are used 
for 3’ RACE to detect the gene of insertion or freezing. C) To use the CD tagging vectors as potential 
screening tool for lentiviral shRNA screens, PURO resistance was replaced with the indicated resistance 
markers as demonstrated by gel electrophoresis.  D) p53-/- MEFs were infected overnight with CD-TAG 
Null (no-resistance marker), Neomycin, or Hygromycin constructs, along with an FUGW control.  Cells 
were sorted for eYFP positive cells.
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Figure 2.9 (continued)
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Multiple attempts to generate an YFP-tagged type I interferon using the CD tagging 
approach were unsuccessful (Figure 2.9D) though we feel this may be a useful strategy 
for future studies.  
ISD-induced cell-surface marker expression 
Double-stranded nucleic acids induce expression of multiple genes related to 
antigen processing and presentation including B7.1 (CD80)[117], MHC Class II, CD40 and 
B7.2 (CD86)[44]. We therefore assessed the utility of cell-surface markers as a screening 
tool to interrogate the ISD-sensing pathway.  
In additions to multiple IFN-gamma-inducing TLR-ligands, we transfected dsDNA 
into the human RS4-11 B-cell line and murine RAW264.7 cells for 24-hours and 
measured cell surface marker expression of CD40 and CD80 by FACS, respectively 
(Figure 2.10).  While there were four-fold increases of CD40 positive cells in response to 
Poly (dA:dT) in human RS4-11 cells, we detected only a modest increase of CD80 
positive cells following dsDNA stimulation in RAW264.7 monocyte/macrophages.  
Furthermore, we demonstrated that RS4-11 B-cells are not amenable to transfection with 
siRNAs, and are difficult to passage in the context of a large-scale genome-wide shRNA 
screen (data not shown). 
Detection of type I IFN by quantitative RT-PCR 
Quantitative real-time PCR is a sensitive and flexible tool for assessing gene 
expression. As a screening tool, quantitative RT-PCR is compatible with 384-well cell 
culture format and high throughput robotic workflow, including liquid handling and 
automated quantitative RT-PCR[131-133]. To this end, we developed a Taq-man based 
dual-reporter quantitative PCR system that simultaneously reports on both Cxcl10 and a 
control gene (Gapdh). The dual reporter system simultaneously reports two unique 
hydrolysis probes that are labeled at the 5' end with Light-Cycler 555 Yellow or 
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Figure 2.10 
Developing a cell-autonomous assay for selecting bioactive RNAi treated cells.  Assessment of 
cell-surface markers following TLR stimulation in human and murine cells.  Human RS4-11 B-cells 
and murine RAW264.7 monocyte/macrophage cells were stimulated with the indicated ligands for 24 
hours. CD40 and CD80 cell surface expression was measured by FACS.
 NoStim  LPS  zymosan  polyI:C  poly(dA:dT) 
 NoStim  LPS  zymosan  polyI:C  poly(dA:dT) 
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fluorescein (FAM) or and at the 3' end with a dark quencher dye for the probes. 
Following ISD stimulation, we carried out cDNA synthesis directly on cell lysates from 
384-well plates, eliminating the RNA purification step, allowing us to proceed directly to 
perform RT-PCR. We compared a two-PCR SYBR-green primer-based system to the 
dual-reporter system following stimulation of MEFs with DNA and RNA ligands (Figure 
2.11). Dual reporter detection of Cxcl10 expression demonstrated greater than 100-fold 
increase over unstimulated cells (p-value <0.001, unpaired t-test). Though the cost of the 
qPCR reagents were reasonable in the context of a genome-wide screen, the 
preparation of cDNA from whole cell lysates exceeded the screening budget. We 
explored further Taq-man-based multiplexing options, reporting up to four genes per well 
using lysate-direct cDNA synthesis. Though the large scale of our screen put the Taq-
man based method out of reach, a multiplex system targeting the expression of a few 
key genes could be useful in the context of a smaller screen.  
Detection of type I IFN by ISRE Luciferase reporters 
 To report on inflammatory responses in primary human bronchial epithelial cells, 
we developed a Luciferase interferon stimulated response element (ISRE) reporter 
assay using 293T cells as a surrogate cell for transferred supernatants (Figure 2.6)[134]. 
Type I interferons mediate signaling through STAT1 and STAT2 components of the 
JAK/STAT-signal transduction pathways. The STAT1/STAT2-responsive Luciferase 
construct encodes the firefly Luciferase reporter gene under the control of a mCMV 
promoter and tandem repeats of the ISRE. The demonstrated efficacy of the ISRE 
reporter in human cells persuaded us to develop an equivalent reporter for murine cells.  
We infected p53-/- MEFs with a lentivirus containing ISRE-Luciferase and, following 
selection, we stimulated the resulting polyclonal ISRE reporters either directly with ISD or 
with supernatants transferred from ISD-stimulated MEFs (Figure 2.12). ISRE Luciferase 
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Figure 2.11 
Developing a cell-autonomous assay for selecting bioactive RNAi treated cells.  Quantitative-RT-
PCR dual-reporter. Comparison of SYBR-green based two-step RT-qPCR with TaqMan based hydroly-
sis probes that are labeled at the 5’ end with Light-Cycler 555 Yellow or fl uorescein (FAM) or and at the 3’ 
end with a dark quencher dye for the probes. p53-/- MEFs were stimulated with the indicated DNA or RNA 
ligands for 0, 6 or 8 hours. Lysates were prepared using one-step Cells-to-CT and directly analyzed by 
RT-PCR.
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Figure 2.12
Developing a cell-autonomous assay for selecting bioactive RNAi treated cells. Luciferase inter-
feron stimulated response element (ISRE) reporter development.  A) p53-/- MEFs were infected with 
a lentivirus containing ISRE-luciferase, Puromycin-selected and then directly stimulated with 1-2 ug/mL 
(Lo, Hi, respectively) of dsDNA ligands for 24 hours or stimulated with supernatants for identically treated 
p53-/- MEFs. ISRE relative luminescent units were measured and compared to mouse IFNb stimulated 
cells (inset).  B) Supernatant transfer induced a titratable ISRE response. C) Stably infected cells were 
cloned by limiting dilution and tested for responsiveness to mouse IFNβ. D) ISRE reporter cells were 
stimulated with the indicated amounts of Adenovirus and Sendai Virus for 24 hours.  E) siRNA transfected 
ISRE reporter MEFs were stimulated directly with dsDNA and IVT-RNA (3p-RNA) 72-hours following 
siRNA treatment. ISRE RLUs were measured 24-hours following stimulation. F) ISD complexes remain 
active following supernatant transfer. Supernatants were collected following three-hours or 24-hours fol-
lowing stimulation and response was detected by Cxcl10 ELISA or ISRE reporter cells in parallel. ISRE 
reporters were stimulated with either fresh or frozen ISD complexes.
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60
luminescence indicated a seven and nine-fold increase relative to unstimulated cells, for 
transferred supernatant and direct transfection, respectively. Responses correlated 
directly to supernatant volume (Figure 2.12A-B). Next, we developed monoclonal ISRE 
reporter MEFs. Following selection with puromycin, stably infected cells were cloned by 
limiting dilution and tested for responsiveness to mouse Ifn-β. A clone with high signal to 
background ratio was selected and found to be sensitive to low levels of Ifn-β (<1U/mL) 
with a >50× dynamic range (Figure 2.12C). Furthermore, ISRE reporter clones were 
sensitive to viral infection following stimulation with either Adenovirus or Sendai virus 
(negative sense, single-stranded RNA virus) (Figure 2.12D).  
 To distinguish the effects of genetic perturbation on the ISD-sensing pathway 
from RNAi-associated toxicity, it is crucial to detect type I IFN responses on a per-cell 
basis. Cell viability can be measured directly in the context of the ISRE reporter with a 
dual-reporter Luciferase/Renilla system or indirectly by transferring supernatants to ISRE 
reporter cells and measuring viability in the siRNA treated cells by luminescent detection 
of ATP (CellTiter-Glo). We pursued the supernatant transfer model to fit within our 
screening budget.  However, complexes from supernatants transferred from p53-/- MEFs 
continued to stimulate ISRE reporter cells (Figure 2.12E). Supernatants collected 
following three-hours of stimulation fail to induce a response in directly stimulated cells 
as detected by Cxcl10 ELISA but induce a potent response in ISRE reporter cells. 
Furthermore, supernatants from cells washed three hours following stimulation and 
collected 24-hours later induced Cxcl10 expression to levels similar to un-washed 
supernatants as detected by ELISA. Only supernatants collected at 24-hours induced a 
similar response in ISRE reporter cells, further supporting evidence that complexes 
remain active following transfer to reporter cells. Lastly, we determined that ISRE 
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detection in 384-well plates was not feasible due to crosstalk with neighboring wells 
(data not shown).   
Detection of type I IFN by ELISA 
 Lastly, we considered enzyme-linked immunoblot staining assays as a screening 
tool for the detection of ISD-sensing pathway responses. CXCL10 protein detection by 
ELISA in ISD-stimulated primary human cells led to robust expression. We reasoned that 
ISD triggered responses would be similar in mice. Stimulation of p53-/- MEFs with ISD or 
IVT-RNA ligands induced Cxcl10 protein at levels greater than 30-fold compared to 
unstimulated cells (Figure 2.13A). In addition to Cxcl10, we assessed for Ifn-β, Ifn-α, and 
Il1b (data not shown). 
We next considered the utility of an ELISA-based detection tool in the context of 
an siRNA-based loss-of-function screen of the ISD-sensing pathway. In MEFs treated 
with a non-targeting control siRNA we detected normal responses to nucleic acids. 
MEFs treated with an Irf3-directed siRNA demonstrated strongly reduced responses 
(more than 40-fold) to both dsDNA and IVT-RNA (p-value <0.001, Studentʼs t-test). 
Furthermore, we demonstrated abrogated Cxcl10 expression in IVT-RNA stimulated 
MEFs with siRNA-directed knockdown of Rig-i and Mavs as well as in ISD-stimulated 
cells treated with Tbk1 siRNA. 
  To further optimize the Cxcl10 ELISA, we considered both length of ISD complex 
stimulation time and volume of supernatant.  We demonstrated that the detection of 
Cxcl10 protein expression was dependent both on the amount of time DNA complexes 
are present on the cell and the volume of supernatant added to the ELISA (Figure 
2.13B). Additionally, we showed that cell viability was higher in wells with no media 
change, in spite of the continued presence of ISD-transfection complexes. Cells 
stimulated without additional washing had nearly identical viability as unstimulated cells 
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Figure 2.13
Developing a cell-autonomous assay for selecting bioactive RNAi treated cells.  ELISA-based pro-
tein detection of Cxcl10. A) p53-/- MEFs treated with the indicated siRNAs were stimulated with 1.0ug/
mL ISD and 0.1ug/mL 3p-RNA for 26 hours. Cxcl10 protein was measured by ELISA. Data analysis was 
performed by converting the Abs 450 to the predicted Cxcl10 value in pg/mL based on a 4n-polynomial 
standard curve (inset). B) ISD complexes were incubated for the indicated time and supernatant volumes 
were diluted in 25ul increments. Sixty-fi ve ul of CellTiter-Glo was added to each ISD-stimulated well for 
10 minutes prior to analysis.
A
B
63
as detected by CellTiter-Glo. To generate a normalized value, we divided pg/mL of 
Cxcl10 by the number of cells per well, reported in relative luminescence units (RLUs). 
By normalizing CXCL10 protein expression to cell number, the ELISA/CellTiter-Glo 
combination is an effective and scalable screening tool with a high signal to background 
ratio that is sensitive to low levels of stimulation yet has large dynamic range. In the 
context of our screen, we developed a more precise mode of normalization. To more 
accurately predict the effect of siRNA on the ISD-pathway we seeded cells in a dilution 
curve of increasing cell numbers. Subsequent stimulation with ISD provides expected 
Cxcl10 expression for a given cell number.  In conjunction with cell viability 
measurements via CellTiter-Glo, we demonstrated that Cxc10 ELISA effectively captures 
ISD-sensing pathway responses. Furthermore, detection of proteins also provides a level 
of detection that mRNA expression cannot provide; nominally that mRNA does not 
represent the final gene product.  
 
2.5 – Genetic perturbation using RNA interference   
 With the identification of a model cell and type I Interferon-detection method, we 
considered two screening strategies; pooled genome-wide lentiviral shRNA and 
candidate-based siRNA screens (Figure 2.14).  
Genome-wide lentiviral shRNA-based screens 
Initial efforts focused on lentiviral-based shRNA pooled screens, developed in-
house at the Broad Institute[135, 136]. To enable arrayed RNAi screening in a broad range 
of cells, our laboratory, in collaboration with several others, founded the Broad Institute 
RNAi Consortium (TRC) in 2004. The goal of TRC was to generate a genome-wide RNAi 
library in a high-titer lentiviral vector that can stably infect most cell types and effectively 
knockdown gene expression. The library consists of >180,000 sequence-verified 
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Figure 2.14
Genetic perturbation using RNAi interference. Schematic of shRNA and siRNA screen workfl ow. Left, 
pooled shRNA screen: cells are infected with a pool of 15,000 shRNAs and separated into experimental 
and control populations. ShRNAs are amplifi ed from each population, cut to avoid hairpin structures, and 
fl uoresceinated. Custom microarrays are used to detect the enrichment of specifi c shRNAs in the experi-
mental vs. control population. Right, candidate siRNA screen: cells are transfected with siRNA pools tar-
geting 1003 genes and stimulated with ISD 72-hours following treatment. Cxcl10 response was detected 
by ELISA.
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lentiviral constructs targeting most human and mouse gene (TRC public portal: 
www.broad.mit.edu/genome_bio/trc/). There are at least five independent shRNAs per 
gene and producing high-titer virus that can infect a wide range of primary and 
immortalized cell lines. Knockdown efficiency of the entire shRNA library will be available 
to the public shortly. 
 Using a streamlined lentiviral vector, we can generate high-titer lentivirus 
particles for each library construct in a high-throughput fashion, and thus perform 
arrayed screens in 96 or 384-well plates, in which each well contains many virus 
particles targeting a single gene or pooled screens where each cell is infected with a 
single shRNA-containing virus. Using quantitative RT-PCR, we have demonstrated that 
90% of genes have ≥1 shRNA that knocks down mRNA levels by ≥70% in A549 cells[135].  
 Selecting a subset of the human lentiviral RNAi library targeting all human 
kinases and phosphatases, we performed a screen using automated fluorescence 
microscopy to identify genes that regulate mitosis as determined by DNA content and 
phospho-H3 staining. We were able to recover many of the known cell cycle regulators 
(such as CDC2, AURKB and PLK1) and identify new ones, thereby demonstrating the 
utility of the library in identifying critical genes in a cellular process.  
 A major concern with the use of RNAi in mammalian cells is off-target effect. To 
mitigate this problem, shRNAs were designed to have several mismatches to all known 
human or mouse cDNAs. As this does not eliminate the possibility of off-target effects 
with shorter stretches of identity, we also produced five distinct shRNAs targeting each 
gene and routinely require that screen hits have ≥2 constructs inducing the same 
phenotype. Because distinct shRNAs are expected to have non-overlapping off-target 
effects, this criterion is expected to filter out most off-target effects. 
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 Pooled screens are carried out by infecting a large population of cells with a 
single pool of lentiviral particles targeting thousands of genes, such that each cell is 
infected with a single virus targeting one gene. Cells are then selected with puromycin to 
eliminate uninfected cells. Finally, cells that exhibit the desired phenotype are isolated, 
and the identity of the shRNAs within those cells is determined using microarrays that 
contain probes for all library shRNAs (Figure 2.14).  
 To test the pooled screening approach, Luo et al[137] infected human Jurkat T 
cells with ~45,000 shRNAs in duplicate infections. One infected population was treated 
with FASL to kill cells through the FAS pathway. The other population was not treated.  
By this design, shRNAs that cause resistance to FASL were enriched in the treated 
population, and their target genes to be essential for the FAS killing pathway.  Next, DNA 
was isolated from the infected population, amplified the shRNAs, labeled with fluorescent 
nucleotides and hybridized to a custom Affymetrix array containing probes 
complementary to all the shRNAs in our library. When cells were treated with FASL for 
one week, a group of shRNAs was enriched in cells that were resistant to FASL 
compared to untreated cells.  shRNAs conferring FASL resistance were re-infected 
individually into Jurkat cells and were able to induce resistance to FASL similarly to the 
pooled screen results. Of the 14 genes identified with multiple targeting hairpins, several 
known genes were identified, including FAS, FAD and caspase 8.  Eleven additional 
genes were identified, four out of five of which showed correlation of phenotype and 
knockdown, suggesting that the hit shRNAs were acting through the intended target. The 
powerful capability of pooled library screening coupled with custom microarrays to detect 
enriched or depleted shRNAs enables rapid identification of essential genes, and makes 
it feasible to consider parallel genome-wide screens to test specific hypotheses and 
explore multiple experimental conditions. 
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 Compared to genome-wide arrays, pooled shRNA screens are ideal for rapidly 
finding a small number of robust hits and for conducting comparative screens across 
conditions and cell types. In contrast, arrayed screens are best for identifying many hits 
because of their high sensitivity, but are not suited to comparative screening due to their 
higher cost of reagents and labor. Initially, we proposed to use both approaches to 
dissect nucleic acid responses in order to isolate the most dramatic hits using pooled 
libraries but to test more deeply a high-value candidate set using arrayed screens. 
Arrayed candidate siRNA screens 
Using HBECs optimized for siRNA transfection (Figure 2.6), we demonstrated the 
efficacy of siRNA-based arrayed screens in a dissection of host-influenza 
interactions[134]. In this screen, 1745 candidate genes identified through physical 
interactions, transcriptional responses and associated pathways were interrogated for a 
role in influenza infection regulation. To assess the functional contribution of the 
candidate genes on viral replication and type I IFN production, three functional assays 
were used to measure the effect following genetic perturbation with siRNA pools. First, 
siRNA-transfected primary HBECs were infected with PR8 virus and virus production 
was measured after 48 hours using a cellular reporter system that is analogous to 
conventional plaque assays. Additionally, a reporter cell line detecting IFN-β was used to 
detect changes in siRNA-transfected HBECs in response to either ΔNS1 virus infection 
or viral RNA transfection. The resulting data point to potential roles for some 
unanticipated host and viral proteins in viral infection and the host response, including a 
network of RNA binding proteins, components of WNT signaling and viral polymerase 
subunits. 
 The success of our host-influenza interaction screen, coupled with our difficulty in 
generation an effective reporter cell and inherent genome-wide screening costs, 
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influenced our decision to continue with a candidate-based siRNA screen. The candidate 
list of ~800 genes of both experimentally derived and hypothesis-based candidates 
discussed are discussed in detail in Chapter 3.   
 
2.6 – Screening Strategy 
The final phase of screening development was divided into two parts: siRNA 
transfection optimization and ISD stimulation. For the transfection of siRNAs we 
considered siRNA concentration, multiple transfection reagents, transfection application 
methods (forward vs. reverse transfection methods) and siRNA-to-transfection reagent 
ratio. Additionally, we tested cell seeding density, media/serum concentration conditions, 
time to optimal knockdown of a panel of positive, negative, and transfection control 
siRNAs. Secondly, in the context of our siRNA screens we reevaluated ISD transfection 
conditions including ligand concentration and time of supernatant collection. 
Furthermore, with the goal of reducing edge effects associated with long-term incubation 
of tissue culture microplates, we considered plate layout design and investigated outer 
well contents and incubator plate stacking variables.  Finally, we tested experimental 
workflow by testing a combination of robotic versus by-hand setups and assessed our 
screening performance using the Z-factor scoring method[138].  
Optimization of siRNA conditions 
First, we sought out to optimize siRNA transfection conditions in p53-/- MEFs. 
MEFs were transfected with increasing concentrations of a non-targeting control and Irf3 
siRNAs (10-50nM) then stimulated with ISD 72-hours following treatment (Figure 2.15A). 
Cxl10 protein expression reduction correlated with Irf3 knockdown efficiency at an 
optimal 25nM concentration (>12-fold CXCL10 reduction compared to ISD and >60% Irf3 
knockdown, p-value <0.001, Studentʼs t-test). We compared a large panel of transfection 
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Figure 2.15
Optimization of siRNA conditions in p53-/- MEFs: siRNA transfection conditions. A-B) Cxcl10 protein 
expression was measured by ELISA 72-hours following siRNA transfection and 6-hours after ISD stimu-
lation across a range of indicated siRNA concentrations. Reduction in IRF3 expression was measured 
by quantitative RT-PCR. siRNA complexes were generated with the indicated transfection reagents 
and stimulated with ISD 72-hours following treatment. p53-/- MEFs that constitutively express GFP were 
treated with transfection complexes added to cells as they were being seeded (Forward) or 24-hours 
following seeding (Reverse) (C) or with the indication volume (in ul) of transfection reagent per well (D). 
GFP expression was detected by quantitative RT-PCR. A matrix of the indicated siRNA transfection 
reagent volume and siRNA concentration were assessed by RT-qPCR (E) and by automated microplate 
cytometry plotted as a ratio GFP mean fl uorescent intensity to Hoecsht mean intensity for the indicated 
conditions (F). G) Fluorescent microscopy images of optimal knockdown conditions.
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reagents (DharmFECT1-4 (Dharamcon), Lipofectamine LTX, Lipofectamine 2000 and 
Lipofectamine RNAiMAX (Invitrogen), and HiPerfect, Attractene and Effectene (Qiagen) 
transfection reagents) (data not shown) and demonstrated that one reagent 
(Lipofectamine LTX) resulted in the largest fold-change reduction of Cxcl10 response 
(>12-fold) and knockdown efficiency (>60% IRF3 relative to non-targeting control) 
(Figure 2.15B). 
To better demonstrate siRNA transfection conditions, we generated p53-/- MEFs 
that constitutively expressed GFP and compared independent GFP-targeting siRNAs 
across a number of conditions (Figure 2.15C-D,F-G). To optimize the order in which 
transfection occurred we initiated knockdown in p53-/- MEFs at the same time as cell 
seeding (Forward) or 24-hours after cells were seeded (Reverse) (Figure 2.15C). GFP 
expression was reduced three-times more in reverse-transfected cells than in forward-
transfected cells compared to non-targeting control (p-value <0.001, Studentʼs t-test). 
Additionally, we determined that transfection reagent volume was inversely correlated 
with knockdown (Figure 2.15D). We observed, however, increased cell death with 
increased transfection reagent volume. In an effort to find the ideal ratio of siRNA 
concentration with transfection reagent, we tested a matrix of Irf3-knockdown conditions 
and determined that 0.4ul of transfection reagent per well in conjunction with 25uM of 
siRNA reduced Irf3 expression greater than other conditions and with the least effect on 
cell viability (Figure 2.15E). As independent confirmation, we tested a matrix of 
knockdown conditions and assessed knockdown efficiency by microplate fluorescent 
cytometry and normalized GFP mean fluorescent intensity to Hoecsht mean intensity 
(Figure 2.15 F-G). We identified a condition (0.4ul RNAiMAX per well, with 25nM siRNA) 
that reproducibly maximized knockdown efficiency and reduced siRNA-induced toxicity, 
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resulting in more than 20-fold reduction of GFP expression in siGFP treated cells 
compared to non-targeting control (p-value <0.0001, Studentʼs t-test). 
 Lastly, we considered cell-seeding density, serum percentage in media and 
optimal time to knockdown (Figure 2.16). Additionally, we tested a panel of positive and 
negative siRNA controls to demonstrate the optimal knockdown condition following 
stimulation with ISD. First, p53-/- MEFs were seeded at 500 or 1000 cells per well in 
100ul of media and transfected with control siRNAs 24-hours later. Cells seeded at a 
lower density had a greater fold change of Cxcl10 protein expression of non-targeting to 
Irf3 treated wells possibly due to the fact the siRNA transfection was more efficient at 
lower cell density (>6-fold reduction compared to <3-fold reduction, p-value <0.0001, 
Studentʼs t-test) (Figure 2.16A). Transfection complexes are formed in serum-free media 
and allowed to form for 15-minutes prior to addition to cells. We demonstrated that 
dilution of culture media with serum-free media improved fold-change responses in non-
target to Irf3 and Tbk1-knockdown wells (26-fold difference in media diluted 50 percent 
compared to 9-fold in undiluted media, p-value <0.0001, two-way ANOVA) (Figure 
2.16B). Over a course of four-days following siRNA transfection, we assessed 
knockdown efficiency in the context of ISD stimulation (Figure 2.16C) and expression of 
a panel of control genes (Figure 2.16D). First we compared fold-reduction of Cxcl10 in 
response to ISD following 48 or 72-hours of transfection with siRNAs targeting Irf3, Tbk1 
and Rig-I and noted improved reduction at 72-hours in Irf3 and Tbk1 treated cells. 
Furthermore, we analyzed expression of eight control genes (Aim2, Dai, Ikke, Mavs, Irf3, 
Irf7, Rig-i and Tbk1). Cells transfected with siRNAs for 72-hours consistently showed the 
greatest reduction in gene expression as measured by quantitative RT-PCR. Lastly, in a 
test of screening conditions, p53-/- MEFs were transfected with control panel siRNAs 
and stimulated with ISD 72-hours following RNAi treatment (Figure 2.16E). Cxcl10 
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Figure 2.16
Optimization of siRNA conditions in p53-/- MEFs: Cell culture conditions effect knockdown ef-
fi ciency. Control gene panel validation. A) MEFs were seeded with the indicated number of cells per 
well in 96-well plates, transfected with siRNAs for 72-hours and then stimulated with ISD for 26-hours. 
Cxcl10 expression was measured by ELISA. B) Cell culture media was diluted with Opti-MEM serum-
free media to decrease the percent FBS during transfection of siRNAs. Cells were stimulated with ISD 
for 26-hours and Cxcl10 response was measured by ELISA. C) p53-/- MEFs were transfected with the 
indicated siRNAs for 48 or 72-hours, then stimulated with ISD for 26-hours. Fold reduction in Cxcl10 ex-
pression was determined by ELISA and compared to non-targeting control response to ISD. D) A panel of 
siRNAs targeting known nucleic acid sensing components. Lysates were collected following transfection 
for the indicated times. Gene expression was detected by quantitative RT-PCR. E) Control panel siRNAs 
were transfected for 72-hours and stimulated with ISD for 26-hours. Cxcl10 response was measure by 
ELISA.
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expression was reduced by >50-fold in Irf3 treated MEFs compared to non-targeting 
controls (p-value <0.001, Studentʼs t-test). 
Optimization of ISD stimulation conditions 
Following the optimization of siRNA conditions, we revisited ISD transfection 
variables to validate stimulation conditions in the context of our RNAi system. Following 
knockdown with non-targeting and Irf3 siRNAs, cells were stimulated with a range of ISD 
from 0 to 1.5ug/mL. We demonstrated maximal fold change of Cxcl10 between non-
targeting and Irf3 treated was at 1ug/mL ISD (>13-fold reduction, p-value <0.001, 
Studentʼs t-test) (Figure 2.17A). Furthermore, increased ISD stimulation time correlated 
with increased Cxcl10 expression in non-targeting control treated cells (Figure 2.17B). 
Over a time course with 3-hour increments beginning at 12-hours, Cxcl10 expression 
increased up to a point of saturation (>30-hours, data not shown). Furthermore, fold 
reduction in Cxcl10 expression increased with longer incubation time.  
 We determined that by adding media to the outer wells our sample plates and 
stacking PBS filled plates on the top and bottom of each stack we significantly reduced 
edge effect. Finally, we tested experimental setup by testing a combination of robotic 
versus by-hand setups. Plate-to-plate variation was further reduced with the inclusion of 
these methods (data not shown). 
Assay workflow 
In brief, the final assay workflow is described below (Figure 2.18): 
• Day 0 - Seed 750 cells/well (96-well plate) by hand in 60% DMEM in 
D10/OptiMEM (60ul DMEM with 10%FBS w/out Pen/Strep plus 40ul OptiMEM), 
entire plate is seeded, outer wells are supplemented with an additional 130ul of 
media for a final volume of 230ul for outer wells.  In the incubator, three plates 
are sandwiched between PBS filled plates. 
76
Figure 2.17
ISD stimulation following siRNA knockdown A) Following siRNA treatment, p53-/- MEFs were stimu-
lated with the indicated amounts of ISD for 26-hours. Cxcl10 expression was detected by ELISA. B) Cells 
were stimulated with ISD for the indicated times following transfection with non-targeting control or Irf3 
siRNAs. Supernatants were collected following stimulation, frozen and then assayed for Cxcl10 protein 
expression by ELISA. 
B
A
77
Figure 2.18
Assay workfl ow.  750 p53-/- MEFs per well were seeded in 96-well plates in 60% DMEM and 40% Opti-
MEM.  Each plate included three non-targeting controls (ASN, Dharmacon All-star negative control), two 
Irf3 positive controls, an siDeath control and a buffer control. Outer edges were seeded with cells and 
supplements with an additional 130ul of media (total volume  230ul) but not transfected with siRNAs. 25 
nM siRNA was complexed with 0.5 uL Lipofectamine RNAiMax (Life Technologies) in Opti-MEM, incubat-
ed for 12 min at 22°C, and added to the wells. 72-hours later, cells were transfected with  1ug/mL of ISD. 
26-hours following stimulation, supernatants were collected and Cxcl10 was quantifi ed by ELISA. Cell 
viability was estimated by the CellTiter-Glo Luminescent Cell Viability Assay (Promega).
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Seed 750 cells/well
Day 1 -
25nM siRNA are transfected in triplicate
Day 4 -
1ug/mL ISD transfection and stimulated 
for 26-hours
Day 5 -
Supernatants are collected. 40ul of CTG 
added to each well. CXCL10 ELISA per-
formed for supernatants.
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Figure 2.18 (continued)
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• Day 1 - Transfect siRNAs in triplicate. 25nM final in 20ul OptiMEM with 0.5 ul 
RNAiMAX.  Complexes are formed for 12 minutes at room temperature then 
slowly added drop-wise to each well, 10 wells at a time by hand. 
• Day 4 - 72-hours post siRNA transfection, change media, add ISD transfection 
complexes at 1ug/mL final in 20ul OptiMEM with 0.36 ul Lipofectamine LTX.  
Transfection complexes are formed for 30 minutes at room temperature and then 
slowly added drop-wise to each well, 10-wells at a time by hand. 
• Day 5 - 26-hours post ISD transfection, collect and freeze supernatants. Add 40ul 
CellTiter-Glo, cover and incubate for 8-10 minutes. Read on EnVision plate 
reader. 
• Day 6 - Pre-Elisa. From pre-selected control wells, determine optimal 
supernatant volumes to prevent saturation of luminescent signal. 
• Day 7 – Perform CXCL10 ELISA using calculated supernatant volumes.  
Screening performance assessment 
To assess screening performance we used the Z-factor scoring method[138]. The 
Z-factor reflects both the dynamic range of the assay and the data variation associated 
with the signal measurements, in this case, the variation of the siRNA treatment, tissue 
culture, media changes, etc., and is a critical quality assessment of the screening 
fitness. The closer the Zʼ calculation approaches 1, the more robust the assay. To 
perform this test, we transfected one half of a test plate with a non-targeting control 
(Qiagen All-Star Negative) and the second half with siRNAs against IRF3 (Dharamcon 
On-Target-Plus (OTP) Smart Pools) (n=60), (Figure 2.19). Prior to stimulation media was 
replaced in half of the wells 72-hours following siRNA treatment (n=30). We considered 
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Figure 2.19
Z-factor test of control siRNAs confi rms a robust screening method. p53-/- MEFs were transfected 
with the indicated siRNAs and then stimulated with ISD as described previously. Z-factor for pilot tests 
comparing no media change, media change or whole-plate analysis. N=30/sample x 3 replicates. P-value 
<0.0001, Student’s t-test.
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media change prior to stimulation to eliminate well-to-well difference caused by 
evaporation during the siRNA-treatment phase. 
Following the workflow described above, cells were then stimulated with 1ug/mL 
for 26-hours. A range of supernatants was tested from positive and negative control 
samples to determine the appropriate supernatant volume to screen the samples with. 
Cxcl10 values were normalized to CellTiter-Glo values. The screen performance score, 
Z=1-(3xSDneg+3SDpos)/abs(meanneg-meanpos), was calculated for each condition and for 
the entire plate. The Z-scores for each condition (no media change, media change and 
whole plate) were 0.775, 0.836, and 0.802, respectively, each representing a 20-fold 
reduction in Cxcl10 expression in IRF3-treated samples compared to non-targeting 
control (p-value <0.0001, Studentʼs t-test).  
 
2.7 – Conclusion 
We developed a robust and repeatable high-throughput loss-of-function 
screening tool to aid in the dissection and identification of novel ISD-sensing pathway 
components. In the process of development we assessed multiple nucleic acid DNA and 
RNA ligands, investigated the ISD response in multiple human and murine primary and 
established cells lines, tested multiple type I IFN reporter systems and considered 
multiple genetic perturbation techniques. Our siRNA-based screening system will be 
used to interrogate the function of 1003 candidate genes discussed in the following 
chapters. 
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Chapter 3:  
Generation of a Candidate Gene Set by Curation and Quantitative Proteomics 
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3.1 – Introduction: candidate gene selection 
Following the completion of an siRNA-based screening strategy, we set out to 
generate a set of candidate genes from genomic, proteomic, and domain-based studies 
that we hypothesized contain unidentified ISD-sensing pathway components. We 
selected 1003 ISD-sensing pathway candidates using the following criteria. First, we 
used previously published array data and our own gene expression experiments to 
select genes regulated in response to IFN-β or DNA. Second, we conducted SILAC-
based mass spectrometry experiments using ISD as bait in IFN-β stimulated cells. Third, 
because of the well-established role of helicases in nucleic acid sensing, we 
hypothesized that any annotated helicase could have a potential role in dsDNA sensing 
and included all available helicases as candidates. Fourth, in addition to nucleases, we 
identified genes that had known DNA binding properties and were putatively localized to 
the cytoplasm based on established localization and published predictive algorithms. 
Lastly, we focused on annotated phosphatases and deubiquitinases as part of our pilot 
screen to identify potential negative regulators of the ISD pathway. We supplemented 
the annotated phosphatases and deubiquitinases with putative negative regulators of the 
RIG-I pathway identified in our recent dissection of host-influenza interactions[134]. Our 
final candidate selection integrates genes from genomic, proteomic and domain-based 
data sets that we hypothesized contain unidentified ISD-sending pathway components 
(Figure 3.1).  
 
3.2 – Candidate gene selection: interferon-regulated, DNA-stimulated genes from 
published arrays 
First we selected 355 DNA- and interferon-stimulated genes (ISGs) from existing 
microarray datasets based on the hypothesis that a subset of components of this 
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Figure 3.1
Generation of a candidate gene set by curation and quantitative proteomics.  Sources of the 1003 
ISD-sensing pathway candidates from genomic, proteomic and domain-based datasets.
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pathway is feedback-regulated (Table 3.1)[43, 44, 48]. For example, in an expression-based 
screen of a mouse carcinoma cDNA library reporting IFN-β, TRIM56 was identified as an 
interferon-inducible regulator of the dsDNA-mediated type I IFN response[139]. TRIM56 
interacts with STING, promoting STING ubiquitination and subsequent TBK1 recruitment 
and type I IFN induction. Additionally, biotinylated dsDNA 70-mers derived from Vaccinia 
virus were used to affinity purify DNA-binding proteins from cytosolic extracts of THP-1 
human monocytes[65]. Among the proteins identified was the AIM2-like IFI16. Recent 
studies ascribe a role of IFI16 in the direct association with viral DNA upon stimulation, 
driving recruitment of STING and subsequent IFN induction. 
  We cross-referenced data from three independent microarrays and selected the 
strongest hits among them. Genes with available siRNA pools were included as 
candidates. First, we surveyed arrays from a screen to identify genes that were 
transcriptionally regulated by IFN-β[48]. NIH3T3 and L929 cells were stimulated for four 
hours with recombinant IFN-β, RNA was isolated and global changes in gene expression 
were analyzed by microarray analysis. We selected 225 genes with greater than 3.9-fold 
upregulation after IFN-β stimulation of NIH3T3 cells, and greater than 6.25-fold 
upregulation after IFN-β stimulation of L929 cells (Gene Expression Omnibus database: 
submission #GSE14413), including many well-known interferon-induced genes.  
 In a seminal report providing a dissection of the DNA signaling pathway, MEFs 
from wild-type, Tbk1-/-, Ikki-/- and Tbk1-/-/Ikki-/- mice were stimulated with Poly (dA:dT) for 
four hours and expression profiles were determined by microarray[43]. DNA included the 
upregulation of many interferon-inducible antiviral genes in a mostly Tbk1-dependent 
manner. Amongst the wild-type stimulated cells, we selected 196 genes with greater 6.1-
fold upregulation after poly(dA-dT)–poly(dT-dA) stimulation (Gene Expression Omnibus 
database: submission #GDS1773). Additionally, in a comparison of the ISD pathway to 
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Table 3.1
Candidate Gene List: Published Array Curation
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the CpG/TLR9-dependent response, classical Dendritic Cells (cDCs) were stimulated 
with ISD or CpG[44]. Four hours following stimulation, microarray analysis was performed 
to identify the gene-expression programs activated with each response. As a further 
confirmation of DNA-directed antiviral response, only ISD specifically induced type I 
IFNs. Amongst these, we selected 124 genes with greater than 5.1-fold increases 
relative to unstimulated cells (Gene Expression Omnibus database: submission # 
GSE2197). The resulting list of 355 candidate genes represents the intersection of 
genes upregulated following stimulation with IFN-β (in NIH3T3 and L929 cells) or dsDNA 
(B6 MEFs and cDCs) and includes many uncharacterized ISGs. 
 
3.3 – Candidate gene selection: DNA SILAC  
 Next, we selected an additional 156 candidates from our own mass 
spectrometry-based list of putative STING-interacting proteins[140]. To directly identify 
DNA sensors and their binding partners, we used biotinylated DNA to pull down cytosolic 
binding partners through comparative proteomic screens with stable isotope labeling by 
amino acids in cell culture (SILAC). SILAC, a method developed by a scientist at the 
Broad Proteomics Platform, relies on the incorporation of amino acids with substituted 
stable isotopic nuclei[141, 142]. We utilized this three-state SILAC method to label and 
quantitate peptides via mass spectrometry, with medium isotope-labeled cells used for a 
negative control (beads alone), light isotope-labeled cells for bead-DNA precipitation, 
and heavy isotope-labeled cells for bead-DNA precipitation preceded by IFN-β 
stimulation to upregulate pathway components (Figure 3.2A).  
 We identified 184 proteins with SILAC ratios that showed enrichment for DNA 
binding following mass spectrometry (Figure 3.2B). Among the 184 identified proteins, 
121 (64.2%) were classified by Gene Ontology as having nucleic acid binding function (P 
90
Figure 3.2
Quantitative mass spectrometry identifi es known components of the ISD sensing pathway. A) 
Schematic of DNA-interacting SILAC experiments. MEFs were labeled with light (L)-, medium (M)-, or 
heavy (H)-isotope SILAC solutions. Cells were pre-treated with Ifnβ or left unstimulated. Cytoplasmic 
extracts were prepared and incubated with or without biotinylated ISD. ISD was precipitated with strepta-
vidin beads, and precipitated proteins were trypsinized and subjected to mass spectrometry. B) Quantita-
tive mass spectrometry analysis showing DNA-binding proteins precipitated from cytoplasmic extracts of 
MEFs; proteins were precipitated with biotinylated DNA immobilized on streptavidin beads with strepta-
vidin beads alone used as a negative control. DNA-interacting proteins with colors signify corresponding 
to pathways; white (all signifi cant proteins) red (Aim2 infl ammasome), purple (proteins encoded by genes 
mutated in AGS), blue (RNA polymerase III complex), green (HMGB proteins) and orange (SET complex) 
circles, DNA-interacting proteins with colors corresponding to pathways in c; yellow dots, nonsignifi cant 
precipitated proteins; A, abundance; H, M and L, isotope-labeled samples. Ratio of DNA-binding (DNA 
pull-down, +Ifnβ; AH) to bead-binding (empty bead pull-down, +Ifnβ; AM) per protein on the x axis is 
plotted against ratio of DNA binding with Ifnβ prestimulation (DNA pull-down, +Ifnβ; AH) to DNA binding 
without Ifnβ prestimulation (DNA pull-down, –Ifnβ; AL) per protein on the y axis. Full SILAC results, inset, 
lower right.
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Figure 3.2 (continued)
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= 5.95x10-58; GO:0003676), and others were components of known DNA-binding 
complexes (Table 3.2).  
Of the identified proteins, 20 (10.9%) represent the majority of known players 
involved in the immune sensing of cytosolic DNA. We identified known components of 
DNA sensing pathways including: the HMGB family proteins (HMGB1, HMGB2, 
HMGB3)[143], components of the AIM2 inflammasome (IFI202B and the HMGB 
proteins)[49, 143], and the cytosolic RNA polymerase III complex (POLR3A, POLR3B, 
POLR3C, POLR3D, POLR3E, POLR3F, POLR3G, POLR3H, POLR1C, POLR1D, 
POLR2E, POLR2H, and CRCP). Additionally, we identified three members of the SET 
complex (TREX1, APEX1, and HMGB2) that regulate the ISD pathway as well as HIV-1 
detection and infection[104, 106, 143, 144]. We also identified associated proteins responsible 
for the autoimmune disease, Aicardi-Goutières syndrome (SAMHD1 and TREX1)[100, 145], 
which are involved in regulating retroviral and retroelement detection[104, 146]. Our findings 
validate the utility of quantitative mass spectrometry as an approach to find candidate 
components of cytosolic DNA sensing pathways. Of the 184 identified protein SILAC 
candidates, we found 156 matching siRNAs for inclusion in our arrayed screen.  
 
3.4 – Candidate gene selection: helicases  
The role of helicases in nucleic acid sensing is well established[29, 68, 71, 73, 147, 148]. 
The discovery that TLR3 and TLR7 deficient animals are able to produce type I IFN in 
response to RNA virus infection led to investigations to find TLR-independent 
mechanisms of viral-RNA mediated immune signaling, the RIG-I-like receptor family of 
helicases (RLRs)[2, 149, 150]. A key finding was the identification of three DExD/H box RNA 
helicases, retinoic acid-inducible gene-I (RIG-I), melanoma differentiation-associated 
gene 5 (MDA5), and LGP2, instrumental in mediating viral responses[29]. RIG-I and 
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MDA5 helicases drive production of type I IFNs in all cell types in response to RNA virus 
infection, with the exception of TLR7 dependent pDCs[29, 32, 151]. LGP2 functions both as a 
negative regulator of the RIG-I/MDA5 pathway[152] and, more recently, as a possible co-
receptor for some RIG-I and MDA5 ligands[33]. Additionally, the DExD/H box RNA 
helicase family member DDX3 was identified as another RLR[147, 148, 153]. It was reported 
that DDX3 binds both to transfected Poly I:C and viral RNA and associates with MAVS to 
induce type I IFN production. DDX3 has also been implicated in sensing cytomegalovirus 
whereby phosphorylated DDX3 binds to the IFN-β promoter following CMV infection[154].  
 The aspartate-glutamate-alanine-histidine box (DEAH)/RNA helicases DHX36 
and DHX9 were recently identified as specific sensors for CpG-A and CpG-B, 
respectively[68]. In pDCs treated with CpG, DHX36 and DHX9 are localized in the cytosol 
and bind to Toll-IL receptor (TIR) domain of myeloid differentiation primary response 
gene 88 (MyD88) leading to activation of IRF7 and NF-κB. Subsequently, DHX36 was 
identified as TLR3/MDA5-independent sensor of Poly I:C, that, in a complex with DDX1 
and DDX21, pairs with the adaptor TRIF to trigger type I IFN responses[71]. Furthermore, 
DHX9 was found to pair with MAVS to sense dsRNA in myeloid dendritic cells (MDCs).  
Additionally, the helicase DDX41 was identified as an intracellular DNA sensor in 
MDCs[73]. In a focused shRNA screen targeting 59 members of the DExD/H-box helicase 
family, DDX41 knockdown led to impaired type I IFN and pro-inflammatory cytokine 
production in response to various dsDNA stimuli. Co-immunoprecipitation experiments 
suggest interaction of DDX41 and STING in resting and stimulatory conditions. We 
therefore generated a comprehensive list of helicases via the PANTHER classification 
system (Table 3.3)[155-157]. We identified 174 proteins with known or predicted RNA and 
DNA helicase activity, 118 of which were present in the siRNA library.  
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3.5 – Candidate gene selection: cytoplasmic DNA-binding proteins  
In an extension of our hypothesis that any of the annotated nucleases could have 
a role in dsDNA sensing we subsequently curated a list of proteins that had known DNA 
binding properties and were putatively localized to the cytoplasm. First, 842 nucleic-acid 
binding proteins were identified with the PANTHER classification system, 174 of which 
were the previously described helicases. The balance of the list included 25 ssDNA 
binding proteins, 197 nucleases, 30 dsDNA binding proteins, 321 proteins with other 
DNA binding designations and 108 proteins with uncharacterized nucleic acid binding 
properties. To assess protein localization, we first cross-referenced our list with 
annotated databases and secondly, assessed localization with published predictive 
algorithms. We utilized three annotated databases that provide curated cellular 
localization data, UniPROT, LOCATE and TFCat. LOCATE is a database that houses 
data describing the membrane organization and subcellular localization of proteins 
derived from a genome-wide mouse proteome study[158, 159]. TFCat is a curated catalog 
of mouse and human transcription factors (TF) based on a core collection of annotations 
obtained by review of the scientific literature[160]. Annotated genes are assigned to a 
functional category and confidence level. Together, the databases indicated cytoplasmic 
location data for 17% of the identified nucleic acid binding proteins. 
 To complement the curated database, we assessed cellular location utilizing two 
protein subcellular localization prediction algorithms, CELLO and WoLF PSORT[161-163]. 
CELLO, or Subcellular Localization, utilizes a supervised learning model, or support 
vector machine (SVM)-based classification system. CELLO uses four types of sequence 
coding schemes: amino acid composition, dipeptide composition, partitioned amino acid 
composition and the sequence composition based on the physicochemical properties of 
amino acids.  Combined votes from these classifiers and SVM-jury votes are used to 
98
determine the final assignment. Alternatively, WoLF PSORT converts protein amino acid 
sequences into numerical localization features based on sorting signals, amino acid 
composition and functional motifs such as DNA-binding motifs. After conversion, the k-
nearest neighbor algorithm, a pattern-recognition method for classifying objects based 
on closest training examples, is applied to make predictions.  
 We assessed the utility of the protein prediction methods and annotated 
databases by selecting 20 proteins with known subcellular localization, 15 of which are 
cytosolic (Table 3.4). While the annotated databases agreed with the known prediction 
more than 90 percent of the time, the protein localization algorithm methods predicted 
the correct cellular compartment as one of the top two cellular compartments roughly 55 
percent of the time. In addition to the 78 proteins identified through the annotated 
databases, we added another 25 proteins based on a composite score of the prediction 
algorithms (Table 3.5). First, proteins that were predicted to be cytoplasmic by both 
localization predictions were included. Second, we added proteins that were predicted 
with high confidence by one algorithm as the most likely cytoplasmically localized 
(greater than 60% confidence) and proteins for which cytoplasmic localization was the 
second predicted compartment. The resulting list of 103 proteins includes candidates 
with annotated or predicted cellular localization available in the siRNA library. 
 
3.6 – Candidate gene selection: putative negative regulators and signaling molecules 
 Finally, we added annotated phosphatases and deubiquitinases as part of a pilot 
screen to identify potential regulators of the ISD pathway. Activation of signaling 
molecules critical to the ISD pathway requires phosphorylation and ubiquitination[60, 139, 
164]. For example, TBK1, directly phosphorylates IRF3, and thus mice deficient in Tbk1 
failed to induce type I IFN following stimulation with Poly (dA:dT)[43]. The E3 ubiquitin 
99
Table 3.4
Cytoplasmic protein prediction matrix. Subcellular localization prediction algorithms (CELLO and 
W_PSORT) are assessed on the indicated genes along with annotated localization data from UniProt and 
LOCATE databases. The top two cellular compartments are presented for each prediction tool. CELLO 
values represent the composite prediction fraction of fi ve possible compartments. Wolf PSORT values 
roughly indicate the number of nearest neighbors to the query that localize to each site, adjusted to ac-
count for the possibility of dual localization. Green boxes agree with known protein localizations. Predic-
tive accuracy is presented as percentage. Cytoplasm = cyt. Nucleus = nuc. Mitochondria outer membrane 
= mit out mem. Endoplasmic reticulum = ER. Nuclear envelope = nuc env. Plasma membrane = plasm. 
Extracellular = extr.
gene_name gene_id actual UniProt LOCATE CELLO1 CELLO2 W_PSORT1 W_PSORT2 
ddx58 230073 cyt cyt cyt cyt:2.448 nuc:1.985 cyt:24 nuc:3 
ifih1 71586 cyt cyt. Nuc. cyt nuc:3.355 nuc:1.089 cyt:25.5 cyt_nucl:13.5 
Trim25 217069 cyt - nuc:2.385 extr:1.416 nucl:29.5 cyt_nucl:16.5 
TBK1 56480 cyt cyt cyt:2.860 nuc:1.064 cyt:18 cyt_nucl:12 
IKBKE 56489 cyt cyt cyt nuc:2.144 cyt:1.484 nucl:19 cyto_nucl:17 
ticam1 106759 cyt - nuc:3.662 plasm:0.659 nucl:15 cyto:9.5 
MyD88 17874 cyt cyt cyt nuc:2.604 cyt:0.841 cyto:14 mito:10 
Nod1 107607 cyt cyt cyt nuc:2.002 extr:1.218 cyto_nucl:10 nucl:9.5 
Nod2 257632 cyt cyt cyt plasm:1.703 extr:1.084 cyto_nucl:10.2 cyto:10 
nlrp3 216799 cyt cyt cyt nuc:2.329 extr:1.463 cyto_nucl:10.8 nucl:10.5 
mavs 228607 mit out mem mit out mem nucl:3.373 extr:0.647 extr:7.5 extr_plas:6.5 
gapdh 14433 cyt cyt cyt cyt:3.993 mito:0.418 cyto:16.5 mito:13 
trex1 22040 cyt nuc er, nuc env nucl:2.742 extr:1.667 cyto:8 extr:7.5 
zbp1 58203 cyt - cyt nuc:3.961 cyt:0.732 cysk:15 nucl:15 
aim2 383619 cyt nuc cyt:2.009 nucl:1.958 cyto:15 nucl:14 
ifi204 15951 nuc nuc. Cyto nucleolus nuc:3.230 mit:0.713 cyto_nucl:16 nucl:15 
ifi205 226695 nuc nuc nucl:4.192 cyt:0.372 nucl:21 cyto:8 
rela 19697 cyt. Nuc. nuc. Cyto. nuc:4.610 plasm:0.124 nucl:28 cyto_nucl:18 
myc 17869 nuc nuc nucleus nuc:4.826 cyt:0.103 nucl:32 - 
smarcb1 20587 nuc nuc nucl, cyt nuc:2.952 cyt:0.747 cyt:18 cyt_nucl:15 
93.75% 100% 55.00% 60.00% 
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Table 3.5
Candidate Gene List: Cytoplasmic proteins
Gene GeneID Accession Candidate List CELLO Organelle CELLO Rank Wolfpsort Organelle Wolfpsort Rank
0610010I17RIK 66847 NM_025798 Cytoplasmic - Uniprot nuc 2.67 nucl 32
1700051E09RIK 67338 NM_026097 Cytoplasmic - Uniprot nuc 4.77 nucl 32
2310005K03RIK 69537 NM_027109 Cytoplasmic - Predicted extra 1.93 cyto 20
2410006F12RIK 71957 NM_028020 Cytoplasmic - Uniprot nuc 2.94 nucl 19.5
2810028N01RIK 72662 XM_127907 Cytoplasmic - Uniprot cytop 2.50 cyto 13
4930517K23RIK 403171 NM_207275 Cytoplasmic - Uniprot extra 2.66 cyto_nucl 12.5
4932442K20RIK 231464 NM_144910 Cytoplasmic - Uniprot cytop 1.99 nucl 29.5
4933406L09RIK 74430 NM_028934 Cytoplasmic - Locate nuc 3.89 nucl 32
5830483C08RIK 209334 NM_177331 Cytoplasmic - Predicted nuc 4.00 cyto 21.5
A230103N10RIK 104625 NM_212484 Cytoplasmic - Uniprot cytop 1.65 nucl 22
ANG4 219033 NM_177544 Cytoplasmic - Predicted cytop 3.18 cyto 22.5
ANKRD3 72388 NM_023663 Cytoplasmic - Uniprot TFCat
ARC 11838 NM_018790 Cytoplasmic - Uniprot TFCat
BAT2 53761 NM_020027 Cytoplasmic - Uniprot nuc 3.79 cyto_nucl 18
BC034753 234258 NM_146208 Cytoplasmic - Predicted nuc 4.85 cyto 26
BC052360 231999 NM_001001335 Cytoplasmic - Uniprot
BIN1 30948 NM_009668 Cytoplasmic - Uniprot TFCat
BZW1 66882 NM_025824 Cytoplasmic - Predicted cytop 3.39 nucl 13.5
BZW2 66912 NM_025840 Cytoplasmic - Predicted cytop 2.95 nucl 32
CDC5L 71702 NM_152810 Cytoplasmic - Uniprot TFCat
CSDA 56449 NM_011733 Cytoplasmic - Uniprot TFCat
D11ERTD497E 52626 NM_029976 Cytoplasmic - Predicted cytop 2.47 nucl 32
D630024B06RIK 218973 NM_172598 Cytoplasmic - Predicted nuc 4.01 cyto 19
D7WSU87E 360216 NM_207302 Cytoplasmic - Uniprot nuc 4.37 nucl 23
DFFB 13368 NM_007859 Cytoplasmic - Uniprot nuc 2.63 nucl 25.5
DPF2 19708 NM_011262 Cytoplasmic - Uniprot TFCat
DSIP1 14605 NM_010286 Cytoplasmic - Locate TFCat
EAR1 13586 NM_007894 Cytoplasmic - Uniprot nuc 4.71 nucl 31
EAR2 13587 NM_007895 Cytoplasmic - Uniprot extra 4.08 cyto 17.5
EAR3 53876 NM_017388 Cytoplasmic - Predicted extra 4.05 cyto_nucl 18.8
EAR4 53877 NM_017389 Cytoplasmic - Uniprot nuc 4.28 nucl 31.5
ENDOG 13804 NM_007931 Cytoplasmic - Predicted nuc 4.42 cyto 25.5
EPS15 13858 NM_007943 Cytoplasmic - Uniprot TFCat
ERCC1 13870 NM_007948 Cytoplasmic - Locate plas 2.74 nucl 32
EXOSC2 227715 NM_144886 Cytoplasmic - Uniprot cytop 1.73 cyto 21.5
EXOSC3 66362 NM_025513 Cytoplasmic - Uniprot cytop 1.94 nucl 29.5
EXOSC4 109075 NM_175399 Cytoplasmic - Uniprot nuc 4.08 nucl 32
EXOSC5 27998 NM_138586 Cytoplasmic - Locate cytop 1.81 nucl 25
EXOSC6 72544 NM_028274 Cytoplasmic - Uniprot nuc 1.90 nucl 27
EXOSC8 69639 NM_027148 Cytoplasmic - Locate nuc 2.54 extr 15
EXOSC9 50911 NM_019393 Cytoplasmic - Uniprot cytop 2.57 nucl 29.5
HIC2 58180 NM_178922 Cytoplasmic - Predicted cytop 2.84 nucl 32
JARID1D 20592 NM_011419 Cytoplasmic - Locate TFCat
JTV1 231872 NM_146165 Cytoplasmic - Predicted nuc 3.26 cyto 20.5
LIN28 83557 NM_145833 Cytoplasmic - Uniprot nuc 3.69 mito 20
LSM8 76522 NM_133939 Cytoplasmic - Locate nuc 2.20 nucl 26.5
MAPK14 26416 NM_011951 Cytoplasmic - Uniprot TFCat
MAPK7 23939 NM_011841 Cytoplasmic - Uniprot TFCat
MATR3 17184 NM_010771 Cytoplasmic - Predicted nuc 4.12 cyto 21
MBD1 17190 NM_013594 Cytoplasmic - Predicted nuc 4.52 cyto 18
MBD3L1 73503 NM_028557 Cytoplasmic - Locate nuc 3.71 nucl 14.5
MBD4 17193 NM_010774 Cytoplasmic - Predicted nuc 2.32 cyto 19.5
MBNL2 105559 NM_175341 Cytoplasmic - Uniprot nuc 3.39 nucl 24
MLH1 17350 NM_026810 Cytoplasmic - Predicted nuc 4.42 cyto 18
MRE11A 17535 NM_018736 Cytoplasmic - Predicted cytop 3.18 cyto 22
MRPS28 66230 NM_025434 Cytoplasmic - Predicted nuc 2.72 cyto 20
NANOS1 332397 NM_178421 Cytoplasmic - Uniprot nuc 4.43 nucl 32
NDEL1 83431 NM_023668 Cytoplasmic - Uniprot TFCat
Ndn 17984 NM_010882 Cytoplasmic - Uniprot nuc 3.91 nucl 32
NFKBIA 18035 NM_010907 Cytoplasmic - Uniprot TFCat
NFKBIE 18037 NM_008690 Cytoplasmic - Uniprot TFCat
Otud7a 170711 NM_130880 Cytoplasmic - Uniprot nuc 4.83 cyto 20
PA2G4 18813 NM_011119 Cytoplasmic - Uniprot
PAWR 114774 XM_125814 Cytoplasmic - Uniprot TFCat
PCBP3 59093 NM_021568 Cytoplasmic - Uniprot TFCat
PELO 105083 NM_134058 Cytoplasmic - Uniprot cytop 1.76 cyto 29
PER3 18628 NM_011067 Cytoplasmic - Uniprot TFCat
PLEKHA3 83435 NM_031256 Cytoplasmic - Uniprot
POGK 71592 NM_175170 Cytoplasmic - Locate
PPP1R13B 21981 NM_011625 Cytoplasmic - Uniprot TFCat
Ptrf 19285 NM_008986 Cytoplasmic - Uniprot TFCat
PURG 75029 NM_152821 Cytoplasmic - Predicted nuc 3.12 cyto 18
RABGEF1 56715 NM_019983 Cytoplasmic - Uniprot TFCat
RAD1 19355 NM_011232 Cytoplasmic - Locate nuc 3.52 nucl 32
REX3 19716 NM_009052 Cytoplasmic - Uniprot TFCat
ROCK2 19878 NM_009072 Cytoplasmic - Locate TFCat
RPP21 67676 NM_026308 Cytoplasmic - Predicted cytop 3.25 mito 16
RXRG 20183 NM_009107 Cytoplasmic - Locate TFCat
SART3 53890 NM_016926 Cytoplasmic - Uniprot nuc 2.10 nucl 32
SBDS 66711 NM_023248 Cytoplasmic - Uniprot nuc 3.51 nucl 28
SIRT2 64383 NM_022432 Cytoplasmic - Uniprot TFCat
SNAPC3 77634 NM_029949 Cytoplasmic - Locate nuc 2.90 nucl 32
SSBP2 66970 NM_024186 Cytoplasmic - Predicted cytop 2.03 cyto 14.5
STATIP1 58523 NM_021448 Cytoplasmic - Uniprot TFCat
SWAP70 20947 NM_009302 Cytoplasmic - Uniprot
TCEB2 67673 NM_026305 Cytoplasmic - Locate TFCat
TDRD1 83561 NM_031387 Cytoplasmic - Uniprot nuc 4.04 nucl 32
THAP11 59016 NM_021513 Cytoplasmic - Uniprot cytop 2.22 nucl 31.5
TRERF1 224829 NM_172622 Cytoplasmic - Locate nuc 4.80 nucl 32
TSN 22099 NM_011650 Cytoplasmic - Uniprot nuc 3.84 cyto 11
TTF1 22130 NM_009442 Cytoplasmic - Predicted cytop 3.25 nucl 32
TXK 22165 NM_013698 Cytoplasmic - Uniprot TFCat
USP52 103135 NM_133992 Cytoplasmic - Uniprot nuc 4.49 nucl 23
XAB2 67439 NM_026156 Cytoplasmic - Predicted cytop 2.46 nucl 30
XRN1 24127 NM_011916 Cytoplasmic - Uniprot nuc 4.42 nucl 32
ZFP143 20841 NM_009281 Cytoplasmic - Predicted cytop 2.43 nucl 23
ZFP148 22661 NM_011749 Cytoplasmic - Predicted cytop 2.35 cyto 11
ZFP259 22687 NM_011752 Cytoplasmic - Uniprot TFCat
ZFP281 226442 NM_177643 Cytoplasmic - Locate nuc 4.35 E.R. 8.5
ZFP346 26919 NM_012017 Cytoplasmic - Uniprot nuc 4.80 nucl 32
ZFP36L1 12192 NM_007564 Cytoplasmic - Locate TFCat
ZFP521 225207 NM_145492 Cytoplasmic - Locate TFCat
ZFR 22763 NM_011767 Cytoplasmic - Uniprot nuc 4.34 nucl 32
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Table 3.5
Candidate Gene List: Cytoplasmic proteins (continued)
Gene Uniprot Subcellular locations Panther Biological Process Panther Molecular Function
0610010I17RIK Cytoplasm. Nucleus. DNA repair Damaged DNA-binding protein
1700051E09RIK Cytoplasm  perinuclear region. Membrane; Peripheral membrane protein. Proteolysis Other DNA-binding protein;Ub
2310005K03RIK Endoplasmic reticulum. DNA degradation Endodeoxyribonuclease;Hydro
2410006F12RIK Nucleus. Cytoplasm. mRNA polyadenylation;mRNA end-processing and stability Endoribonuclease;mRNA poly
2810028N01RIK Cytoplasm. Nucleus  nucleolus. RNA catabolism;Mitosis Exoribonuclease;Hydrolase
4930517K23RIK Nucleus. Cytoplasm. Biological process unclassified Nuclease
4932442K20RIK Cytoplasm. mRNA transcription regulation Exoribonuclease
4933406L09RIK Biological process unclassified Transcription factor;Nuclease
5830483C08RIK Nucleus. Biological process unclassified Endodeoxyribonuclease
A230103N10RIK Cytoplasm. Nucleus. mRNA transcription regulation Exoribonuclease
ANG4 RNA catabolism;Angiogenesis Endoribonuclease;Other enzy
ANKRD3 Protein phosphorylation Non-receptor serine/threonine
ARC Biological process unclassified Molecular function unclassified
BAT2 Cytoplasm. Nucleus. Nucleoside, nucleotide and nucleic acid metabolism;Other metabolism Transcription factor;Nuclease
BC034753 Nucleus. DNA repair;Other metabolism Endodeoxyribonuclease;DNA 
BC052360 Cytoplasm. Biological process unclassified Other nucleic acid binding;Tra
BIN1 Endocytosis;Transport;Neurotransmitter release Membrane traffic regulatory p
BZW1 Protein biosynthesis;Translational regulation;Other protein metabolism Nuclease;Translation initiation
BZW2 Protein biosynthesis;Translational regulation;Other protein metabolism Nuclease;Translation initiation
CDC5L mRNA transcription regulation;Cell cycle control Other transcription factor;Nuc
CSDA mRNA transcription regulation Other transcription factor;Nuc
D11ERTD497E Other mRNA transcription Other DNA-binding protein
D630024B06RIK Nucleus  nucleoplasm. mRNA transcription regulation Other DNA-binding protein
D7WSU87E Cytoplasm. Nucleus. Proteolysis;Other protein metabolism Double-stranded DNA binding
DFFB Cytoplasm. Nucleus. DNA degradation;Apoptotic processes Nuclease
DPF2 mRNA transcription regulation;Protein acetylation;Induction of apoptosis;DeveloZinc finger transcription facto
DSIP1 mRNA transcription regulation Other transcription factor
EAR1 Cytoplasmic granule. RNA catabolism Endoribonuclease;Hydrolase
EAR2 Cytoplasmic granule. RNA catabolism Endoribonuclease;Hydrolase
EAR3 RNA catabolism Endoribonuclease;Hydrolase
EAR4 Lysosome. Cytoplasmic granule. RNA catabolism Endoribonuclease;Hydrolase
ENDOG Mitochondrion. DNA replication;Apoptotic processes;DNA replication Endodeoxyribonuclease;Endo
EPS15 Endocytosis;Neurotransmitter release Other G-protein modulator;Se
ERCC1 DNA repair Endodeoxyribonuclease
EXOSC2 Cytoplasm. Nucleus  nucleolus. Nucleoside, nucleotide and nucleic acid metabolism Exoribonuclease
EXOSC3 Cytoplasm. Nucleus  nucleolus. Nucleoside, nucleotide and nucleic acid metabolism;Other metabolism Exoribonuclease;Esterase
EXOSC4 Cytoplasm. Nucleus  nucleolus. tRNA metabolism;rRNA metabolism;RNA catabolism Exoribonuclease;Nucleotidyltr
EXOSC5 Nucleus  nucleolus. tRNA metabolism;rRNA metabolism;RNA catabolism Exoribonuclease;Nucleotidyltr
EXOSC6 Cytoplasm. Nucleus  nucleolus. tRNA metabolism;rRNA metabolism;RNA catabolism Exoribonuclease;Nucleotidyltr
EXOSC8 rRNA metabolism Exoribonuclease;Hydrolase
EXOSC9 Cytoplasm. Nucleus  nucleolus. rRNA metabolism Exoribonuclease;Hydrolase
HIC2 Nucleus. mRNA transcription regulation Zinc finger transcription facto
JARID1D mRNA transcription;Spermatogenesis and motility Other zinc finger transcription
JTV1 Protein biosynthesis Damaged DNA-binding protein
LIN28 Cytoplasm. Nucleus  nucleolus. mRNA transcription regulation Other transcription factor;Oth
LSM8 Nucleus. mRNA splicing;Other metabolism Nuclease;mRNA splicing facto
MAPK14 Protein phosphorylation;MAPKKK cascade Non-receptor serine/threonine
MAPK7 Protein phosphorylation;MAPKKK cascade Non-receptor serine/threonine
MATR3 Nucleus matrix. Miscellaneous Other RNA-binding protein;Ot
MBD1 Nucleus speckle. mRNA transcription Other DNA-binding protein
MBD3L1 Nucleus. mRNA transcription Other DNA-binding protein
MBD4 Nucleus. DNA repair;Developmental processes;Other metabolism Nuclease;Methyltransferase
MBNL2 Nucleus. Cytoplasm. Muscle development Double-stranded DNA binding
MLH1 DNA repair;Meiosis;Oncogenesis Other DNA-binding protein
MRE11A Nucleus. DNA repair;DNA recombination;Meiosis Exodeoxyribonuclease;Endode
MRPS28 Mitochondrion. Biological process unclassified Nuclease
NANOS1 Cytoplasm  perinuclear region. Protein biosynthesis;Translational regulation;Oogenesis;Meiosis;Embryogenesis Nuclease
NDEL1 Biological process unclassified Molecular function unclassified
Ndn Cytoplasm. Nucleus  nucleoplasm. Nucleus matrix. Cell cycle control;Cell proliferation and differentiation Double-stranded DNA binding
NFKBIA mRNA transcription regulation;NF-kappaB cascade;Intracellular protein traffic;SSelect regulatory molecule
NFKBIE Biological process unclassified Molecular function unclassified
Otud7a Cytoplasm. Nucleus. Proteolysis;Other protein metabolism Double-stranded DNA binding
PA2G4 Cytoplasm. Nucleus  nucleolus. Protein biosynthesis;Cell proliferation and differentiation Other transcription factor;Oth
PAWR Apoptosis Molecular function unclassified
PCBP3 Protein metabolism and modification Select regulatory molecule
PELO Nucleus. Cytoplasm. Meiosis;Mitosis Nuclease;Translation release f
PER3 mRNA transcription regulation;Cell communication Transcription cofactor
PLEKHA3 Cytoplasm. Membrane; Peripheral membrane protein. Biological process unclassified Other nucleic acid binding;Tra
POGK Nucleus. Other mRNA transcription;Developmental processes Other nucleic acid binding
PPP1R13B Apoptosis;Cell cycle control;Cell proliferation and differentiation Select regulatory molecule
Ptrf mRNA transcription termination;rRNA metabolism Other transcription factor
PURG Nucleus. General mRNA transcription activities Other transcription factor;Sin
RABGEF1 Endocytosis;Other intracellular protein traffic Guanyl-nucleotide exchange f
RAD1 Nucleus. DNA repair;DNA recombination;Cell cycle control Exodeoxyribonuclease;Hydrol
REX3 Biological process unclassified Molecular function unclassified
ROCK2 Protein phosphorylation;Other intracellular signaling cascade;Cell adhesion;Oth Non-receptor serine/threonine
RPP21 Nucleus  nucleolus. tRNA metabolism Nuclease;Hydrolase
RXRG Regulation of lipid, fatty acid and steroid metabolism;mRNA transcription regulaNuclear hormone receptor;Tra
SART3 Cytoplasm. Nucleus. Nucleus speckle. Other nucleoside, nucleotide and nucleic acid metabolism Nuclease
SBDS Cytoplasm. Biological process unclassified Transcription factor;Nuclease
SIRT2 mRNA transcription regulation;Chromatin packaging and remodeling Chromatin/chromatin-binding
SNAPC3 Nucleus. mRNA transcription;Other metabolism Nuclease
SSBP2 Nucleus. mRNA transcription initiation;mRNA transcription regulation Single-stranded DNA-binding 
STATIP1 Biological process unclassified Molecular function unclassified
SWAP70 Cytoplasm. Cell membrane. Nucleus. Cell projection  lamellipodium. DNA recombination;B-cell- and antibody-mediated immunity Other nucleic acid binding
TCEB2 mRNA transcription elongation Transcription cofactor
TDRD1 Cytoplasm. Nucleoside, nucleotide and nucleic acid metabolism Nuclease
THAP11 Nucleus. Cytoplasm. Biological process unclassified Other DNA-binding protein
TRERF1 Nucleus. DNA metabolism;RNA catabolism Other DNA-binding protein
TSN Cytoplasm. Nucleus. DNA recombination;Immunity and defense Single-stranded DNA-binding 
TTF1 Nucleus. Nucleus  nucleolus. mRNA transcription termination Other DNA-binding protein
TXK Protein phosphorylation;Intracellular signaling cascade;T-cell mediated immunitNon-receptor tyrosine protein
USP52 Cytoplasm. Nucleus. RNA catabolism;Proteolysis Exoribonuclease;Esterase;Cys
XAB2 Nucleus. DNA repair;mRNA transcription;Developmental processes Other transcription factor;Dam
XRN1 Cytoplasm. Nucleoside, nucleotide and nucleic acid metabolism Exoribonuclease
ZFP143 mRNA transcription regulation Zinc finger transcription facto
ZFP148 Nucleus. mRNA transcription regulation Zinc finger transcription facto
ZFP259 Biological process unclassified Other miscellaneous function 
ZFP281 mRNA transcription regulation Zinc finger transcription facto
ZFP346 Nucleus  nucleolus. Cytoplasm. Electron transport;Apoptosis;Other metabolism Zinc finger transcription facto
ZFP36L1 RNA catabolism;Intracellular signaling cascade Other RNA-binding protein
ZFP521 Biological process unclassified KRAB box transcription factor
ZFR Nucleus. Cytoplasm. Cytoplasmic granule. Apoptotic processes;Anterior/posterior patterning;Cell cycle Other RNA-binding protein;Ot
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ligase, interferon-inducible tripartite-motif (TRIM) 56, is a positive regulator of the ISD 
pathway that targets STING for ubiquitination and subsequent type I IFN induction[139]. 
Overexpression of TRIM56 increased IFN-β promoter activation while knockdown 
reduced type I IFN activation. Negative regulators active in other innate immune 
pathways, including CYLD, A-20, and DUBA, shut off activation signals by using 
enzymes that dephosphorylate or deubiquitinate their targets[165-168]. CYLD is a regulatory 
mechanism of the NF-κB pathway that mediates inhibitory activity by reversing the 
ubiquitination of tumor necrosis factor receptor (TRAF)-associated factors TRAF2 and 
TRAF6[165]. Additionally, it has been shown that ectopic expression of CYLD inhibits the 
IRF3 signaling pathway and IFN production triggered by RIG-I; conversely, CYLD 
knockdown enhances the response[166]. Another regulator of the NF-κB pathway, A-20, is 
a potent inhibitor of NF-κB signaling. A-20 deficient mice fail to regulate NF-κB, resulting 
in increased cell death and chronic inflammation[169]. A-20 exerts two opposing activities: 
sequential deubiquitination and ubiquitination of the TNF receptor-interacting protein 
(RIP) an essential mediator of the TNF receptor signaling complex, thereby targeting RIP 
to proteasomal degradation[167]. 
Deubiquitinating enzyme A (DUBA) targets TRAF3, an adapter protein critical to 
the type I IFN response. By selectively cleaving polyubiquitin chains of TRAF3, DUBA 
effectively dissociates TRAF3 from the downstream signaling complex containing 
TBK1[168].  Lastly, the importance of negative regulation of the ISD pathway is 
exemplified by 3ʼ-5ʼ exonuclease, TREX1[100, 104, 170].  Thought to prevent cell-intrinsic 
initiation of autoimmunity through clearance of endogenous retroelements, TREX1 is 
normally involved in clearance of ssDNA, but mice deficient in TREX1 have an 
accumulation of ~60bp ssDNA that drives the activation of DNA-damage associated 
signaling pathways[104, 171]. Loss-of-function mutations in the human gene TREX1 cause 
103
Aicardi- Goutières syndrome (AGS) and chilblain lupus, possibly driven by the 
accumulation of endogenous retroelements. 
 To this end, we identified 126 phosphatases (annotated from GO:0004721, 
phosphoprotein phosphatase activity) and 71 deubiquitinases (annotated from 
GO:0004221, ubiquitin thiolesterase activity, as well as a prior curation[172]) as a source 
of potential negative regulators of the ISD pathway (Table 3.6).  We supplemented the 
phosphatases and deubiquitinases candidates to include 36 putative negative regulators 
of the RIG-I pathway identified in protein-protein interaction networks of influenza-host 
interactions that were also upregulated following stimulation with IFN-β in expression 
profiles of HBECs (included in Table 3.6)[134]. Finally, we added a collection of 38 known 
signaling molecules, and negative (no siRNA or negative control siRNA) and positive 
(siIRF3) controls (Table 3.7). 
 
3.7 - Conclusions 
 In conclusion, we developed a comprehensive candidate list to identify novel 
components of the ISD-sensing pathway. Our list of 1003 genes represents a targeted 
list representative of both experimental and hypothesis-driven evidence. We selected 
candidates from gene expression experiments that were regulated in response to IFN-β 
or transfected DNA. In a study using ISD as bait in IFN-β stimulated cells, we identified 
candidates with SILAC-based mass spectrometry. We hypothesized that any annotated 
helicase could play a role in the ISD sensing pathway and thus, included all proteins with 
enzymatic helicase activity. Additionally, using cellular localization algorithms and 
annotated databases, we selected DNA-binding proteins with cytoplasmic localization. In 
a pilot screen to identify potential negative regulators of the ISD pathway, we included 
annotated phosphatases and deubiquitinases, supplemented with putative negative 
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Table 3.6
Candidate Gene List: MiniScreen /  Phosphatases / Deubiquitinases 
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Table 3.6
Candidate Gene List: MiniScreen /  Phosphatases / Deubiquitinases (continued)
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regulators of the RIG-I pathway identified in a dissection of host-influenza interactions.  
Finally, to complement our list of putative negative regulators, we included known 
signaling molecules.  
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Chapter 4:  
A High-throughput Loss-of-Function RNAi Screen for of the ISD-Sending Pathway 
Reveals Identifies Known Components and Novel Regulators  
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4.1 – Introduction 
Following the development of a high-throughput screening system (Figure 2.18) 
and selection of candidate list (Figure 3.1) to identify novel components of the ISD 
pathway, we screened 1003 putative factors using siGENOME SmartPools (Dharmacon; 
ICCB, Harvard Medical School). We conducted our screening in four stages. First, as 
test of our screening workflow and analysis, we conducted a small pilot screen of 235 
potential negative regulators. Second, we selected the strongest hits from the pilot 
screen, added them to the full screening set and conducted a screen of 783 candidate 
ISD pathway components. Next, we developed a database to quickly access and 
interrogate the top hits. In an attempt to recover candidates lost to siRNA toxicity we 
screened devonvoluted siGENOME SmartPools to identify additional candidates in the 
ISD-pathway. Finally, we conducted a series of secondary screens, including screens of 
our top candidates with deconvoluted siGENOME SmartPools pools and independent 
siRNA pools (Dharmacon On-TargetPLUS SmartPools) to identify DNA-response 
specificity. Select candidates were nominated for further investigation. 
 
4.2 – Pilot Screen: phosphatases and deubiquitinases 
With the completion of an siRNA-based screening strategy and the development 
of a set of candidate genes from genomic, proteomic, and domain-based studies we set 
out to conduct a pilot screen of system testing workflow and analysis. Our pilot screen 
target 235 phosphatases and deubiquitinases (Table 3.6). The average of triplicate wells 
is shown in Figure 4.1. A best-fit line based on non-targeting siRNA, no siRNA and 
siDEATH controls is drawn through Cxcl10. We then calculated Z-scores normalized to 
the best-fit line. Data are presented as Log(2) Cxcl10 pg/mL and CellTiter-Glo relative 
luminesce units (Table 4.1 and Table 4.2).  
110
Figure 4.1 
Pilot Screen: Phosphatases and Deubiquitinases. Following knockdown of siRNAs targeting a total of 
235 phosphatases and deubiquitinases, each well was stimulated with ISD and Cxcl10 was measured by 
ELISA. Log(2) Cxcl10 (pg/mL) is graphed on the y-axis. Cell viability after knockdown was measured by 
CellTiter-Glo; relative luminescence units are graphed on the x-axis. The averages of three replicate wells 
for each gene are represented as circles; red triangles at the bottom-right of each graph represent siIrf3 
positive controls; green triangles at the top-of each graph represent wells with non-targeting control siR-
NAs blue triangles represent siDeath controls and wells with no siRNA. Selected genes are marked with 
purple circles and bold text. A best-fi t line is drawn through the Cxcl10 values of no siRNA, non-targeting 
and siDeath controls.
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 Knockdown of control gene Irf3 reduced Cxcl10 expression by 19.1-fold (p-value 
<0.01, Mann Whitney U test). We identified seven potential negative regulators with 5.5 
to 11.1-fold reduction in Cxcl10 response including the signaling protein Amotl2, 
phosphatases Ctdspl, Dusp8, Mtmr3, and Ppef2 and ubiquitin specific peptidases 
Usp38, Usp43, and Usp49. Furthermore, we identified more than a dozen potential 
negative regulators with 5.09 to 8.8-fold increases in Cxcl10 response including the 
phosphatases Itpkb, Mdp1, Mtmr2, Ppp1ca, and Ptpn20, the deubiquitinase Cyld and 
the ubiquitin specific proteases Usp5, Usp12, and Usp27x. Most interesting among 
these candidates is Cyld, a negative regulator of RIG-I activation[166]. Following 
knockdown of Cyld we demonstrated an 8.8-fold increase in the CXCL10 response. 
Additionally, a strong candidate from the influenza screen, the hypothetical protein 
1110012L19Rik, was replicated in our pilot screen. The strongest of the pilot screen hits 
were added to the 768 candidates selected for the complete screening set. 
 
4.3 – High-throughput loss-of-function RNAi screen 
Following the completion of the pilot screen, we conducted a screen of 783 
siGENOME SmartPools, along with non-targeting, Irf3 and no siRNA controls. A cell 
dilution curve was included to generate predicted Cxcl10 values for a given CellTiter-Glo 
value (Figure 4.2A). Screening fitness was assessed by Z-factor analysis (Figure 4.2B). 
Cxcl10 levels were detected following stimulation of non-targeting and Irf3 controls 
samples at low and high supernatant volumes to determine assay detection limits in the 
context of the entire screen. Z-factor analysis (0.64 for low and 0.84 for high) indicated a 
robust screen. Furthermore, replicate samples (n=3 siGENOME SmartPools per gene on 
independent plates) correlated strongly for both Cxcl10 and CellTiter-Glo values (R2 = 
115
Figure 4.2 
High-throughput Loss-of-Function RNAi Screen: Control siRNA and replicate assessment indi-
cates a robust screen. A) Non-targeting and Irf3 siRNA treated wells (green and red triangles, respec-
tively) and buffer-only controls (blue triangles) were stimulated with ISD. Cxcl10 was measured by ELISA. 
Log(2) Cxcl10 (pg/mL) is graphed on the y-axis. Cell viability after knockdown was measured by CellTiter-
Glo; relative luminescence units are graphed on the x-axis. A cell dilution curve (black squares) was used 
to derive a two-phase association best-fi t line of expected values. Dashed orange lines represent cell dilu-
tion curve and 1.5 standard deviations above and below the predicted curve.  B) Screening fi tness was 
assessed by Z-factor. Non-targeting and Irf3 control siRNA supernatants were tested for Cxcl10 induction 
at the upper (15ul) and lower (4.5ul) limits of detection. C) Top, ELISA of log2 Cxcl10 (pg/ml) production 
was plotted against ELISA of log2 Cxcl10 (pg/ml) production in replicate plates showing robustness of 
siRNA screening assay. Bottom, cell viability (RLU) after siRNA knockdown was plotted against cell viabil-
ity (RLU) after siRNA knockdown in replicate plates showing robustness of siRNA treatment in screening 
assay. R2 values are shown.
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Figure 4.2 (continued)
non-targeting
buffer only
IRF3
IRF3
IRF3
saturated
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15 uL sup
z’ = 0.84
4.5 uL sup
z’ = 0.64
Non-targeting
Non-targeting
A
B
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Figure 4.2 (continued)
C
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0.902 – 0.911 between plates for Cxcl10 values and 0.922 – 0.930 between plates for 
CTG values) (Figure 4.2C).  
 The entire screen (Figure 4.3A) separated by each of the annotated candidates 
lists (Figure 4.3B-G and Table 4.3A-F) were plotted along with controls and the cell 
dilution curve. In addition to control gene Irf3, known components of the ISD-sensing 
pathway including Sting and Tbk1 represented strong hits with over 90% reduction in 
Cxcl10 following stimulation with ISD. The siRNA screen identified 20 genes that, upon 
their knockdown, resulted in over 75% less Cxcl10 production in response to ISD 
stimulation, including ISD or IFN-β regulated candidates Asb13 and Ifitm1, DNA 
interactors (for example, Abcf1, Ifit1 and Reep4), helicases Ddx46, Ddx59 and Ercc3, 
the signaling molecule Chuk (Ikka) and phosphatases and deubiquitinases (including 
Ctdspl, Mtmr3 and ubiquitin specific proteases Usp43 and Usp49). Furthermore there 
were eight genes for which Cxcl10 was upregulated more than three-fold after 
knockdown, including interferon-regulated genes (for example, Tiparp), the signaling 
molecule Ripk1 and phosphatases including, Ppp6c, Ptpn1 and Mdp1 as well as 
deubiquitinases (for example, Usp12 and Cyld). 
 
4.4 – Database development 
Screening results were curated in a database to provide convenient access to 
information regarding each candidate (Figure 4.4). We calculated a non-linear Z-score 
by subtracting average Cxcl10 values from an expected value derived from the cell 
dilution curve, divided by the standard deviation. The Z-scores were ranked and used as 
primary sorting field for the database. Screening data are presented for each candidate 
as CellTiter-Glo and Cxcl10 averages with fold-change relative to a negative control. A 
screenshot of the actual replicate data points is also included. Expression data from ISD 
119
Figure 4.3 
High-throughput Loss-of-Function RNAi Screen: Full screening results. A) Non-targeting and Irf3 
siRNA treated wells (green and red triangles, respectively) buffer-only controls (blue triangles) and can-
didate genes (black circles) were stimulated with ISD. Cxcl10 was measured by ELISA. Log(2) Cxcl10 
(pg/mL) is graphed on the y-axis. Cell viability after knockdown was measured by CellTiter-Glo; relative 
luminescence units are graphed on the x-axis. A cell dilution curve (black squares with orange outlines) 
was used to derive a two-phase association best-fi t line of expected values. Dashed orange lines repre-
sent cell dilution curve and 1.5 standard deviations above and below the predicted curve. B-G) Screening 
results separated by annotated candidate group: Microarry, DNA SILAC, helicases, cytoplasmic DNA-
binding proteins, signaling molecules and selected phosphatases and deubiquitinases from pilot screen, 
respectively.
120
F
ig
ur
e 
4.
3 
(c
on
tin
ue
d)
A
121
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Figure 4.4 
High-throughput Loss-of-Function RNAi Screen: Database development. Screening results are cata-
logued in a searchable database. Basic screening results and gene characteristics including molecular 
function and biological process are displayed in the upper left hand corner. Replicate siRNAs are dis-
played in the context of the entire screen, upper right-hand side. Expression data are displayed in the top 
middle. On the top row in light blue, genes with human homology are displayed and are linked to genome-
wide association study (GWAS) data based on chromosomal position. Gene expression across multiple 
mouse and human tissues can be accessed through the BioGPS Gene Portal radio button. Candidate 
genes are link directly to the specifi ed NCBI Gene. Protein architecture, putative protein-protein interac-
tions and post-translational modifi cation data for each candidate are linked through the SMART database. 
Bottom table details Lentiviral shRNAs for each candidate, including glycerol stock location and validation 
data.
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and IFN-β stimulated microarrays are linked directly to each candidate[43, 44, 48]. To 
identify potential connections to human diseases, candidate genes were linked by 
homology to human genes. Drawing on a curated catalog of genome-wide association 
studies based on SNP-trait associations with p-values < 1.0 x 10-5, homologous genes 
were linked by nearest chromosomal band proximity[173]. Also, tissue-specific patterns of 
mRNA expression can be accessed for 79 human and 61 mouse tissues using the 
BioGPS portal[174]. Domain architecture, predicted functional partners and post-
translation modification can be viewed for each candidate gene and its human 
homologue via the SMART (Simple Modular Architecture Research Tool) browser[175]. 
Additionally, location and knockdown validation of lentiviral shRNA clones available 
through the RNAi Consortium (Broad Institute) are provided.    
 
4.5 – Secondary screening 
Secondary screening involved three distinct phases. First, we recovered siRNA 
candidates lost to toxicity. Next, in attempt to identify ISD-specific responses, we 
compared top candidates stimulated ISD or IVT-RNA. Third, we further interrogated 
candidates for ISD-specific responses with independent siRNA pools stimulated with 
ISD, Poly I:C, IVT-RNA or recombinant mouse IFN-β. The roles of the strongest 
candidates as regulators of the ISD pathway are dissected in the following chapter. 
First we identified siRNAs from the full screen that had toxic effects. Toxicity 
could be caused by off-target effects of siRNAs, knockdown of an essential cellular 
component, or a reduction of a cell-intrinsic component required for the response to 
cytosolic DNA. Candidate siRNAs with CellTiter-Glo values below the 25th percentile 
were considered toxic (Figure 4.5A). To recover toxic candidates, siRNA pools were 
deconvoluted and knocked down separately. Following siRNA knockdown, samples 
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Figure 4.5
Deconvolution of toxic siRNA pools reveals additional ISD pathway candidates.  A) Selection of 
toxic siRNA pools and controls from high-throughput screen for secondary screening with individual 
Dharmacon siGENOME siRNAs and stimulated with B) 1ug/mL ISD for 26 hours. CellTiter-Glo relative 
luminescent unites are on the x-axis, Log(2) Cxcl10 protein pg/mL, as detected by ELISA, are on the 
y-axis. Cxcl10 production was compared between stimuli. Control siRNAs (non-targeting controls, green 
triangles, Irf3, red triangles) are labeled, circles represent 1 of 4 individual siRNA candidates (red, orange, 
blue and green circles represent 1 of 4 deconvoluted siRNAs), strongest individual siRNAs are labeled.
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were stimulated with ISD and Cxcl10 protein levels were subsequently detected by 
ELISA. Seven candidates, including the helicase Ddx18 and DNA-SILAC candidate 
Sfrs2, and two with multiple siRNA targets (DNA-pathway regulated genes Ikbkg and 
Sap30l), had fourfold or greater reduction in Cxcl10 (Figure 4.5B). We included these 
recovered candidates in the following secondary screen designed to distinguish DNA-
specific responses. 
 In an effort to identify ISD pathway-exclusive factors, we selected the top 200 
potential positive and negative regulators and performed additional screens stimulated 
with both ISD and IVT-RNA, respectively (Figure 4.6A). We predicted that DNA-specific 
positive regulators of the ISD-sensing pathway provided the best chance at identifying a 
cytosolic DNA-sensor. Furthermore, focusing on DNA-specific response may simplify 
any subsequent validation of ISD-sensing pathway candidates. As expected, Irf3 
knockdown reduced expression of Cxcl10 in both ISD and IVT-RNA stimulated samples 
(greater than 90% reduction in Cxcl10), while knockdown of Mavs and Rig-i resulted in 
reduced Cxcl10 for RNA samples only and Tbk1 knockdown reduced CXCL10 for ISD-
stimulated samples (Figure 4.6B). 
 Twenty-five of the tested candidates produced 25% less Cxcl10 when stimulated 
with ISD than those stimulated with IVT-RNA including DNA-SILAC candidates Abcf1, 
Hmgb1, Reep4 and Skp1a (greater than 40-fold reduction in Cxcl10 compared to non-
targeting control siRNA treated wells), microarray candidates Ifit1, Ifitm1, Ikka and Plagl 
(18-fold or greater reduction in Cxcl10 levels), cytoplasmic DNA-binding candidate Csda, 
and helicases Dhx15 and Dhx16 (greater than 9-fold reduction of Cxcl10).   
 Conversely, a number of candidates produced 25% less Cxcl10 when stimulated 
with IVT-RNA than those stimulated with ISD including regulated genes Hmx3, Stat1 and 
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Figure 4.6
Secondary screening of top 200 candidates identifi es DNA-specifi c responses.  A) Selection of top 
screening candidates and controls from high-throughput screen for secondary screening with Dharmacon 
siGENOME SmartPools and stimulated with B) 1ug/mL ISD, and 0.1 ug/mL in vitro transcribed RNA (IVT-
RNA) for 26 hours. Data points are Cxcl10 protein pg/mL, as detected by ELISA. Cxcl10 production was 
compared between stimuli. Control siRNAs (red triangles) are labeled, black circles represent assayed 
candidates, strongest hits are labeled.
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putative negative regulators of the ISD-pathway Mtmr2 and Tiparp (greater than 12-fold 
reduction in Cxcl10), and DNA-binding protein Mbd3l1 (21.38 fold-reduction in Cxcl10). 
 Finally, we sought independent confirmation of our top hits using independent 
siRNA pools. To help reduce the potential of off-target effects of siRNA, we screened 
independent pools of siRNAs (Dharmacon On-Target PLUS SmartPools), corresponding 
to the top 40 candidates (Figure 4.7A). To further distinguish the ISD-pathway from 
RNA-responses, the top 40 candidates genes were knocked down and then stimulated 
with either ISD, Poly I:C or IVT-RNA for 26 hours (Figure 4.7B-C). Control siRNAs 
responded as expected; Cxcl10 responses were reduced for each nucleic acid stimulus 
in Irf3-siRNA treated samples (6.9, 6.8 and 6.0-fold reduction following stimulation with 
ISD, Poly I:C and IVT-RNA, respectively). Both Poly I:C and IVT-RNA induced Cxcl10 
stimulation was reduced in Mavs-siRNA treated samples but only IVT-RNA responses 
were reduced in Rig-i-siRNA treated samples, consistent with the finding that RIG-I 
requires a 5ʼ-triphosphate group on RNA to be detected[31]. Consistent with our previous 
findings, amongst others, signaling molecule Ikka and DNA-SILAC candidates Abcf1, 
Ifit1 and Reep4 appear to be DNA-specific positive regulators.  
 To further clarify the ISD-sensing capacity of the candidate genes, samples were 
stimulated with recombinant mouse IFN-β. Candidate genes may directly effect Cxcl10 
production by an off-target effect or by targeting a component crucial in the secondary 
signaling cascade of events downstream of Irf3. In addition to cytoplasmic candidates 
including Cnot6, signaling molecule Ikka and DNA-SILAC candidates (Abcf1, Ifit1 and 
Reep4) stimulation with recombinant mouse IFN-β demonstrated DNA-specific reduction 
in Cxcl10 production.  
 While chemical modifications effectively reduce off-target effects, a limitation of 
the On-Target PLUS siRNAs is reduced knockdown efficiency[176]. While we identified a 
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Figure 4.7
Secondary screening of top 40 candidates identifi es DNA-specifi c responses.  A) Selection of top 
screening candidates and controls from high-throughput screen for secondary screening with independent 
siRNA pools (Dharmacon On-Target PLUS SmartPools) and stimulated with B) ISD, Poly (I:C), in vitro 
transcribed RNA (IVT-RNA) or recombinant mouse IFNβ (mIFNβ) for 26 hours. Data points are Cxcl10 
protein pg/mL, as detected by ELISA. CXCL10 production was compared between each stimulus. Control 
siRNAs (red triangles) are labeled, black circles represent assayed candidates, strongest hits are labeled. 
C) Absorbance values (450nm) of Cxcl10 ELISA in descending order for each stimulus, ISD, Poly (I:D), 
IVT-RNA and mIFNβ, respectively. Red bars represent putative negative regulators. Pink bars represent 
putative positive regulators. Screening controls (non-targeting, no-siRNA and IRF3) are indicated as light 
blue bars. Known ISD and RNA-sensing pathway components are represented as dark blue bars.
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number of candidates shared with siGENOME candidates, reduced knockdown 
efficiency may have obscured the role of potential candidate in the ISD pathway (Figure 
4.7B-C and data not shown).  
 
4.6 – Conclusion 
Our high-throughput RNAi screen of 1003 putative ISD-pathway components 
revealed a number of novel factors representing candidates from our curated gene set of 
genomic, proteomic and domain-based candidates. By deconvoluting toxic siRNA pools, 
we recovered additional candidates. Top candidates were knocked down with 
independent siRNAs and stimulated with ISD, RNA or recombinant Ifn-β to identify 
putative ISD-specific components. We identified putative positive regulators including 
expression-induced genes (including Ifitm1, Sp110, Trim56, and Tifa), DNA-SILAC 
candidates (including Abcf1, Ascc3, Hmgb2, Ifit1, Reep4, and Skp1a), helicases (Ddx18, 
Ddx46, Ddx59, Dhx15, Dhx16, Hells, Srcap, and Znfx1), cytoplasmically located DNA-
binding proteins (Cnot6, Dffb, Endog and Zfp143), phosphatases and deubiquitinases 
previously identified in our pilot screen including Amotl2, Ctdspl, Mtmr3, Rasgrp1, and 
deubiquitinases Usp38, Usp43 and Usp49, and the signaling molecule Ikka. 
Furthermore, a number of putative negative regulators were identified including 
microarray candidate Tiparp, signaling molecule Ripk1, phosphatases (Itpkb, Mdp1, 
Mtmr2, Ppp6c, and Ptpn1), the deubiquitinase Cyld and ubiquitin specific proteases 
Usp5, Usp12, and Usp27x.  
We identified putative ISD-pathway candidates through a high-throughput screen 
and secondary screens that will be further validated through siRNA-resistant cDNA 
rescue or targeted knockout. On their own, however, these candidates provide an 
enriched dataset of genes with likely roles in the ISD pathway. 
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Chapter 5:  
Validation and Characterization of Novel Regulators of the DNA Sensing Pathway 
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5.1 – Introduction 
Following the identification of several potential components of the ISD-sensing 
pathway, we selected several of the strongest candidates to investigate in more detail. 
We pursued candidates that were putative DNA sensors identified in our DNA-SILAC 
and RNAi screens, as well as novel components of the ISD-pathway signaling cascade, 
and screening hits with no known ISD-pathway interaction partners. We used three 
parallel modes of validation; first, to reduce the risk of off-target siRNA effects, we 
investigated our strongest hits through deconvolution of siRNA pools, testing with 
additional sh- and siRNAs and targeted cDNA rescue, secondly, we validated candidate 
genes through the use of chemical inhibitors. Furthermore, we investigated several 
candidates with targeted knockouts of putative ISD-sensing components.  
 
5.2 – Validation of putative DNA-sensors 
Consistent with the reported function of HMGB proteins as sentinels for nucleic 
acid responses, we identified Hmbg2 in our DNA-SILAC screen and in our siRNA screen 
as a regulator of the ISD-sensing pathway[143]. We demonstrated that MEFs deficient in 
Hmgb2 abrogate the IFN-response to dsDNA ligands but not to IVT-RNA, consistent with 
an established binding preference for dsDNA by HMGB2 (Figure 5.1). While HMGB 
family proteins act as promiscuous sensors of immunogenic DNA and RNA, DNA-SILAC 
hits that demonstrated strong, DNA-specific reduction in Cxcl10 following siRNA 
knockdown were selected for further investigation (Figure 5.2A). As previously 
described, our DNA-SILAC screen successfully identified known ISD-pathway 
components including the HMGB family proteins[143], AIM2 inflammasome components[49, 
143] and the cytosolic RNA polymerase III complex as well as members of the SET 
complex[104, 106, 143, 144] and Aicardi-Goutières syndrome-associated proteins SAMHD1 
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Figure 5.1 
Hmgb2 is a putative regulator of the ISD pathway. Hmgb2 wild-type and defi cient MEFs were stimulat-
ed with the indicated dsDNA or IVT-RNA (inset) ligands for 6 hours. From top to bottom, Ifnb, Cxcl10 and 
Hmgb2 mRNA expression is measured by quantitative RT-PCR. P-value <0.0001 (***), Student’s t-test.
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Figure 5.2
Putative DNA sensors Abcf1, Ifi t1 and Reep4 have DNA-specifi c responses; independent of se-
quence or source of DNA ligand and partially replicate in an independent cell line.  A) Selection of 
top candidates (red text) and controls (black text) from high-throughput siRNA screen. B) Selected can-
didates and control genes are knocked down and then stimulated with 1ug/mL ISD or 0.1ug.mL IVT-RNA 
for 26 hours. Cxcl10 expression is measured by quantitative RT-PCR. C) Candidate genes are stimulated 
with the indicated sources of DNA following knockdown. Cxcl10 production is measured by ELISA and 
normalized to CellTiter-Glo. D) Mouse lung fi broblast were treated with the indicated siRNAs and then 
stimulated with ISD for 26 hours. Cxcl10 production was measured by quantitative RT-PCR (left) and 
ELISA (right). P-value <0.01, 0.001, 0.0001 (*, **, ***, respectively), Student’s t-test.
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and TREX1[100, 145, 170]. The combination of quantitative proteomic evidence, microarray-
derived expression data and our siRNA-screen results place Abcf1, Ifit1 and Reep4 at 
the top of our candidate list. 
We validated our screening results by repeating knockdown with independent 
siRNAs targeting each gene. Following knockdown, cells were stimulated with ISD or 
IVT-RNA. Cxcl10 induction and cell viability were measured by ELISA and CellTiter-Glo, 
respectively (Figure 5.2B). We demonstrated 5.1-, 5.4- and 5.6-fold reduction in Cxcl10 
production for Abcf1, Ifit1 and Reep4, respectively. Stimulation of siRNA-treated cells 
with multiple dsDNA ligands demonstrated that the phenotype was not limited to ISD 
(Figure 5.2C). DNA isolated from bacteria (Listeria monocytogenes), adenovirus, and 
mice, as well as a random ISD ODN, was transfected following knockdown. Viability-
normalized Cxcl10 response was significantly reduced following knockdown with Irf3 as 
well as for each of the candidate genes. Next, we demonstrated significant reduction in 
Cxcl10 levels following knockdown of each candidate gene in an independent cell line by 
investigating Cxcl10 responses in siRNA-treated mouse lung fibroblast cells (Figure 
5.2D). Expression levels of candidate genes correlated with reduction in Cxcl10 
expression (data not shown). Knockdown of Ifit1 and Reep4 resulted in 8.0- and 8.5-fold 
reduction in Cxcl10 response but only a 10% reduction following Abcf1 knockdown, 
indicative of a cell-specific role of Abcf1 in embryonic fibroblasts.  
Following initial validation of these putative DNA sensors, we set out to further 
investigate the role of the Abcf1, Ifit1 and Reep4 in the DNA-sensing pathway. 
 
5.3 – Abcf1  
Abcf1 is member of the ATP Binding Cassette protein family, which, unlike most 
ABC proteins, lacks a transmembrane domain. Localized in the cytoplasm and ER, 
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Abcf1 interacts with eukaryotic initiation factor 2 (eIF2) to promote translation 
initiation[177]. Although a role in cytosolic DNA sensing has not been previously described 
for Abcf1, there is evidence that Abcf1 functions as a negative regulator of IL-6 and 
TNFα from Abcf1 heterozygote mice stimulated with CpG[178]. Additionally, recent 
evidence demonstrates that ABCF1 interacts with human polyomavirus 6 and 7[179]. 
We used 17 siRNAs targeting Abcf1 in MEFs and measured Cxcl10 expression 
by RT-PCR in response to stimulation of the ISD-sensing pathway. Knockdown of Abcf1 
correlated with reduced Cxcl10 expression in ISD stimulated cells (R2=0.615) (Figure 
5.3A). A panel of Abcf1-mRNA-targeting siRNAs demonstrated a DNA-specific reduction 
when stimulated with either DNA or IVT-RNA, the strongest of which reduced Cxcl10 
expression more than 94% compared to non-targeting control siRNAs as detected by 
ELISA (Figure 5.3B). We subsequently confirmed Abcf1 knockdown by immunoblot 
detection (Figure 5.3C). We also demonstrated that the phenotype could be significantly 
reversed in a doxycycline-dependent manner used to titrate the expression of an siRNA-
resistant cDNA (Abcf1 rescue gene) but not a Renilla luciferase cDNA control[140]. 
Abcf1 deficient mice are embryonic lethal at day 3.5 days post coitus, indicative 
of a crucial role in translation initiation[178]. Abcf1 heterozygote (Abcf1+/-) mice, however, 
appear to be developmentally normal, are fertile and show no significant differences in 
their gross anatomy when compared to their wild-type littermates. We investigated ISD 
responses in heterozygote Abcf1 MEFs from independent littermates and observed 
conflicting results. Passage immortalized Abcf1+/- MEFs (passage number >8) were 
stimulated with dsDNA (ISD or HSV60, a 60 base-pair ODN derived from HSV-1). Ifn-β 
and Cxcl10 expression are reduced over 95% following stimulation with either ISD or 
HSV60 dsDNA ligands (Figure 5.3D). In contrast, neither low passage MEFs from either 
Abcf1 wild-type or heterozygous mice responded to ISD (Figure 5.3E). We also infected 
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Figure 5.3
Abcf1 is a putative regulator of the ISD pathway. A) Cxcl10  mRNA expression in MEFs treated with 
17 different siRNAs targeting Abcf1 and stimulated with DNA, plotted against Abcf1 mRNA expression for 
corresponding siRNA treated MEFs, measured by quantitative RT-PCR. B) ELISA of CXCL10 in MEFs 
treated with non-targeting and Irf3 siRNAs and the indicated panel of Abcf1-targeting siRNAs were stimu-
lated with ISD or IVT-RNA. Values were normalized to cell viability detected by CellTiter-Glo (right panel). 
Orange line represents p-value <0.05 cutoff for ISD stimulated samples compared to non-targeting control 
C) Immunoblot assay showing knockdown effi ciency of non-targeting control siRNA and a representative 
siRNA targeting Abcf1 mRNA; B-actin serves as a loading control. D) Passage immortalized Abcf1 wild-
type and heterozygous MEFs were stimulated with dsDNA ligands (ISD and HSV60) for 6 hours. Quan-
titative RT-PCR was used to detect Abcf1, Ifnb and Cxcl10 expression from lysates. E) Low and high 
passage MEFs were stimulated with HSV60 or infected with HSVd109 (MOI=10) for 6 hours. Expression 
was determined by quantitative RT-PCR. F) MEFs were treated with the indicated siRNAs and stimulated 
with HSV60 or infected with HSVd109 for 6 hours. Expression for the indicated ISGs was determined by 
quantitative RT-PCR. P-value <0.01, 0.001, 0.0001 (*, **, ***, respectively), Student’s t-test.
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low and high passage MEFs with replication-defective herpes simplex virus-1 (HSV-1) 
d109, a strain with mutations in the five immediate-early genes (ICP0, ICP4, ICP22, 
ICP27, and ICP47) effectively blocking all viral gene expression during infection, 
subsequently driving robust type I IFN expression[66, 180]. HSVd109 infection stimulated 
the expression of Ifn-β and Cxcl10 in low passage Abcf1 wild-type and heterozygous 
mice as well as high passage wild-type MEFs but not high passage Abcf1+/- MEFs. 
Abcf1 mRNA expression was similar between heterozygotes (~50%) and wild-type 
MEFs, regardless of passage number. The phenotype described in the high-passage 
heterozygote Abcf1 MEFs is indeed striking. How the two cell lines diverged is difficult to 
unravel. It is possible that passage immortalization drove these phenotypic differences. It 
appeared that with each passage wild-type cell ISD response increased, inversely 
correlated to a decrease in type I IFN responses in Abcf1+/-. We have recently acquired 
embryonic stem (ES) cells from Abcf1-deficient mice. It is possible to convert ES cells to 
fibroblast-like cells by anti-MEF-antibody-mediated purification of embryoid bodies[181]. 
However, embryonic lethality of Abcf1-deficient mice suggests a key role in early 
development that may make the differentiation from MEFs from ES cells impossible. 
In our recent publication, we further elucidated the role of Abcf1 in the ISD-
sensing pathway[140]. To further our understanding of Abcf1, we performed unbiased 
quantitative mass-spectrometry to identify 53 proteins that significantly (p-value <0.01) 
precipitated with hemagglutinin epitope-tagged (HA) Abcf1, three of which are members 
of the ER-associated SET complex (SET, Hmgb2 and Anp32a), and includes proteins 
identified in our DNA-SILAC experiments, Trex1 and Apex1. None of these proteins were 
present in a parallel pull-down experiment of HA-tagged Sting. Consistent with previous 
reports that Abcf1 localizes to both ER and cytosolic compartments, we found that a 
subset of Abcf1 localized with SET and the ER marker calreticulin by 
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immunofluorescence staining. In addition to the SET complex, we found that Abcf1 
interacts with Hmgb2 and the putative DNA sensor Ifi204[65]. Additionally, we 
demonstrated that siRNA mediated knockdown of Abcf1 suppressed Tbk1 and Irf3 
phosphorylation following stimulation with ISD. 
  We also considered the role of Abcf1 in the response to viral infection. We 
demonstrated significant reduction of Ifn-β and ISG induction in p53-/- MEFs following 
siRNA-targeted knockdown of Abcf1 and stimulation with the dsDNA ligand HSV60 or 
infection with HSVd109 (Figure 5.3F). Furthermore, expression of Ccl5, Cxcl10, Ifi44, 
Ifih1, Ifit1, Ifn-β, Irf7, Isg1, Mx1, Rig-i and Stat1 was reduced more than 90% following 
stimulation with HSV60. There was no significant effect on Ifn-β and ISG induction by 
Sendai virus (which stimulates the Rig-i pathway) or by recombinant IFN-β[140]. These 
data indicate a potential role for Abcf1 in the response to cytosolic viral DNA but not 
RNA. 
Lastly, we examined the role of Abcf1 in regulating host responses to retroviral 
infection[140]. Upon infection with an HIV-based retrovirus, Trex1-/- MEFs but not wild-
type MEFs, produce Ifn-β and many ISGs[106]. It is thought that HIV-1 allocates Trex1 to 
degrade HIV retroelements and thus avoid detection by cytosolic DNA sensors. 
Knockdown of Abcf1 in Trex1-/- MEFs and subsequent infection with an HIV-based 
retrovirus significantly reduced Ifn-β and Cxcl10 expression implicating an Abcf1-
associated mechanism for detecting retroelements.  
Taken together, Abcf1 appears to be a critical factor in the DNA-sensing network. 
Abcf1 interacts with the SET complex, Hmgb2 and Ifi204, affects Ifn-β and ISG 
responses following infection with HSV-1 and may play a role in the innate immune 
response to retroviral infection as demonstrated by genetic perturbation and retroviral 
infection in Trex1-/- MEFs. The precise mechanism of Abcf1 remains to be elucidated. 
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Abcf1-SILAC data strongly suggest, however, that Abcf1 is part of a greater complex, the 
SET complex, which may be involved in early detection of DNA-based pathogens. The 
generation of an inducible Abcf1-knockout mouse may aid in the elucidation of its role in 
the ISD-sensing pathway. 
 
5.4 – Ifit1 
We identified the interferon-inducible protein Ifit1 among our DNA-SILAC 
candidates as a strong DNA-binding partner. Ifit1 is a member of the IFIT family of 
cytoplasmic proteins consisting mainly of tetracopeptide repeats, a structural motif 
thought to mediate the assembly of multiprotein complexes, but contains no annotated 
nucleic-acid binding domain[182, 183]. Ifit1 is strongly induced following stimulation with 
nucleic acids and has recently been implicated as an antiviral protein that recognizes the 
5ʼ triphosphate group on viral RNAs[184]. Identified in a similar manner to our mass 
spectrometry approach, IFIT1, along with IFIT5, an IFIT protein found in humans but not 
mice, were found to directly associate with 5ʼ triphosphate RNAs in human embryonic 
kidney cells (HEK293). The authors propose that the tetracopeptide repeats behave with 
an inherent binding plasticity that may facilitate promiscuous binding to RNA and 
potentially other nucleic acid ligands[185]. Prior to these recent discoveries, we pursued 
Ifit1 as a putative regulator of the ISD-pathway. 
We tested seven siRNAs targeting Ifit1 in MEFs and measured Cxcl10 
expression by RT-PCR in response to stimulation of the ISD-sensing pathway. 
Knockdown of Ifit1 correlated with reduced Cxcl10 expression in ISD stimulated cells 
(R2=0.748) (Figure 5.4A). Deconvolution of the siGENOME SmartPool used in our siRNA 
screen revealed one of four Ifit1-targeting siRNAs reduced Cxcl10 expression following 
stimulation with ISD. The reduction in Cxcl10 strongly correlated with the amount of 
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Figure 5.4
Validation of Ifi t1 and its homologues as putative regulators of the ISD pathway  A) Cxcl10  mRNA 
expression in MEFs treated with 7 different siRNAs targeting Ifi t1 and stimulated with DNA, plotted 
against Ifi t1 mRNA expression for corresponding siRNA treated MEFs, measured by quantitative RT-PCR. 
Dilution curve (red line) of single Ifi t-targeting siRNA from 5nM to 50nM siRNA. B) Deconvolution of Ifi t1-
targeting siGENOME SmartPools. Cxcl10 protein expression was detected by ELISA in MEFs treated with 
non-targeting and Irf3 siRNAs and the indicated panel of Ifi t1-targeting siRNAs were stimulated with ISD 
or IVT-RNA. Values were normalized to cell viability detected by CellTiter-Glo. C) MEFs were infected with 
lentiviral shRNAs targeting Ifi t1. Three days following puromycin selection, cells were stimulated with ISD 
for 6 hours. Cxcl10 and Ifi t1 expression was determined by quantitative RT-PCR. D) Immunoblot assay 
showing knockdown effi ciency of non-targeting control siRNA and a representative siRNA targeting Ifi t1 
mRNA; B-actin serves as a loading control. E) ProteinBLAST alignment of Ifi t1 antibody epitope to homol-
ogous proteins. F) Schematic of the Ifi t family, chromosome 19C1. G) Left panel, expression of Ifi t family 
genes following stimulation with 1ug/mL ISD or 1000 units recombinant mouse IFNb. Right panel, expres-
sion of Ifi t1 family genes after siRNA transfection with the indicated siRNAs and stimulation with ISD. Ifi t 
family expression detected by quantitative RT-PCR. H) Screen of Ifi t1 and homologous genes following 
siRNA treatment and stimulation with ISD. I) CXCL10 expression is normalized to cell viability of Ifi t1 and 
homologous genes. (Dotted orange line, p-value, <0.001, Student’s t-test).  MEFs knocked down with Ifi t1 
super-family siRNAs are stimulated with 1.0 ug/mL of the indicated dsDNA ligands. Cxcl10 expression is 
detected by ELISA and normalized to cell viability. J) Wild-type and Ifi t1-/- MEFs were stimulated with ISD 
for the indicated times. Expression of was determined by quantitative RT-PCR. K) Wild-type and Ifi t1-/- 
MEFs were transfected with the indicated siRNAs and stimulated with ISD. Expression of was determined 
by quantitative RT-PCR.
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transfected siRNA (R2=0.955) (Figure 5.4A, B). The reduction in Cxcl10 was DNA-
specific, as response to transfected IVT-RNA remained unchanged. Additionally, p53-/- 
MEFs were infected with lentiviral shRNAs targeting Ifit1 and, following puromycin 
selection, were stimulated with ISD. Cxcl10 protein levels, detected by ELISA, correlated 
with Ifit1 expression (R2=0.58) (Figure 5.4C). Specificity of Ifit1 siRNA knockdown was 
further demonstrated by immunoblot of Ifit1 protein. Expression was reduced in MEFs 
treated with the strongest siRNA targeting Ifit1 (Figure 5.3D). However, sequence 
alignment of the IFIT1 antibody epitope revealed homology with two proteins, GM14446 
and 20100002M12RIK clustered within the IFIT family of proteins in a 110kb region on 
chromosome 19C1 (Figure 5.4E, F). We hypothesized that these proteins may contribute 
to the putative role of Ifit1 as a regulator of the ISD-pathway.  
The murine IFIT family includes Ifit2, and Ifit3, as well as three interspersed IFIT-
like genes, whose mRNAs may not have been fully sequenced. Little is known about 
their expression but sequence analysis reveals one or two ISREs in proximity to the 
transcriptional start site of each gene, tentatively named Ifit3b (official gene symbol, 
I830012O16Rik), Ifit1b (2010002M12Rik), and Ifit1c (Gm14446) [183]. Sequence analysis 
revealed that Ifit3b is 96% identical to Ifit3, and Ifit1b and Ifit1c are closely related to Ifit1; 
the encoded proteins share 78% identical amino acids with each other and 60% with 
murine Ifit1, both of which have reverse orientations with respect to Ifit1 within the locus.
 We explored the role of these putative Ifit1 homologues by measuring gene 
expression following activation of the ISD-sensing pathway. MEFs stimulated with ISD 
strongly induced the expression of Ifit1, homolog Ifit1c, Ifit3 and its homolog Ifit3b but not 
Ifit2 or the Ifit1 homolog Ifit1b (Figure 5.4G). Recombinant Ifn-β, however, induced Ifit1, 
Ifit2, Ifit3, Ifit3b, and to a lesser extent, Ifit1c. Additionally, we assessed whether siRNAs 
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targeting Ifit1 affected the expression of Ifit family. Knockdown of Ifit1 by siRNA reduced 
expression of Ifit1 but no other Ifit family members.  
Following the discovery that ISD induced the expression of Ifit family members, 
we investigated their potential role in the ISD pathway by designing siRNAs that targeted 
each gene and their respective homology clusters (e.g. the Ifit super-family; Ifit1, Ifit1b, 
Ifit1c). In a screen of Ifit1 family members, Cxcl10 protein expression was measured 
following knockdown and ISD stimulation of 43 Ifit family-targeting siRNAs (Figure 5.4H). 
Five siRNAs targeting Ifit1 and its homologous genes reduced Cxcl10 expression four-
fold or more. An siRNA targeting the Ifit1 homologue Ifit1b showed more than 7-fold 
reduction in Cxcl10 (compared to 28 and 30-fold reduction of Cxcl10 following Irf3 and 
Ifit1 knockdown, respectively) (Figure 5.4I). We confirmed knockdown of Ifit1 super-
family members by quantitative RT-PCR (data not shown) and selected the strongest 
siRNAs for a screen of various dsDNA sources. In addition to Ifit1, siRNAs targeting 
Ifit1b and Ifit1c reduced Cxcl10 protein expression by 60% or more following stimulation 
with viral, bacterial, mammalian and synthetic DNA (Figure 5.3J). Furthermore, 
knockdown Ifit2, Ifit3 and Ifit3b appeared to have no effect on type I IFN production in 
ISD-stimulated MEFs (data not shown). 
The discovery that siRNAs targeting multiple IFIT1 super-family members 
reduced ISD-directed IFN responses provided a compelling argument for a pan-IFIT1 
role in the ISD-pathway, but it complicated the potential role of off-target siRNA effects in 
obscuring the role of each gene. Incomplete knockdown of one gene, or partial 
knockdown of multiple genes could further obscure the function of Ifit1 in the ISD-
pathway, as compensatory mechanisms of homologous family members will be difficult 
to distinguish. To rule out off-target or partial knockdown effects of siRNA, we stimulated 
MEFs from wild-type and Ifit1 deficient mice and measured IFN production (Figure 5.4K). 
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There was no difference between wild-type and Ifit1-/- MEFs following stimulation with 
ISD. Next we treated wild-type and knockout MEFs with siRNAs targeting Ifit1 and then 
stimulated with ISD (Figure 5.4L). Knockdown with siRNAs targeting Ifit1 had no effect 
on Cxcl10 expression of Ifit1-/- MEFs and only a mild reduction in wild-type MEFs. 
Knockdown appeared to be efficient for Irf3 as demonstrated by quantitative RT-PCR 
suggesting that our transfection of siRNAs was effective. However, reduction of Ifit1 in 
wild-type MEFs was uncharacteristically low (~30% reduction). The unusual siRNA data 
make the experiment difficult to interpret. However, we can speculate that in the absence 
of Ifit1, homologous Ifit proteins may play a compensatory role, masking the effect of Ifit1 
deficiency in the ISD-sensing pathway. Early attempts at overexpression of Ifit1 did not 
affect ISD-sensing pathway responses in MEFs treated with non-targeting control, Irf3, 
Tbk1 or Ifit1 siRNAs (data not shown). Furthermore, we have not measured the 
expression of IFIT family members in Ifit1 deficient mice following stimulation of the ISD-
sensing pathway. If our compensation hypothesis is correct, we may see increased IFIT 
family expression in Ifit1 knockout MEFs compared to wild-type.       
While the role for Ifit1 remains unclear with regards to the ISD-pathway, more 
details as to its potential role in innate immunity have begun to take shape. It has 
previously shown that IFIT1 binds to the eukaryotic initiation factor eIF3 and may limit 
the translation of viral mRNA by blocking the interaction of eIF3 with the ternary complex 
eIF2[186-188]. Subsequent knockout of Ifit1 revealed susceptibility to a West Nile Virus 
mutant defective in its mRNA 2ʼ-0 methylation, but had no increased sensitivity to 
intranasal infection of vesicular stomatitis virus (VSV) or encephalomyocarditis virus 
(EMCV) infection[189]. More recently, it has been demonstrated that Ifit1 (and human 
IFIT5) promote antiviral immunity by sensing 5ʼ-triphosporylated RNA, similar to Rig-i[184]. 
Knockdown of IFIT1 in HeLa cells lead to increased replication of VSV or influenza A but 
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not EMCV, which does not generate 5ʼ triphosphate RNAs during replication. 
Furthermore, in support of our findings, IFIT1 deficiency did not affect the 
phosphorylation of IRF3 following transfection with IVT-RNA, Poly I:C, ISD and Poly 
(dA:dT). Wild-type and IFIT1 deficient MEFs, bone marrow-derived macrophages and 
bone marrow-derived dendritic cells produced similar levels of IFN and interleukin-6 
following transfection of DNA and RNA nucleic acid ligands. Conversely, Ifit1-deficient 
mice succumbed to VSV infection more readily than wild-type mice while EMCV infected 
MEFs had equal viral loads, regardless of their genotype. The emerging evidence does 
not provide a clear role for Ifit1 or its homologues in the ISD-sensing pathway. It is 
possible that Ifit1 and its homologous genes form a complex mediated by the protein-
protein complex-forming activity commonly associated with the repetitive tetracopeptide 
domains. These promiscuous domains, that behave with a protein binding plasticity not 
dissimilar from the leucine-rich repeats regions of TLRs, could bind DNA and promote 
antiviral sensing much in the same way it recognizes 5ʼ-triphosphorylated RNA. This 
concept is further supported by a recent report demonstrating reduced ISRE activity in 
Ifit1-deficient mice following LPS or CpG treatment[184]. Furthermore, a recent report 
dissected transcriptional data of TLR-mediated response and identified IFIT1 as a critical 
bottleneck in regulating the expression downstream immune genes[190].  
Though we have provided evidence supporting a role for Ifit1 in the ISD-sensing 
pathway, we could not rule out the possibility of off-target effects. Were we to pursue Ifit1 
further, we would generate targeted knockouts of the entire Ifit1 super-family locus. The 
precise genomic editing function of transcription activator-like effectors (TALE)-based 
zinc-fingers may be a viable means to ask this question on a gene-by-gene basis[191, 192]. 
More immediately, we could investigate binding partners of Ifit1 in an Ifit1-SILAC screen.  
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 5.5 – Reep4 
Receptor expression-enhancing protein 4 (Reep4) is a member of REEP family 
of genes involved in intracellular trafficking and secretion. REEP proteins appear to 
partner with G-protein couple receptors (GPCR) to promote cell-surface expression of 
mammalian odorant and taste receptors[193]. Little is known about the function of Reep4. 
In a Xenopus tropicalis model, REEP4 deficiency causes paralysis in embryos as a 
result of defects in both muscle and neural development[194]. Mutations in human REEP1 
have been linked to hereditary spastic paraplegia (OMIM 610250) and distal hereditary 
motor neuronopathy type VB (OMIM 614751) though the molecular basis of these 
phenotypes is unclear [195, 196]. Although no known role in the immunity has been ascribed 
for Reep4, it was strong candidate in our DNA-SILAC screen and knockdown of Reep4 
resulted in a 24-fold reduction in Cxcl10 expression. 
To help rule out off target effects, we used 14 different siRNAs targeting Reep4 in 
MEFs and measured Cxcl10 expression by RT-PCR in response to stimulation of the 
ISD-sensing pathway. Knockdown of Reep4 correlated with reduced Cxcl10 expression 
in ISD stimulated cells (R2=0.524) (Figure 5.5A). Seven of 14 siRNAs targeting Reep4 
reduced Cxcl10 protein expression 10-fold or more, while response to transfected IVT-
RNA remained largely unchanged when corrected for cell viability (Figure 5.5B). To 
illustrate siRNA specificity, immunoblot of Reep4 demonstrated reduced expression in 
MEFs treated with the strongest siRNA targeting Reep4 (Figure 5.5C). We generated an 
siRNA resistant cDNA (Reep4 rescue gene) but failed to demonstrate a reversal of the 
phenotype following administration of doxycycline (data not shown).  
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Figure 5.5
Reep4 is a putative regulator of the ISD pathway. A) Cxcl10 mRNA expression in MEFs treated with 
14 different siRNAs targeting Reep4 and stimulated with DNA, plotted against Reep4 mRNA expression 
for corresponding siRNA treated MEFs, measured by quantitative RT-PCR. B) ELISA of Cxcl10 in MEFs 
treated with non-targeting and Irf3 siRNAs and the indicated panel of Reep4-targeting siRNAs were 
stimulated with ISD or IVT-RNA. Values were normalized to cell viability detected by CellTiter-Glo (right 
panel). Orange line represents p-value <0.05 cutoff for ISD stimulated samples compared to non-targeting 
control C) Immunoblot assay showing knockdown effi ciency of non-targeting control siRNA and a repre-
sentative siRNA targeting Reep4 mRNA; B-actin serves as a loading control.
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We further examined whether Reep4 also regulated the innate immune response 
to retroviral infection[140]. Knockdown of Reep4 in Trex1-/- MEFs, followed by infection 
with an HIV-based retrovirus, resulted in significantly reduced Cxcl10 expression.  
The human antimicrobial peptide LL-37, implicated in the pathogenesis of IFN-driven 
autoimmunity in psoriasis and lupus erythematosus, has recently been shown to 
facilitate the transport of self-DNA into monocytes via lipid rafts[197, 198]. LL-37 mediated 
transfer of dsDNA ligands induced the production of type I IFNs in a STING and TBK1-
dependent manner. Additionally, recent evidence suggests that REEP family member 
REEP2 recruits sensory receptors into lipid-raft microdomains, improving GPCR receptor 
signaling and receptor access[199]. It is possible that Reep4 acts similarly to REEP2 but 
as an LL37-DNA complex recruiting mechanism for lipid-raft mediated endocytosis. This 
poses in interesting hypothesis, potentially placing Reep4 in the pathway of viruses that 
require lipid-raft formation to trigger endocytosis[200]. Cellular entry of the non-enveloped 
DNA Polyomaviruses requires caveolar/lipid-raft formation for endocytosis. Perhaps 
Reep4 plays a similar sentinel role to HMGB family proteins by surveying lipid-raft 
mediated viral entry. As a recent study predicted that Abcf1 interacts with polyomavirus, 
it is possible that Reep4 is similarly involved[179]. Polyomavirus infection of GM-CSF-
differentiated dendritic cells induces the dramatic expansion of CD8+ T-lymphocytes[201]. 
To elucidate a potential role of Reep4 in polyomavirus-induced antiviral response, cDCs 
infected with lentiviral shRNAs targeting Reep4 could subsequently be infected with 
polyomavirus. Analysis of antiviral signatures in Reep4 knockout cDCs may provide a 
link to Reep4 regulation of the ISD-pathway. 
Taken together, these data suggest that Reep4 is a putative regulator of the ISD 
pathway. Although we were unable to rescue the phenotype with siRNA-resistant cDNA 
clones, and could therefore not rule out off-target effects, we demonstrated nucleic acid 
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specificity and described a potential regulatory role in the response to retroviral infection. 
Future investigations of Reep4 may focus on demonstrating a potential role in the 
regulation of lipid-raft mediated viral entry. 
 
5.6 – Putative ISD-sensing pathway signaling molecules  
In our recent publication, we demonstrated a role for novel regulators that interact 
with primary signaling molecules in the ISD-sensing pathway including Cdc37, a 
molecular chaperone that interacts with Hsp90, a putative interacting partner of Tbk1[140, 
202]. We demonstrated that siRNA-mediated knockdown of Cdc37 decreased Tbk1 
protein expression and subsequently abrogated phosphorylation at key sites on Irf3. 
Furthermore, we demonstrated that small molecules targeting Cdc37, Hsp90 or Tbk1 
decreased Ifn-β and Cxcl10 production in ISD-stimulated mouse lung fibroblast and 
human monocyte derived dendritic cells (MoDCs). 
Similarly, signaling events downstream of the interferon receptor are also critical 
in the ISD-sending pathway. In addition to the identification of known mediators Irf9 and 
Stat1, we investigated the role of putative ISD-sensing signaling molecules including the 
serine-threonine phosphatase Ppp6c and protein tyrosine phosphatase Ptpn1[140]. 
Although IkB-e is a proposed substrate for Ppp6c, and while tyrosine-phosphorylated 
proteins JAK2 and TYK2 are established substrates for Ptpn1, no targets in the ISD 
pathway have been established[202, 203]. In agreement with our siRNA screen, small 
molecule inhibition of Ppp6c by okadaic acid increased ISD-stimulation CXCL10 
production in MoDCs. We also demonstrated that inhibition of PTPN1 in MoDCs 
increased CXCL10 expression following ISD-stimulation.  Furthermore, consistent with 
our screen and small molecule-directed inhibition, Ptpn1 deficient MEFs produced up to 
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2.4-fold more Cxcl10 than rescued MEFs in response to stimulation with increasing 
doses of ISD (Figure 5.6).  
 
5.7 – Putative ISD-sensing pathway candidates with no known ISD-interaction partners  
We also investigated the role of a number of candidate genes for which there are 
no known molecular interaction partners in the ISD-pathway including the interferon-
regulated nuclear body protein Sp110 and the helicase Hells.  
First detected in the Mycobacterium tuberculosis-susceptible C3HeB/FeJ mice, 
positional cloning of the tuberculosis susceptibility locus, sst1 (for super-susceptibility to 
tuberculosis 1) identified the candidate gene Sp110[204]. Upregulated following infection 
with tuberculosis or Listeria monocytogenes, Sp110 limits bacterial multiplication in 
macrophages and mediates a switch in the cell death pathway from necrosis. 
Additionally, mutations in SP110 have been associated with hepatitis C virus 
susceptibility and may interact physically with hepatitis C virus core protein as well as 
the Epstein-Barr virus SM protein[205, 206]. 
We demonstrated a putative role for Sp110 in the ISD-sensing pathway by 
stimulating conventional dendritic cells (cDCs) from C3H-sst1s mice (sst1 susceptible 
strain carrying a natural deleterious mutation in Sp110) with dsDNA. C3H-sst1s cDCs 
produced 40% less Ifnb1 compared to wild-type cDCs confirming our siRNA screen 
finding (Figure 5.7). While interacting partners to Sp110 remain unclear, a putative pro-
apoptotic binding partner, Mybbp1a, has been identified[207]. In addition to activation of 
the ISD-sensing pathway and the Aim2-dependent inflammasome, cytosolic DNA 
induces DNA-damage signaling proteins that trigger mitochondrial apoptosis[208]. 
Perhaps, Sp110, via a pro-apoptotic intermediary Mybbp1a, mediates cross-talk 
generated by intracellular DNA or pathogens that regulates activation, gene expression 
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Figure 5.6
Ptpn1 is a putative negative regulator of the ISD pathway. Top, Cxcl10 expression was detected by 
ELISA following stimulation with indicated ug/mL of ISD for 26 hours in MEFs from Ptpn1-/- (-/-) and Ptpn1-
/- reconstituted with wild-type (WT REC) mice. Bottom, mRNA expression of Ptpn1 and Cxcl10 following 
simulation with ISD in Ptpn1 WT REC and -/- MEFs, measured by quantitative RT-PCR. P-value <0.01, 
0.0001 (*, ***, respectively), Student’s t-test.
ug/mL ISD    0.0                   0.25                 0.5                   0.7                 1.0   
W
T R
EC -/
-
W
T R
EC -/
-
W
T R
EC -/
-
W
T R
EC -/
-
W
T R
EC -/
-
0
1000
2000
3000
No Stim   0.25ug/mL  0.5ug/mL   0.75ug/mL  1.0 ug/mL
C
X
C
L1
0 
[p
g/
m
L]
***
***
***
***
172
Figure 5.7
Sp110 is a putative regulator of the ISD pathway. Mouse conventional dendritic cells (cDCs) were 
prepared from wild-type (WT) or B6.C3H-sst1 (Sp110 LoF)(-/-) and stimulated with the indicated dsDNA 
ligands for 6 hours. From top to bottom, Ifnb, Cxcl10 and Sp110 mRNA expression is measured by quanti-
tative RT-PCR. P-value <0.0001 (***), Student’s t-test.
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and apoptosis of host cells through unknown ISD-sensing pathway components[204]. 
Sp110 interacting partner Mybbp1a co-localizes with the nuclease NME1, a critical 
component apoptosis, regulated by SET complex proteins[209, 210]. Sp110 may therefore 
play a role in SET-complex-mediated ISD-sensing responses through yet-to-be-
discovered interactions with pro-apoptotic molecules regulated by SET-complex 
proteins.  
We also identified the lymphoid specific helicase Hells as a putative regulator of 
the ISD-sensing pathway. Hells is a chromatin remodeling ATPase, similar to the 
SWI/SNF family of chromatin remodelers, that modulates genome-wide cytosine 
methylation patterns at non-repeat sequences[211]. In addition to DNA hypomethylation, 
Hells-deficient mice show delayed growth, multiorgan and skeletal defects, premature 
graying, kyphosis, cachexia and early death[212]. An independent animal model deficient 
in Hells shows neonatal death, low birth weight, lymphocyte defects (T-cells are reduced 
by 60% and B-cells are reduced by 40%) and renal lesions[213].   
Though there is no known interaction with ISD-sensing sensing components, we 
investigated the role of Hells as a putative regulator in the ISD-sensing pathway. The 
IFN response to dsDNA stimulated Hells deficient MEFs was significantly reduced by 
more than 90% compared to matching wild-type MEFs (Figure 5.8A).  To demonstrate 
specificity of the ISD-sensing effect, we stimulated Hells-/- MEFs with Adenovirus, Sendai 
Virus, dsDNA and dsRNA ligands. The reduced type I IFN response appeared to be 
specific to DNA as stimulation with Poly I:C and Sendai Virus did not significantly reduce 
Ifn-β production (Figure 5.8B). Because Adenovirus failed to induce an Ifn-β response, 
we infected Hells-/- MEFs with HSVd109, inducing a robust Cxcl10 response in wild-type 
MEFs but demonstrated a 95% reduction in Hells-deficient MEFs (Figure 5.8C). Because 
HSVd109 is replication deficient, we infected Hells-/- MEFs with replication competent 
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Figure 5.8
Hells is a putative regulator of the ISD pathway.  A) Wild-type (HELLS WT, gray bars) and Hells-/- 
MEFs (HELLS -/-, black bars) were stimulated with the indicated dsDNA ligands for 6 hours. Left to right, 
Ifnb, Cxcl10 and bottom, Hells mRNA expression was measured by quantitative RT-PCR. B) Wild-type 
and Hells-/- MEFs were infected with adenovirus (AdV), Sendai virus (SeV) or stimulated with dsDNA or 
dsRNA ligands for 26 hours. Ifnβ (pg/mL) was detected by ELISA. C) MEFs were infected with HSV vari-
ant d109 or transfected with increasing doses of dsDNA for 6 hours. Cxcl10 expression was measured 
by quantitative RT-PCR. D) MEFs were infected with replication-competent adenovirus stably expressing 
GFP for 24 hours. Mean fl uorescence intensity and percent GFP positive were measured by FACS. E) 
Global changes in gene expression in Hells/ MEFs compared with wild-type controls as detected by ex-
pression microarrays. Black circles, Log2 values of normalized intensities for Hells/ MEFs (y-axis) versus 
wild-type MEFs (x-axis) are shown. Blue circles, 893 Putative immunome genes (ImmTree/ (http://bioinf.
uta.fi /ImmTree/)). Red circles, 1003 ISD-pathway candidates, gene names included for 150 top linear Z-
ranked screen hits. P-value <0.01, 0.001, 0.0001 (*, **, ***, respectively), Student’s t-test.
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Adenovirus that constitutively expresses GFP to further dissect the role of Hells in the 
ISD-pathway. Wild-type and Hells-/- MEFs are both infectible, however viral load was 
greatly reduced in Hells-/- MEFs as detected by GFP mean fluorescence intensity. 
The putative role of Hells in chromatin remodeling suggested that reduced ISD 
response could be the result of an epigenetic modification of an ISD-sensing pathway 
component. A comprehensive genomic map of cytosine methylation for wild-type and 
Hells-/- MEFs revealed global changes in gene expression in Hells-/- MEFs compared 
with wild-type controls as detected by microarrays[211]. Changes in expression coincided 
with hypo- and hypermethylated promoters suggesting the Hells is a critical epigenetic 
modulator required for the normal distribution of cytosine methylation throughout the 
murine genome. Because Hells deficiency resulted in significant modification of 
promoters in more than five percent of the murine genome, we investigated whether 
changes in gene expression in the absence of Hells resulted in the modification of known 
immune genes (sourced from ImmTree Immunome[214]) or candidates from our siRNA 
screen (Figure 5.8E). Twenty-eight siRNA candidates were expressed at least 2.5 fold 
less in Hells deficient MEFs than in wild-type MEFs including the ISD-regulated zinc 
finger protein Plagl1[44]. Additionally, Hells deficiency led to the increases in three ISD-
sensing candidate proteins including the guanylate binding protein Gbp2. Highly induced 
following stimulation with Poly (dA:dT), Gbp2 has been implicated in the inhibition of 
VSV and EMCV replication and may mediate early resistance to Toxoplasma gondii 
infection in mice[43, 215, 216]. Furthermore, our screen for putative cytosolic DNA-binding 
proteins identified SET complex components including the chromatin-modifying proteins 
SET and ANP32A, along with the nucleic acid co-receptor HMGB2[140]. Along with recent 
evidence implicating a role for the SET complex in viral DNA recognition[217], our findings 
suggest that the SET complex may form a DNA-sensing sensing complex coordinating 
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the detection, response, modification and degradation of viral and retroelement DNA[140]. 
The chromatin modifications directed by SET and ANP32A further implicate Hells as a 
regulator of the ISD-sensing pathway. 
Global changes in Hells-mediated gene expression, including putative ISD-
sensing components, suggests that epigenetic modifications may influence unknown 
ISD-sensing pathway components during any aspect of the response to cytosolic DNA. 
 Finally, we tested the role of putative ISD-sensing factors Endog, Gpr34, Polq 
and Rasgpr1 by investigating ISD-specific responses in targeted knockouts. In each of 
these models, we failed to demonstrate the phenotype first recognized in our siRNA 
screen. 
 
5.8 – Conclusion 
By combining genomic, proteomic and domain-based data sets with a loss-of-
function screen we identified several novel components of the ISD-sensing pathway.  
The DNA-associated protein Abcf1 appears to be a critical factor in the ISD-sensing 
pathway. Abcf1 interacts with the SET complex, Hmgb2 and Ifi204, and, as we 
demonstrated a role in the innate immune response to retroviral infection, Abcf1 may 
play a part in the early detection of retroviruses.  Furthermore, Abcf1 knockdown 
significantly decreases Ifn-β and ISG responses following infection with HSV-1. We 
demonstrated that perturbation of Ifit1 and Reep4 leads to reduced type I IFN responses 
to ISD stimulation. Identified as putative cytosolic DNA-binding components, Ifit1 and 
Reep4 may play a role in sequestration and delivery of cytosolic DNA. However, the 
evidence to date (with some caveats) suggests that the siRNAs targeting Ifit1 and Reep4 
were off-target, and may not be worth pursuing.   
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We also identified novel primary and secondary signaling components in the ISD-
pathway. We demonstrated that chemical inhibition of several molecules, including the 
serine-threonine phosphatase Ppp6c and protein tyrosine phosphatase Ptpn1 (also 
shown with knockout cells), modulates the ISD response. The administration of okadaic 
acid mimics genetic perturbation of these putative negative regulators, suggesting that 
these small-molecules may provide a means to boost immune response to DNA viruses 
or retroviruses[140]. In our recent publication we also demonstrated that administration of 
small molecules targeting DNA-sensing components, including Tbk1, Hsp90 or Cdc37, 
to diseases with overactive DNA-sensing pathways (AGS and SLE), may be useful in 
providing therapeutic benefits [104]. Furthermore, we identified novel components with no 
known ISD-sensing interactors. The interferon-regulated nuclear body protein Sp110 and 
the helicase Hells provide new lines of evidence for regulation of the ISD-pathway 
including the cross-talk with apoptotic pathway components and epigenetic regulation, 
respectively. 
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6.1 – Overview:  Screening development, analysis and outcome  
 With the goal of identifying novel components of the ISD-sensing pathway, we 
integrated genomic, proteomic and domain based datasets to reveal novel components 
implicated in the detection, signaling and response to cytosolic DNA by way of a loss-of-
function genetic perturbation screen and subsequent validation. The resulting candidates 
provide novel insights into the ISD-sensing pathway and will be a valuable resource to 
future researchers investigating the cytosolic DNA response. 
 The development of the screen required the dissection of many basic ISD-
pathway attributes. We recognized critical differences in the ISD-pathway between mice 
and human (such as the RIG-I-dependent response to Poly (dA:dT) in primary human 
bronchial epithelial cells), ligand-specific responses (ISD vs. Poly (dA:dT), and nucleic 
acid receptor expression across multiple cell types. We considered many different 
approaches to detect cell-autonomous ISD-pathway responses. In doing so we 
developed a number of useful approaches for detecting IFN responses that may be 
useful for future research. For example, we developed Ifn-β- and Cxcl10-GFP reporters 
that, while ineffective for detection of ISD-induced signals, may be useful for detecting 
RNA-based ligands and viral responses. Similarly, we developed robust tools reporting 
ISRE by luciferase for human and murine systems. While we did not successfully 
produce a CD-tagging-vector-based YFP-reporter, this unique system is worth revisiting 
for use in large-scale genomic loss-of-function or gain-of-function screens. Furthermore, 
we optimized conditions for use of a highly accurate tool for detecting the simultaneous 
expression of multiple genes by RT-qPCR directly from cell lysates.   
The development of our siRNA-based screening system required critical 
assessment of many variables. To maximize siRNA-directed knockdown, we considered 
many factors including transfection reagent volume, time of knockdown, media changes 
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and sell seeding density. The resulting product will continue to be a useful screening tool 
for future genetic perturbation screens, including the cDNA over-expression library 
currently being developed at the Broad Institute. 
Our candidate gene selection integrated data culled from multiple resources 
including proteomic, genomic and domain-based datasets. The subsequent siRNA 
screen revealed many novel factors contributing to the ISD response. Secondary 
screening of our top candidates yielded putative regulatory components specific to the 
ISD-pathway. We selected the most compelling of these candidates for subsequent 
validations. The remaining candidates may prove to be an invaluable resource for future 
studies. 
 Most notably, the SILAC screens described in our recent publication will continue 
to be a valuable resource for cytosolic DNA-binding proteins, as well as Abcf1- and 
Sting-interacting proteins[140]. Three of our strongest candidates, Abcf1, Ifit1 and Reep4, 
were identified in our SILAC-based screens. In addition to these candidates, 
components of the RNA Polymerase III complex, the SET complex, as well as Hmgb2 
and Ifit16 were purified. Identification of the SET complex-association with the ISD-
sensing pathway yielded one of the most interesting aspects of our screen, potentially 
linking Trex1 and Abcf1 to early control of exogenous retroelements from HIV 
infection[140]. 
The combined microarray dataset yielded compelling candidates that were 
revealed in our ISD-sensing pathway screen, including Ifit1 and Sp110. The inclusion of 
helicases in our screening set proved useful as well, resulting in the identification of the 
chromatin remodeling factor Hells. We also included genes with putative DNA-binding 
domains with predicted cytoplasmic localization. While we did not pursue candidates 
from this set further, we identified a number of genes with no previously ascribed ISD-
183
pathway role, including the nuclear matrix protein Matr3 and DNA fragmentation factor B 
(DFFB). Our pilot screen of putative negative regulators, consisting of phosphatases and 
deubiquitinases, yielded many valuable candidates; most notably Ptpn1 and Ppp6c. 
Candidates from our negative regulator screen may continue to be a valuable source of 
candidates for small molecule screens targeting regulators of the IFN response. Like 
Ptpn1 and Ppp6c, we may identify chemical inhibitors with therapeutic potential in 
treating patients with over-active ISD-pathway etiologies, including SLE, AGS and 
chilblain lupus.  
 In addition to Hmgb2, validated in our screen as a DNA-specific component of 
the nucleic-acid sentinel HMGB-complex, we investigated seven candidates for 
involvement in the ISD-sensing pathway (Table 6.1). Discussed further below, we 
proposed putative roles for each of these candidates in the ISD-sensing pathway as 
sensors (Abcf1, Ifit1, Reep4 and Sp110), negative regulators (Ppp6c and Ptpn1) and 
transcriptional modifiers of the ISD sensing pathway (Hells), described previously.  
 
6.2 – Protein-protein interaction network analysis 
We have proposed roles for each of these candidates based on our own and 
existing experimental data. To better define their roles in ISD-sensing, it will be important 
to find their interacting partners. Our candidate genes and their interacting partners 
make attractive targets for therapeutics. In an effort to find associated proteins, we 
performed network analysis of each candidate group (sensor, negative regulators, et 
cetera) using a network association tool (GeneMANIA) that derives associations 
between proteins from large function data sets that include protein and genetic 
interactions, pathways, co-expression, co-localization and protein domain similarity[218]. 
To this end, we generated four network association maps corresponding to the following 
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groups: SILAC candidates (Abcf1, Ifit1 and Reep4), Sp110, Hells and putative negative 
regulators (Ppp6c and Ptpn1)(Figures 6.1-6.4).  
To identify novel components of the SILAC-ISD-sensing candidates, we 
constructed a network map that includes SET complex proteins (Trex1, Apex1 and 
Hmgb2), Ifi16, Samhd1 and signaling components of the ISD-sensing pathway (Sting, 
Tbk1, Irf3 and Ifnar1)(Figure 6.1). Putative connections are delineated by functional 
connection (i.e., physical interactions, co-expression, etc.). Network analysis of the 
putative sensors reveals interesting connections, including physical interactions between 
Sting and Ifit family members Ifit1 and Ifi2. 
Similarly, we constructed network maps for Hells and Sp110 (Figures 6.2 and 
6.3). As there are no known ISD-pathway components associated with Hells, we 
generated a network map based on proteins previously revealed in our SILAC screen 
and ISD-signaling pathway components as described previously. Mitogen-activated 
protein kinase 1 (Mapk1) is predicted to associate with Hells based on yeast-2-hybrid 
protein-protein interaction data, providing a compelling candidate connecting Hells to 
Nod-like-receptor and TLR signaling. The pro-apoptotic protein Mybbp1a is predicted to 
interact with Sp110 and was therefore included in the predictive network analysis of 
Sp110 and ISD-sensing components.  Network analysis revealed a number of co-
expressed proteins including Ifit1, Samhd1, and Trex1. Furthermore, Sp110 shares 
domain similarities to the Autoimmune Regulator gene Aire including the SAND domain, 
which has been linked to various human diseases including autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). 
To construct a network for putative negative regulators Ppp6c and Ptpn1, in 
addition to known ISD-pathway signaling components, we added known interactors 
Jak2, Tyk2, and Ikbke to network analyses (Figure 6.4). Of note is the physical 
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Figure 6.1
Functional association predictions of SILAC candidates Abcf1, Ifi t1 and Reep4. Functional asso-
ciation prediction of SILAC candidates (yellow circles) were evaluated in combination with known SET 
complex members (Set, Apex1, Hmgb2), Trex1, Samhd1, and ISD-sensing pathway signaling compo-
nents including Sting, Tbk1, Irf3, and Ifnar1 (black circles). Colored lines correspond to network prediction 
method (see legend). 
Co-expression
Co-localization
Pathway
Physical interactions
Genetic interactions
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Figure 6.2
Functional association predictions of Sp110 and putative pro-apoptotic binding partners. Func-
tional association prediction of Sp110 and putative binding partner Mybbp1a (yellow circles) were evalu-
ated in combination with known SET complex members (Set, Apex1, Hmgb2), Trex1, Samhd1, and ISD-
sensing pathway signaling components including Sting, Tbk1, Irf3, and Ifnar1 (black circles). Colored lines 
correspond to network prediction method (see legend). 
Co-expression
Co-localization
Pathway
Physical interactions
Shared protein 
domains
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Figure 6.3
Functional association predictions of Hells. Functional association prediction of Hells (yellow circle) 
was evaluated in combination with known SET complex members (Set, Apex1, Hmgb2), Trex1, Samhd1, 
and ISD-sensing pathway signaling components including Sting, Tbk1, Irf3, and Ifnar1 (black circles). 
Colored lines correspond to network prediction method (see legend). 
Co-expression
Co-localization
Pathway
Physical interactions
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Figure 6.4
Functional association predictions of putative negative regulators Ppp6c and Ptpn1. Functional 
association prediction of Ppp6c and Ptpn1 (yellow circles) were evaluated in combination with known ISD-
sensing pathway signaling components including Sting, Tbk1, Irf3, and Ifnar1 (black circles). Colored lines 
correspond to network prediction method (see legend). 
Co-expression
Physical interactions
Shared protein 
domains
Pathway
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interaction between Ptpn1 and leukocyte receptor tyrosine kinase Tyk1. Tyk1 shares 
protein domains with Tbk1 and is interferon inducible. Additionally, Ppp6c interacts 
directly with Tbk1. 
 The integration of network analysis provides a compelling layer of data to the role 
of our candidates in regulating the ISD-sensing pathway. Future studies will interrogate 
network predictions in the context of our candidate genes to connect and reveal novel 
roles in the ISD-sensing pathway. Furthermore, proteins revealed in network analysis 
may be drug-able targets with therapeutic potential for patients with an overacting ISD-
sensing pathway. 
 
6.3 – Predictions and concluding remarks 
The putative roles of the candidate genes identified in our screen of the ISD- 
sensing pathway as sensors, negative regulators and chromatin remodelers are 
summarized in Figure 6.5.  The putative cytosolic DNA sensor Abcf1 binds DNA and 
interacts with the SET complex, whose role in nucleic acid sensing is only beginning to 
be understood. Recent evidence suggests a role for the SET complex in the early 
detection of viral infection, including HIV infection, during which SET complex member 
Trex1 is sequestered by HIV to eliminate retroviral DNA thus abrogating early viral 
detection[106]. Although pull down of Abcf1 did not include Sting, knockdown of Abcf1 
reduces the expression of Sting regardless of stimulation (Figure 5.3). Perhaps, Abcf1, 
as part of the SET complex, modulates the expression of Sting through an unknown 
mechanism. 
The putative DNA sensor Sp110 may also play a role in SET complex-based 
response to DNA. Sp110-interacting protein Mybbp1a interacts with Aire, which in turn 
co-localizes with SET complex members including Set, Apex1 and Nme1. Though we did 
191
Figure 6.5
Putative roles of candidate genes as sensors, negative regulators and chromatin remodelers of 
the ISD pathway. Putative DNA sensors Abcf1 and Sp110 may interact with SET complex components 
and direct ISD-sensing responses via Sting and Tbk1 or through an unknown Sting-independent pathway. 
Reep4, by way of lipid-raft mediated viral endocytosis may directly detect DNA or recruit a DNA sensor, 
akin to the antimicrobial peptide LL37 leading to what is presumed to be Sting-dependent-IFN expres-
sion. Ifi t1 and homologous family members Ifi t1b and Ifi t1c may separately or in conjunction be involved 
in the promiscuous detection of viral RNA and DNA. Putative negative regulators Ppp6c and Ptpn1 may 
inhibit IFN expression by blocking NFκB or Jak1/Tyk2 phosphorylation, respectively. Cytosine methylation 
patterns directed by Hells may infl uence the expression of ISD-sensing pathway components during any 
phase of detection. 
192
Figure 6.5 (continued)
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not identify Sp110 in our initial SILAC-based DNA-binding study, Sp110 may interact 
with SET complex members through an unknown sensing pathway that further 
implicates a novel role for Aire in early pathogen detection. While there are many 
unanswered questions, these new insights into Sp110 suggest a broader role in 
pathogen response beyond the reported antimicrobial roles following tuberculosis or 
Listeria infection. 
Potential siRNA off-target effects and the high homology of Ifit1 family members 
Ifit1b and Ifit1c cloud the role of Ifit1 as a putative sensor of the ISD-sensing pathway. 
However, recent evidence implicates Ifit1 in the sensing of 5ʼ triphosphorylated RNA, 
supporting the hypothesis that the tetratcopeptide repeats that comprise the Ifit1 protein 
behave promiscuously and may thus also bind DNA and promote antiviral sensing. We 
propose that Ifit1, in conjunction with homologous family members Ifit1b and/or Ifit1c, 
may be involved in the direct detection of DNA leading to the activation of Type I IFNs. 
An Ifit1-locus targeted knockout approach may reveal the nature of the ISD response 
obscured by the knockout of only a single Ifit1-superfamily gene. 
We also implicated the trafficking protein Reep4 as a novel component of the 
ISD-sensing pathway. Although we were unable to fully validate the role of Reep4 in the 
response to DNA, it was isolated as a DNA-interacting protein in our DNA-SILAC screen 
and additionally demonstrated abrogated DNA-induced responses following knockdown 
with multiple siRNAs. Reep4 may be involved in lipid-raft mediated endocytosis, similar 
to REEP family member REEP2. Perhaps Reep4 recruits LL-37, an antimicrobial peptide 
implicated in the transport of self-DNA into monocytes via lipid rafts, to aid in the 
detection of DNA viruses that enter the cell via lipid-raft mediated endocytosis, such as 
Polyomaviruses. Thus, Reep4 may act as a DNA sensor itself or as a trafficking 
mechanism associated with lipid-rafts that directly recruits DNA sensing components. 
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In addition to putative DNA sensors, we identified two potential novel negative 
regulators of the ISD response, Ppp6c and Ptpn1. Though the mechanism of these 
components needs further clarification, protein-protein interaction data provides 
compelling insight as to their roles in the ISD-sensing pathway. Ppp6c has been 
implicated as a substrate for Ikbke, an NFκB inhibitor and may thus regulate ISD-
induced IFN expression by preventing phosphorylation of Ikki, thereby inhibiting 
Tbk1/Ikki co-activation of Irf3 and subsequent IFN expression. Consistent with this 
hypothesis, knockdown or chemical inhibition of Ppp6c dramatically increases ISD-
induced IFN responses. Additionally, we demonstrated a role for protein tyrosine 
phosphatase Ptpn1 as a negative regulator of the ISD-sensing pathway. Chemical 
inhibition, siRNA knockdown and MEFs from Ptpn1-deficient mice demonstrate 
increased IFN responses to DNA. While we have not identified the substrate for Ptpn1 in 
the DNA-sensing pathway, we predict that Ptpn1 acts as an inhibitory substrate to 
interferon-receptor signaling molecule Jak1 and/or Tyk2. Understanding the exact 
mechanism by which DNA stimulation induces the inhibitory capacity of Ptpn1 may have 
broad therapeutic implications in the regulation of inflammatory responses across 
autoimmune and infectious diseases.  
Finally, we discussed the potential role of the helicase Hells in the ISD-sensing 
pathway. The genome-wide effect of Hells deficiency on chromatin modification and 
subsequent gene expression implicates Hells in a potential epigenetic role in the ISD-
sensing pathway. We demonstrated that the expression of many immune function genes 
was significantly changed in the absence of Hells. How global changes in Hells-mediated 
gene expression influences ISD-sensing pathway components remains unclear and 
opens a novel avenue to pursue additional ISD-pathway components. It is possible that, 
in the absence of Hells, DNA sensors are not expressed and thus, in-depth analysis and 
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loss-of-function screens of differentially expression genes may reveal novel components 
of the ISD-sensing pathway. 
In conclusion, we identified a number of novel ISD pathway components 
including Abcf1, Ptpn1 and Hells. We validated hits through siRNA-resistant cDNA 
rescue, chemical inhibition, or targeted knockout. Additionally, we evaluated protein-
protein interactions of our strongest validated hits to develop a network model of the ISD 
pathway. In addition to the identification of novel ISD pathway components, our enriched 
screening data set may provide a useful resource of candidate genes involved in the 
response to cytosolic DNA.  The resulting data set may prove a useful resource to 
immunologists seeking to identify factors involved in any aspect of the response to 
cytosolic DNA and may further reveal therapeutic targets for patients with ISD-sensing 
pathway-driven diseases. 
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Chapter 7: 
Materials and Methods 
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Cells, viruses and reagents 
HEK293T, A549, HELA, and RAW 264.7 cells were obtained from the American 
Type Culture Collection. Cells were maintained in DMEM (Mediatech) with 10% FBS 
(Sigma). RS4-11 cells were a gift from T. Means (Massachusetts General Hospital). 
Primary HBECs (Lonza, Basel, Switzerland) derived from normal human bronchial 
epithelium were cultured as previously described[134]. KBM7 cells were provided by J.E. 
Carette and T.R. Brummelkamp (Whitehead Institute) and maintained as previously 
described[122]. p53−/− MEFs were derived from p53−/− mice (gift from D.J. Kwiatkowski 
(Harvard Medical School) and D.M. Sabatini (Massachusetts Institute of 
Technology)). ISRE-luciferase 293T and p53−/− MEFs were generated as previously 
described[134]. GFP-expressing IFNb and CXCL10-promoter reporters, IFNb-PLJM6-GFP 
and CXCL10-PLJM6-GFP, were a gift from A. Luster (Massachusetts General Hospital). 
Abcf1-/- and wild-type and MEFs were a gift from S. Wilcox (University of British 
Columbia)[178]. Ifit1-/- and wild-type and MEFs were a gift from M. Diamond (Lerner 
Research Institute, Cleveland Clinic, Cleveland, Ohio)[189]. Ptpn1−/− MEFs 
and Ptpn1−/−MEFs rescued with Ptpn1 cDNA were a gift from B.G. Neel (Ontario Cancer 
Institute)[219]. Primary murine lung fibroblasts were derived from lung tissue of 4-8 wk old 
female C57BL/6 mice. Mouse conventional dendritic cells (cDCs) were prepared from 
wild-type or B6.C3H-sst1 (Sp110 LoF) mice as previously described[126, 204]. Hells-/- and 
wild-type and MEFs were a gift from K. Muegge(NCI)[211]. Endog MEFs were a gift from 
J. Chung (National Heart, Lung, and Blood Institute)[220]. Gpr34 MEFs were provided by 
T.Schöneberg (University of Leipzig)[221]. Polq MEFs were a gift from J. Schimenti 
(Cornell)[222]. Rasgpr1 MEFs were a gift from J. Stone (University of Alberta)[223]. 
Adenovirus, Sendai virus and Listeria monocytogenes genomic DNA, were obtained 
from ATCC. Viruses were used at a multiplicity of infection (MOI) of 1 unless otherwise 
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indicated. HSV-1 d109 was obtained as a gift from N.A. DeLuca (University of 
Pittsburgh) and used at an MOI of 1[180].  
ISD, shISD, 12bpISD, Random-ISD and HSV60 dsDNA were annealed from 
oligonucleotides (IDT) as described[44, 106]; sequences are listed in Table 7.1. PR-8 and 
3p-RNA In vitro–transcribed RNA ligands were synthesized as described[31]. ODN 1668 
CpG type B TLR and Poly (dA:dT) were from Invivogen and Poly (I:C) from Enzo Life 
Sciences. Nucleic acids were mixed with Lipofectamine LTX (Life Technologies) at ratio 
of 1:3 (wt/vol) in Opti-MEM (Life Technologies) and added to cells at 1 μg/ml (DNA) or 
0.1 μg/ml (RNA) unless otherwise indicated. Recombinant IFN-β was obtained from PBL 
InterferonSource, murine CXCL10 ELISA kit from R&D, NE-PER from Pierce, 
Luminescent cell viability assay was from Promega (CellTiter Glo). Antibodies used were 
anti-Human CD40 (14-0409, eBioscience), anti-CD80 (ab64116, Abcam), anti-IFIT1 (SC-
134949, Santa Cruz Biotechnology), anti-β-actin (ab6276, Abcam), and anti-HA (High 
Affinity 3F10; Roche). 
CD-Tagging  
The pBabe-YFP1 CD tagging plasmid was a gift from A. Sigal (Weizmann 
Institute of Science) and were utilized following established protocols[130]. 
Quantitative RT-PCR 
Total RNA was extracted using RNeasy Mini kit (Qiagen). cDNA was synthesized 
using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Real-time 
qPCR was performed using SYBR Green and LightCycler 480 system (Roche). Dual 
reporter real-time PCR was performed using AptaTaq Master Mix (Roche), Universal 
Probe Library Probe # 3 (Cat. No. 04685008001, Roche), UPL Mouse GAPDH Gene 
Assay (Cat. No. 05046211001, Roche). The primers used for qPCR are listed in Table 
7.2. 
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Table 7.1 
DNA and RNA ligands
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Table 7.2
Quantitative RT-PCR Primers
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RNA interference screen 
We seeded 750 p53−/− MEFs per well in 96-well plates in 60% DMEM and 40% 
Opti-MEM. siRNA (25 nM) was complexed with 0.5 μl Lipofectamine RNAiMax (Life 
Technologies) in Opti-MEM, incubated for 12 min and added to wells. Cells were 
transfected with DNA 72 h later. Supernatants were collected 26 h later, and CXCL10 
was quantified by ELISA. Cell viability was estimated by CellTiter-Glo Luminescent Cell 
Viability Assay (Promega); CellTiter-Glo values below 3.75 × 105were considered toxic. 
Dharmacon siGENOME SMARTpools from Harvard ICCB were used for screening. ON-
TARGETplus Nontargeting Pool (Dharmacon) was used as negative control (siCtrl). 
Individual siRNAs are listed in Table 7.3. 
shRNA Knockdowns 
High-titer lentiviruses expressing shRNAs were obtained from The Broad RNAi 
Platform and used to infect BMDCs as previously described[126]. 
Statistics 
Statistical significance was determined by paired Student's t-test, unless 
otherwise noted. P < 0.05 was considered statistically significant. 
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